
<html lang="en"     class="pb-page"  data-request-id="1cb23fb0-8116-4086-9fb1-aba5e75b8e59"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm500973a;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2014.57.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor" /></meta><meta name="dc.Creator" content="M. Raymond V.  Finlay" /></meta><meta name="dc.Creator" content="Mark  Anderton" /></meta><meta name="dc.Creator" content="Susan  Ashton" /></meta><meta name="dc.Creator" content="Peter  Ballard" /></meta><meta name="dc.Creator" content="Paul A.  Bethel" /></meta><meta name="dc.Creator" content="Matthew R.  Box" /></meta><meta name="dc.Creator" content="Robert H.  Bradbury" /></meta><meta name="dc.Creator" content="Simon J.  Brown" /></meta><meta name="dc.Creator" content="Sam  Butterworth" /></meta><meta name="dc.Creator" content="Andrew  Campbell" /></meta><meta name="dc.Creator" content="Christopher  Chorley" /></meta><meta name="dc.Creator" content="Nicola  Colclough" /></meta><meta name="dc.Creator" content="Darren A. E.  Cross" /></meta><meta name="dc.Creator" content="Gordon S.  Currie" /></meta><meta name="dc.Creator" content="Matthew  Grist" /></meta><meta name="dc.Creator" content="Lorraine  Hassall" /></meta><meta name="dc.Creator" content="George B.  Hill" /></meta><meta name="dc.Creator" content="Daniel  James" /></meta><meta name="dc.Creator" content="Michael  James" /></meta><meta name="dc.Creator" content="Paul  Kemmitt" /></meta><meta name="dc.Creator" content="Teresa  Klinowska" /></meta><meta name="dc.Creator" content="Gillian  Lamont" /></meta><meta name="dc.Creator" content="Scott G.  Lamont" /></meta><meta name="dc.Creator" content="Nathaniel  Martin" /></meta><meta name="dc.Creator" content="Heather L.  McFarland" /></meta><meta name="dc.Creator" content="Martine J.  Mellor" /></meta><meta name="dc.Creator" content="Jonathon P.  Orme" /></meta><meta name="dc.Creator" content="David  Perkins" /></meta><meta name="dc.Creator" content="Paula  Perkins" /></meta><meta name="dc.Creator" content="Graham  Richmond" /></meta><meta name="dc.Creator" content="Peter  Smith" /></meta><meta name="dc.Creator" content="Richard A.  Ward" /></meta><meta name="dc.Creator" content="Michael J.  Waring" /></meta><meta name="dc.Creator" content="David  Whittaker" /></meta><meta name="dc.Creator" content="Stuart  Wells" /></meta><meta name="dc.Creator" content="Gail L.  Wrigley" /></meta><meta name="dc.Description" content="Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a nu..." /></meta><meta name="Description" content="Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a nu..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 1, 2014" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500973a" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500973a" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500973a" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500973a" /></link>
        
    
    

<title>Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500973a" /></meta><meta property="og:title" content="Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0029.jpeg" /></meta><meta property="og:description" content="Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a number of years. Despite encouraging clinical efficacy with these agents, in many patients resistance develops leading to disease progression. In most cases, this resistance is in the form of the T790M mutation. In addition, EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea. We describe herein the evolution of an early, mutant selective lead to the clinical candidate AZD9291, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor. Following observations of significant tumor inhibition in preclinical models, the clinical candidate was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompanied by an encouraging safety profile." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500973a"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500973a">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500973a&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500973a&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500973a&amp;href=/doi/10.1021/jm500973a" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8249-8267</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5007935" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/jm500497v" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M.+Raymond+V.++Finlay">M. Raymond V. Finlay</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Anderton">Mark Anderton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Ashton">Susan Ashton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Ballard">Peter Ballard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Bethel">Paul A. Bethel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Box">Matthew R. Box</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+H.++Bradbury">Robert H. Bradbury</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon+J.++Brown">Simon J. Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sam++Butterworth">Sam Butterworth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Campbell">Andrew Campbell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Chorley">Christopher Chorley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicola++Colclough">Nicola Colclough</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Darren+A.+E.++Cross">Darren A. E. Cross</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gordon+S.++Currie">Gordon S. Currie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Grist">Matthew Grist</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lorraine++Hassall">Lorraine Hassall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George+B.++Hill">George B. Hill</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++James">Daniel James</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++James">Michael James</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Kemmitt">Paul Kemmitt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Teresa++Klinowska">Teresa Klinowska</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gillian++Lamont">Gillian Lamont</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+G.++Lamont">Scott G. Lamont</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathaniel++Martin">Nathaniel Martin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heather+L.++McFarland">Heather L. McFarland</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martine+J.++Mellor">Martine J. Mellor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathon+P.++Orme">Jonathon P. Orme</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Perkins">David Perkins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paula++Perkins">Paula Perkins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Graham++Richmond">Graham Richmond</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Smith">Peter Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Ward">Richard A. Ward</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Waring">Michael J. Waring</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Whittaker">David Whittaker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stuart++Wells">Stuart Wells</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gail+L.++Wrigley">Gail L. Wrigley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Oncology Innovative Medicines, <sup>‡</sup>Drug Safety and Metabolism, <sup>§</sup>Global Medicines Development, and <sup>∥</sup>Discovery Sciences, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#97e5f6eeb9f1fef9fbf6eed7f6e4e3e5f6edf2f9f2f4f6b9f4f8fa"><span class="__cf_email__" data-cfemail="a4d6c5dd8ac2cdcac8c5dde4c5d7d0d6c5dec1cac1c7c58ac7cbc9">[email protected]</span></a>. Phone: +44(0)1625510379.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500973a&amp;href=/doi/10.1021%2Fjm500973a" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8249–8267</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 1, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 June 2014</li><li><span class="item_label"><b>Published</b> online</span>1 October 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 October 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500973a" title="DOI URL">https://doi.org/10.1021/jm500973a</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8249%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DM.%2BRaymond%2BV.%2BFinlay%252C%2BMark%2BAnderton%252C%2BSusan%2BAshton%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D20%26contentID%3Djm500973a%26title%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BEGFR%2BInhibitor%2B%2528AZD9291%2529%2Bof%2BBoth%2BSensitizing%2Band%2BT790M%2BResistance%2BMutations%2BThat%2BSpares%2Bthe%2BWild%2BType%2BForm%2Bof%2Bthe%2BReceptor%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8267%26publicationDate%3DOctober%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500973a"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">67255</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">292</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500973a" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Raymond V. Finlay&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Anderton&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Ashton&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Ballard&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Bethel&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Box&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;H. Bradbury&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;J. Brown&quot;},{&quot;first_name&quot;:&quot;Sam&quot;,&quot;last_name&quot;:&quot;Butterworth&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Campbell&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Chorley&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;Colclough&quot;},{&quot;first_name&quot;:&quot;Darren&quot;,&quot;last_name&quot;:&quot;A. E. Cross&quot;},{&quot;first_name&quot;:&quot;Gordon&quot;,&quot;last_name&quot;:&quot;S. Currie&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Grist&quot;},{&quot;first_name&quot;:&quot;Lorraine&quot;,&quot;last_name&quot;:&quot;Hassall&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;B. Hill&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;James&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;James&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Kemmitt&quot;},{&quot;first_name&quot;:&quot;Teresa&quot;,&quot;last_name&quot;:&quot;Klinowska&quot;},{&quot;first_name&quot;:&quot;Gillian&quot;,&quot;last_name&quot;:&quot;Lamont&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;G. Lamont&quot;},{&quot;first_name&quot;:&quot;Nathaniel&quot;,&quot;last_name&quot;:&quot;Martin&quot;},{&quot;first_name&quot;:&quot;Heather&quot;,&quot;last_name&quot;:&quot;L. McFarland&quot;},{&quot;first_name&quot;:&quot;Martine&quot;,&quot;last_name&quot;:&quot;J. Mellor&quot;},{&quot;first_name&quot;:&quot;Jonathon&quot;,&quot;last_name&quot;:&quot;P. Orme&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Perkins&quot;},{&quot;first_name&quot;:&quot;Paula&quot;,&quot;last_name&quot;:&quot;Perkins&quot;},{&quot;first_name&quot;:&quot;Graham&quot;,&quot;last_name&quot;:&quot;Richmond&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Ward&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Waring&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Whittaker&quot;},{&quot;first_name&quot;:&quot;Stuart&quot;,&quot;last_name&quot;:&quot;Wells&quot;},{&quot;first_name&quot;:&quot;Gail&quot;,&quot;last_name&quot;:&quot;L. Wrigley&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;8249-8267&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500973a&quot;},&quot;abstract&quot;:&quot;Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a number of years. Despite encouraging clinical efficacy with these agents, in many patients resistance develops leading to disease progression. In most cases, this resistance is in the form of the T790M mutation. In addition, EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea. We describe herein the evolution of an early, mutant selective lead to the clinical candidate AZD9291, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor. Following observations of significant tumor inhibition in preclinical models, the clinical candidate was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompa&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500973a&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500973a" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500973a&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500973a" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500973a&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500973a" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500973a&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500973a&amp;href=/doi/10.1021/jm500973a" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500973a" /></input><a href="/doi/pdf/10.1021/jm500973a" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26pmid%3D25271963%26genre%3Darticle%26aulast%3DFinlay%26date%3D2014%26atitle%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BEGFR%2BInhibitor%2B%2528AZD9291%2529%2Bof%2BBoth%2BSensitizing%2Band%2BT790M%2BResistance%2BMutations%2BThat%2BSpares%2Bthe%2BWild%2BType%2BForm%2Bof%2Bthe%2BReceptor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jmcmar.2014.57.issue-20/20141023/jmcmar.2014.57.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a number of years. Despite encouraging clinical efficacy with these agents, in many patients resistance develops leading to disease progression. In most cases, this resistance is in the form of the T790M mutation. In addition, EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea. We describe herein the evolution of an early, mutant selective lead to the clinical candidate AZD9291, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor. Following observations of significant tumor inhibition in preclinical models, the clinical candidate was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompanied by an encouraging safety profile.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The role of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is well-known, and substantial therapeutic progress in the treatment of this disease has been made over the past 10 years through the exploitation of this insight.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Inhibition of the kinase domain of EGFR and resultant oncogenic cell signaling disruption by small molecule inhibitors such as gefitinib <b>1</b> and erlotinib <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) have been shown to be particularly beneficial in those patients carrying the so-called “sensitizing mutations” such as L858R and the exon-19 deletion.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> However, emergence of resistance to these targeted therapies continues to be a cause for concern, with the T790M mutation in particular being highlighted as a key therapeutic target.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The subsequent identification of irreversible EGFR inhibitors such as dacomitinib <b>3</b> and afatinib <b>4</b><a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) that inhibit both mutants described above as well as the wild type receptor potentially offers therapeutic options for T790M positive patients. However, the high wild-type potency and accompanying toxicities associated with such activity may well limit their utility in this setting.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of reversible and irreversible EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, both ourselves<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (compound <b>5</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) and others<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> (<i>N</i>-[3-[5-chloro-2-[[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide (WZ-4002), <b>6</b>, Gatekeeper Pharmaceuticals Inc.; <i>N</i>-[3-[[2-[[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino]-5-chloropyrimidin-4-yl]amino]phenyl]prop-2-enamide (CO-1686), <b>7</b>, Clovis Oncology) have described efforts to identify mutant selective inhibitors that target both the sensitizing mutations and the T790M resistance mutation while also sparing the wild type form of the receptor, inhibition of which can lead to dose limiting toxicities including skin rash and diarrhea. Herein, we describe some of our work that has led to the identification of the clinical candidate AZD9291 (<b>8)</b>, a potent inhibitor of both sensitizing and double mutant (sensitizing and T790M resistance) forms of EGFR with selectivity over the wild type form (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mutant selective EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Previously, we had described our efforts in this area that culminated in the identification of <b>5</b>, a potent and selective EGFR inhibitor that had demonstrated in vivo efficacy in both activating and double mutant human xenograft disease models while also displaying minimal activity in a wild type setting.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and Selected Properties of Lead Optimization Start Points</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0024.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>5</b></th><th class="colsep0 rowsep0" align="center"><b>9</b></th><th class="colsep0 rowsep0" align="center"><b>10</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.091</td><td class="colsep0 rowsep0" align="left">0.063</td><td class="colsep0 rowsep0" align="left">0.019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AM cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.388</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE (DM cell)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nude mouse po 50 mg/kg: <i>C</i><sub>max</sub> (μM), AUC (μM·h)</td><td class="colsep0 rowsep0" align="left">5.8, 67</td><td class="colsep0 rowsep0" align="left">0, 0</td><td class="colsep0 rowsep0" align="left">2.7, 13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup> cells)]</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility, pH 7.4 (μM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">828</td><td class="colsep0 rowsep0" align="left">>973</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">9.1</td><td class="colsep0 rowsep0" align="left">7.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R (enz) IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">0.004 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">0.813 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase panel<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> hits (>90% inhibition at 1 μM)</td><td class="colsep0 rowsep0" align="left">CHK2 (90%)</td><td class="colsep0 rowsep0" align="left">not tested</td><td class="colsep0 rowsep0" align="left">CAMKKβ (92%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CAMKKβ (94%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IGF1R (97%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IGF1R (98%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">INSR (97%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Inhibition of EGFR phosphorylation. All cell IC<sub>50</sub> measurements reported are the geometric mean of at least two independent measurements unless otherwise indicated. The standard error of the mean (SEM) is not shown, as all three assays were found to be highly reproducible on repeat testing (pIC<sub>50</sub> SEM typically <0.2; see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for more detail). Because of the irreversible nature of inhibition of the compounds employed in this study, IC<sub>50</sub> values are time dependent and are quoted as measured following an incubation period of 2 h. Double mutant (DM) cell line: H1975. Activating mutant exon 19 del (AM) cell line: PC9. Wild type (WT) cell line: LoVo.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Ligand lipophilicity efficiency (LLE) is calculated from DM cell pIC<sub>50</sub> – log <i>D</i><sub>7.4</sub>.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Aqueous solubility measurement was performed under thermodynamic conditions using solid material.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">MRC protein phosphorylation unit at the University of Dundee.<a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">(9a)</a></p></div></div></div><div class="NLM_p">During the course of these studies, we had also identified <b>9</b> and <b>10</b> as potent and selective mutant EGFR inhibitors, where the pendent basic center, normally resident on the terminal position of the acrylamide, had been migrated to the aryl ring adjacent to the amide functionality. Our interest was piqued by this architectural modification for a number of reasons, not least of which was the improved potency offered by <b>10</b> for no apparent increase in lipophilicity. In our previous work,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> we had encountered a log <i>D</i>/cell potency correlation whereby although cellular potency could be increased, it was generally accompanied by an increase in lipopilicity of the inhibitor compounds, and this tended to both increase their plasma protein binding and reduce their aqueous solubility. While compound <b>9</b> showed broadly similar double mutant potency to <b>5</b>, its reduced IGF1R activity and increased activating mutant activity again with no increase in lipophilicity were of great interest. Kinase selectivity for these inhibitors, as judged by profiling in a kinase selectivity screen (Dundee panel),<a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">(9a)</a> appeared acceptable with only a small number of significant hits (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Compound <b>10</b> appeared to offer superior selectivity for the mutant forms of the receptor, although it should be noted that <b>9</b>, as mentioned above, did carry significantly less activity against the methionine gatekeeper bearing receptor tyrosine kinase IGF1R. A lipophilic group at the pyrimidine 5-position appears to offer a potentially favorable interaction with the methionine in both IGF1R and the double mutant ATP binding sites, and we reasoned that kinetic selectivity might be achievable because of irreversible binding to the double mutant, whereas the IGF1R interaction would be reversible. While IGF1R inhibitors have been employed in a clinical setting, their lack of selectivity with respect to inhibition of insulin receptor signaling has in some instances led to dose limiting toxicity and monitoring these effects can complicate study designs.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> An additional driver for favoring <b>10</b> was that in contrast to <b>9</b>, it did offer modest exposure when dosed orally at 50 mg/kg in SCID mice. The aqueous solubility and hERG inhibition profile of <b>10</b> were also viewed as offering a good starting point, and we focused our initial efforts on further evolution of this lead.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">A body of work focused on preparing amides of the distal piperazine nitrogen of <b>10</b> was first instigated. By use of chemistry similar to that described above (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), fluoro intermediate <b>11</b><a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> was exposed to various piperazine amides bearing protected amino/hydroxyl groups. The nitro group was then reduced, and the resulting aniline was acylated with acryloyl chloride using the chemistry described previously. Protecting groups (either BOC or TBDMS) were then removed to afford the required compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0021.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Piperazine Amides <b>12</b>–<b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) piperazine amide, DIPEA, DMA, 140 °C (microwave); (ii) iron, NH<sub>4</sub>Cl, EtOH, water, 100 °C; (iii) acryloyl chloride, DIPEA, DCM, 0 °C; (iv) functional group deprotection if required; TFA, DCM, rt; or TBAF, THF, rt.</p></p></figure><div class="NLM_p">A variety of alternative diamine reagents were available in house, and guided by a calculated lipophilicity threshold (log <i>D</i> of no more than 3 to try and maintain good physicochemical properties), we targeted the examples shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. We employed our previously described chemistry to access these compounds, using late-stage fluoro intermediate <b>11</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Introduction of the amine side chain was achieved via S<sub>N</sub>Ar reaction; subsequent reduction of the nitro group and reaction with acryloyl chloride furnished the desired final compounds.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0022.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Basic Side Chain Compounds <b>20</b>, <b>21</b>, and <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) R<sub>1</sub>R<sub>2</sub>NH, DIPEA, DMA, 85–100 °C; (ii) iron, NH<sub>4</sub>Cl, EtOH, water, 100 °C; (iii) acryloyl chloride, DIPEA, DCM, −15 to 0 °C.</p></p></figure><div class="NLM_p">To access indole compounds <b>23</b>–<b>27</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>), commercial pyrimidines with R2 = H, Me and Cl were used. Introduction of the indole was achieved by deprotonation with methylmagnesium bromide (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) and subsequent S<sub>N</sub>AR in adequate yield. Where R1 = Me, deprotonation of the indole NH and methylation with methyl iodide proceeded in good yield. Introduction of the aniline side chain and further elaboration into the desired compounds were achieved in a similar manner to the compounds detailed in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div><div class="NLM_p">In the case where R2 was cyano, this group was introduced at the penultimate step (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Although isolated in modest yield, this approach yielded sufficient material to deliver the desired compound.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0023.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthesis of Indole Compounds <b>23</b>–<b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MeMgBr (1 equiv, 3.2 M in 2-methyl THF), indole (1 equiv), THF, 0 °C → 60 °C; (ii) sodium hydride (1.05 equiv), methyl iodide (1.05 equiv), THF, 0 °C; (iii) 4-fluoro-2-methoxy-5-nitroaniline (1.05 equiv), tosic acid (1.1 equiv), 2-pentanol, 125 °C; (iv) <i>N</i>,<i>N</i>,<i>N</i>′-trimethylethane-1,2-diamine (2.2 equiv), DMA, 140 °C; (v) iron (3 equiv), ammonium chloride (0.7 equiv), EtOH, water, 100 °C; (vi) Zn(CN)<sub>2</sub> (0.6 equiv), zinc (0.1 equiv), tris(dibenzylideneacetone)dipalladium(0) (0.1 equiv), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine (XPhos) (0.2 equiv), DMA, 95 °C; (vii) acryloyl chloride (1 M, THF, 1 equiv), DIPEA (1.1 equiv), THF, 0 °C.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and Selected Properties of Piperazine Amides <b>12</b>–<b>19</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0025.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0026.gif" alt="" id="fx3" /></img><div></div></div><div class="NLM_p">As can be seen from Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, it became apparent that while initial compounds such as <b>12</b> and <b>13</b> offered reasonable potency profiles, all subsequent attempts to achieve further improvements provided less potent analogs, particularly against the activating mutant cell line. The enantiomeric pair of compounds <b>14</b> and <b>15</b> showed virtually identical cellular inhibition profiles, whereas in contrast, the enantiomeric pair of <b>13</b> and <b>19</b> did appear to favor the <i>S-</i>enantiomer. Removal of a methyl group from <b>12</b> to give <b>16</b> slightly reduced activity, and replacement of the NH<sub>2</sub> group of <b>13</b> with a hydroxyl to give <b>17</b> again reduced activity. The urea analogue <b>18</b> also led to modest levels of activity in cells. We concluded (particularly in the light of the emerging data for the basic side chain anlaogues; vide infra) that amides such as these did not offer the levels of potency to justify additional investigation, and these compounds were not pursued further.</div><div class="NLM_p">A number of other carbon and oxygen linked basic side chains were also examined, but they offered little advantage in terms of potency, physical properties, or oral exposure when compared to the nitrogen linked systems described above. In contrast, the compounds where the piperazine group had been replaced with certain particular basic side chains produced a number of examples with exquisite cellular potency, in some cases being below 1 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Of particular interest was the observation that the increase in potency observed did not come with increasing lipophilicity (as also noted for <b>9</b> and <b>10</b>), and in contrast to the previously described series with the pendent base on the acrylamide, the log <i>D</i>/cell potency correlation appeared to be weaker. Intrigued by these findings, we elected to further profile a variety of the most potent examples from this set. As can be seen from Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, the compounds showed excellent cellular potency against both mutants in phosphorylation and phenotypic antiproliferation assays with selectivity over wild type EGFR, log <i>D</i> values of around 3, modest aqueous solubility in pH 7.4 buffer, and acceptable free fractions in rat and human plasma. Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> also highlights the observation that the compounds again showed moderate affinity for the hERG channel and potent IGF1R activity in a similar fashion to <b>9</b> and <b>10</b>. Nevertheless, additional profiling in a broad kinase selectivity panel (Dundee panel,<a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">(9a)</a> 1 μM) did show that the compounds possessed good overall kinase selectivity and had improved selectivity relative to <b>10</b> and <b>5</b>. We had previously<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> employed a glutathione (GSH) reaction assay to determine the relative reactivity of inhibitor compounds,<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11-14)</a> and the GSH reaction half-lives of these novel analogues fell within our earlier defined suitable “reactivity window”. Interestingly, a small dependence of GSH half-life on the p<i>K</i><sub>a</sub> of the basic group is seen, suggestive of intramolecular base catalysis. The intrinsic clearance of the compounds was relatively high, but encouraged by the overall profile of the series, we elected to investigate the exposure of the compounds when dosed orally in the SCID mouse. Compounds were prioritized for in vivo work based on cell potency, free fraction, and aqueous solubility.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures and Selected Properties of Compounds <b>20</b>, <b>21</b>, and <b>22</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0027.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>20</b></th><th class="colsep0 rowsep0" align="center"><b>21</b></th><th class="colsep0 rowsep0" align="center"><b>22</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AM cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">357</td><td class="colsep0 rowsep0" align="left">145</td><td class="colsep0 rowsep0" align="left">938</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">384</td><td class="colsep0 rowsep0" align="left">180</td><td class="colsep0 rowsep0" align="left">846</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LLE (DM cell)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">5.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">min sol. pH 7.4 (μM)</td><td class="colsep0 rowsep0" align="left">28 (Xtl)</td><td class="colsep0 rowsep0" align="left">222 (Xtl)</td><td class="colsep0 rowsep0" align="left">43 (Xtl)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat % free<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">5.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human % free</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nude mouse % free</td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup> cells)]</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup> cells)]</td><td class="colsep0 rowsep0" align="left"><3</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup> cells)]</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R (enz) IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">0.007</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">0.026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSH mean <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">257</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub> (measured)</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase panel<a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">(9a)</a> hits (>90% inhibition at 1 μM)</td><td class="colsep0 rowsep0" align="left">IGF1R (98%)</td><td class="colsep0 rowsep0" align="left">IGF1R (97%)</td><td class="colsep0 rowsep0" align="left">IGF1R (97%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">INSR (98%)</td><td class="colsep0 rowsep0" align="left">INSR (99%)</td><td class="colsep0 rowsep0" align="left">INSR (98%)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Double mutant (DM) cell line: H1975. Activating mutant (AM) cell line: PC9. Wild type (WT) cell line: Calu3.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Plasma protein binding was assessed by equilibrium dialysis in the appropriate species at 37 °C in 10% plasma and extrapolated to100% with a single site binding model. Free and bound concentrations were quantified by LCMS.</p></div></div></div><div class="NLM_p">We selected <b>20</b> as our initial compound to be administered (the opposite enantiomer of <b>20</b> showed 2- to 3-fold less potency in cells), and as in our previous work,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> we employed a 50 mg/kg once daily oral dose (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The compound was well tolerated at this dose, and excellent exposure was observed. As can be seen from Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, the plasma levels achieved were substantial and well in excess of the concentrations needed to achieve free cover over the cellular IC<sub>50</sub> values. As a consequence, for subsequent compounds in the series, we moved to 10 mg/kg as our initial dose. At this lower dose, multiples of free cover were still achieved for compounds <b>21</b> and <b>22</b> (although more modest in the latter, Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), and these inhibitors were selected for evaluation in a pharmacodynamic (PD) study.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mouse Plasma <i>C</i><sub>max</sub> Concentration Data after a 50 mg/kg Oral Dose of Compound <b>20</b> and a 10 mg/kg dose of <b>21</b> and <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center">free <i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center">free cover over DM cell IC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">free cover over AM cell IC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">free cover over WT cell IC<sub>50</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">0.40</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">0.025</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.065</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">0.06</td></tr></tbody></table></div></div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mouse plasma concentration data following a 50 mg/kg oral dose of compound <b>20</b>, a 10 mg/kg oral dose of compound <b>21</b>, and a 10 mg/kg oral dose of compound <b>22</b>. Data points shown are concentrations from individual animals with mean values being represented by lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A single dose of compounds <b>20</b>, <b>21</b>, and <b>22</b> were dosed orally in SCID mice at 10 mg/kg, and the percentage knockdown of EGFR phosphorylation in H1975 (double mutant) and PC9 (activating mutant) xenografts was measured compared to control (Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> and Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). All three compounds showed a profound effect on the PD biomarker. In the PC9 tumor cell line, <b>22</b> and <b>21</b> showed broadly similar effects with maximal inhibition (85% and 83% respectively) at the 6 h time point. Compound <b>20</b> showed slightly less biomarker modulation at this point, but in contrast to the other two compounds where p-EGFR levels began to return toward normal when measured at subsequent points, <b>20</b> continued to show sustained inhibition at the 24 h time point. In contrast, in the H1975 PD study, all three compounds showed sustained biomarker inhibition out to 24 h, although <b>21</b> now showed the most marked effect. By the 30 h time point, <b>22</b> inhibitory effects seemed to have been reduced whereas <b>21</b> still displayed a significant level of biomarker modulation. Given the clear evidence of in vivo effects on the target protein, the three compounds were selected for further evaluation in efficacy studies.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. % Inhibition of p-EGFR (Measured by R&D Systems ELISA Kits, Not Site Specific and Expressed as Ratio of Phosphorylated/Total) in Mice Bearing PC9 Tumors after 10 mg/kg Oral Dose of Compounds <b>20</b>, <b>21</b>, and <b>22</b><a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">1 h</th><th class="colsep0 rowsep0" align="center">6 h</th><th class="colsep0 rowsep0" align="center">16 h</th><th class="colsep0 rowsep0" align="center">24 h</th><th class="colsep0 rowsep0" align="center">30 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">76*</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">68*</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">83***</td><td class="colsep0 rowsep0" align="left">60**</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">57**</td><td class="colsep0 rowsep0" align="left">85**</td><td class="colsep0 rowsep0" align="left">52*</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>a</sup><p class="last">Statistical significance (<i>p</i> values) was calculated by comparing compound treated and vehicle groups using a two-tailed <i>t</i>-test, unequal variance. <i>p</i> values are indicated as follows: (∗) <0.05, (∗∗) <0.01, (∗∗∗) <0.001. See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for further detail.</p></div></div></div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. p-EGFR inhibition time course profile in PC9 (sensitizing mutant) xenograft bearing mice following 10 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. % Inhibition of p-EGFR in Mice Bearing H1975 Tumors after 10 mg/kg Oral Dose of Compounds <b>20</b>, <b>21</b>, and <b>22</b><a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">1 h</th><th class="colsep0 rowsep0" align="center">6 h</th><th class="colsep0 rowsep0" align="center">16 h</th><th class="colsep0 rowsep0" align="center">24 h</th><th class="colsep0 rowsep0" align="center">30 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">94***</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">88***</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">89***</td><td class="colsep0 rowsep0" align="left">100***</td><td class="colsep0 rowsep0" align="left">94**</td><td class="colsep0 rowsep0" align="left">93**</td><td class="colsep0 rowsep0" align="left">80***</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">99***</td><td class="colsep0 rowsep0" align="left">82***</td><td class="colsep0 rowsep0" align="left">79***</td><td class="colsep0 rowsep0" align="left">50**</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last"><i>p</i> values are indicated as follows: (∗) <0.05, (∗∗) <0.01, (∗∗∗) <0.001.</p></div></div></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. p-EGFR inhibition time course profile in H1975 (double mutant) xenograft bearing mice following 10 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For this work, in vivo xenograft models representing the drug-resistant double mutant (H1975), sensitizing mutant (PC9), and wild type (A431) were selected. Compounds were dosed orally once a day for 7 days (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo efficacy of <b>22</b>, <b>21</b>, and <b>20</b> when dosed orally in tumor bearing immune compromised mice at 10 mg kg<sup>–1</sup> day<sup>–1</sup> q.d. H1975 efficacy is represented in blue, with PC9 data in green and A431 in red. Statistical significance (<i>p</i> values) was calculated by comparing compound treated and vehicle groups using a one-tailed <i>t</i> test. “NS” indicates % TGI was not significant from vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From examination of Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, it can be seen that at 10 mg kg<sup>–1</sup> day<sup>–1</sup>, each of the compounds showed pronounced tumor growth inhibition in the two mutant models, with significant tumor regression being achieved in each case while having relatively little impact on the A431 wild type model. In addition, these data allowed us to build on the observation that approximately 6 h cover over the free cell IC<sub>50</sub> translated into both meaningful and prolonged in vivo PD biomarker modulation as well as substantial disease model efficacy (based on a range of additional compounds, data not shown).</div><div class="NLM_p">With these highly encouraging in vivo data in hand, we elected to more fully characterize the pharmacokinetic properties of these compounds in species other than mice, and this information is captured in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>. In vivo clearance in rodents was moderate to high, and at low doses (5 mg/kg) oral bioavailability was low. Upon increasing dose however (>50 mg/kg), substantial oral levels could be obtained, and we postulated that this was probably occurring because of saturation of clearance mechanisms. However, dog pharmacokinetic profiling revealed medium clearance and generally good oral bioavailability.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vivo Pharmacokinetic Parameters for <b>20</b>, <b>21</b>, and <b>22</b><a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>20</b></th><th class="colsep0 rowsep0" align="center"><b>21</b></th><th class="colsep0 rowsep0" align="center"><b>22</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a> iv CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat HW po <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse iv CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse po <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog iv CL<sub>p</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog po <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">56</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">Rat oral bioavailability is from a 5 mg/kg dose. Mouse oral bioavailability is from a 10 mg/kg dose. Dog oral bioavailability is from a 5 mg/kg dose.</p></div><div class="footnote" id="t7fn1"><sup>b</sup><p class="last">Han Wistar strain.</p></div></div></div><div class="NLM_p">Clearly the incorporation of the three basic side chains described above in <b>20</b>, <b>21</b>, and <b>22</b> combined with the migration of the base from the acrylamide had brought significant benefits relative to the start point <b>5</b>, and we proposed that this advance in SAR understanding might be applicable to some degree to the previously described indole analogues such as <b>9</b>. Although we had previously moved away from the indole headgroup because of its more modest oral PK properties (vide supra) and smaller wild type margin relative to the pyrazolopyridine,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> the enhanced potency available from this novel basic side chain SAR combined with the synthetic diversity handle offered by the indole N-H prompted us to re-examine this subseries. Thus, we decided to explore a matrix of compounds where we would incorporate favored groups at the 4 and 5 positions of the pyrimidine core with the newly identified basic side chain SAR (vide supra). Leading examples from this work are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>. It should be noted that in addition to varying R1 and R2 as depicted in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>, additional examples were also prepared where the basic side chain was replaced with amines such as those in <b>22</b> and <b>20</b>, but none of these offered the levels of potency afforded by the <i>N</i>,<i>N</i>,<i>N</i>′-trimethylethylenediamine.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Structure and Selected Data for Indole Compounds <b>23</b>–<b>27</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0028.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>23</b></th><th class="colsep0 rowsep0" align="center"><b>24</b></th><th class="colsep0 rowsep0" align="center"><b>25</b></th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th><th class="colsep0 rowsep0" align="center"><b>27</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R1/R2</td><td class="colsep0 rowsep0" align="left">Me/CN</td><td class="colsep0 rowsep0" align="left">Me/Cl</td><td class="colsep0 rowsep0" align="left">H/Cl</td><td class="colsep0 rowsep0" align="left">Me/Me</td><td class="colsep0 rowsep0" align="left">Me/H</td><td class="colsep0 rowsep0" align="left">H/H</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AM cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">480</td><td class="colsep0 rowsep0" align="left">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">2 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">4 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">2 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">4 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AM antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">0.8 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">3 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">2 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">2 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">101 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">192 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">144 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">970 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">264</td><td class="colsep0 rowsep0" align="left">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">38 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">40 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">7 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">196 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">2900</td><td class="colsep0 rowsep0" align="left">263</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">7.4</td><td class="colsep0 rowsep0" align="left">14.8</td><td class="colsep0 rowsep0" align="left">15.6</td><td class="colsep0 rowsep0" align="left">16.2</td><td class="colsep0 rowsep0" align="left">17.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">min sol. pH 7.4 (μM)</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="left">759</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">576</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat HW % free</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human % free</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">7.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse % free</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup>cells)]</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup> cells)]</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left"><3</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left"><3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat HW iv Cl (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat HW po <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse AUC/<i>C</i><sub>max</sub> (μM·h/μM), 10 mg/kg po</td><td class="colsep0 rowsep0" align="left">0.28/0.11</td><td class="colsep0 rowsep0" align="left">1.3/0.31</td><td class="colsep0 rowsep0" align="left">3.3/1.2</td><td class="colsep0 rowsep0" align="left">0/0</td><td class="colsep0 rowsep0" align="left">1.4/0.38</td><td class="colsep0 rowsep0" align="left">0.203/0.047</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSH mean <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">136</td><td class="colsep0 rowsep0" align="left">123</td><td class="colsep0 rowsep0" align="left">121</td><td class="colsep0 rowsep0" align="left">191</td></tr></tbody></table></div></div><div class="NLM_p">It can be seen that incorporation of the newly identified basic side chains delivered high cellular potency across all the examples shown (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). The presence or indeed absence of a substituent at the 5-position of the pyrimidine ring also had a differential effect on double mutant potency, IGF1R potency, and hERG binding.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pyrimidine 5-substituent analysis. N-H indoles appear in red, with N-Me indoles in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a> and the matched pair analysis in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, it is apparent that a 5-substituent has a beneficial impact on double mutant cell potency, possibly driven by interaction with the methionine gatekeeper residue, although in the case of the more polar cyano 5-substituent, the conformational effect on the indole group may also play a role. A similar trend is observed for IGF1R potency, again perhaps driven by this kinase’s methionine gatekeeper, although it should be noted that the potency increase imparted by the 5-Cl is of a greater magnitude for IGF1R than any of the EGFR mutants or wild type receptor. Potency against the activating mutant (data not shown) and wild type forms of the receptor was also increased, and the hERG potency for the compounds also followed a similar trend, although this is more difficult to rationalize. The presence or absence of a methyl group on the indole 1-position nitrogen also had interesting effects. Again, examination of Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a> and matched pair analysis shown in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a> reveals that the removal of the methyl group does appear to drive increased cell potency against all three EGF receptors (only double mutant shown graphically), with hERG potency having no discernible trend. The picture for IGF1R potency is more straightforward, with the NH indole analogues showing increased IGF1R potency. The SAR for wild type selectivity is also shown, with double mutant selectivity over wild type showing a statistically significant trend to be greater in the N-methylated compounds, whereas the N-Me indole examples when examined as a whole showed no statistically significant activating mutant selectivity over the wild type form of the receptor when compared with their NH matched pairs. When profiled in the Millipore kinase selectivity panel,<a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a> it became evident that for the two 5-H compounds tested, in addition to reducing IGF1R and INSR activity, we had also maintained the high selectivity of our above-described inhibitors.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Matched pair analyses for N-H-indole and N-Me examples. Each marker represents an individual compound matching the substructure shown. Lines connect exact structural matches (∗ = positions of variation). Top left mean pIC<sub>50</sub> difference is 0.61 (SE = 0.1, <i>n</i> = 11). Top right mean pIC<sub>50</sub> difference is 0.06 (SE = 0.078, <i>n</i> = 11). Middle left mean pIC<sub>50</sub> difference is 0.77 (SE = 0.09, <i>n</i> = 11). Middle right mean pIC<sub>50</sub> difference is 0.072 (SE = 0.02, <i>n</i> = 11). Bottom mean pIC<sub>50</sub> difference is 0.04 (SE = 0.02, <i>n</i> = 11).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">By examination of the data for this matrix of compounds in more detail, it can be seen that while very attractive, the profiles of most of the compounds were broadly similar to the earlier examples <b>20</b>, <b>21</b>, and <b>22</b> described above. Given the wealth of available attractive options, additional candidate compounds would need to offer something quite different from those already selected to proceed further. Compound <b>8</b> demonstrated improved rat PK, reduced hERG affinity, and improved IGF1R margins relative to the previously described compounds, and so this compound was selected for further investigation. Compound <b>8</b> also offered an additional degree of broader chemical and profile diversity when compared to the previously described lead compounds. Upon dosing <b>8</b> in our three efficacy models, we observed comparable efficacy at relatively low doses (10 mg kg<sup>–1</sup> day<sup>–1</sup>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). Intriguingly, excellent efficacy was also observed when <b>8</b> was dosed at 5 mg kg<sup>–1</sup> day<sup>–1</sup> and this unprecedented level of activity combined with its previously mentioned attractive attributes added to our interest in this compound, despite the slightly lower wild type selectivity relative to <b>20</b>, <b>21</b>, and <b>22</b>. Given our earlier free cover model, it seems difficult to explain how this level of efficacy could be achieved with the relatively modest exposure achieved with <b>8</b> (free <i>C</i><sub>max</sub> = 13 nM, 0.9-fold free cover over DM cell IC<sub>50</sub>), but further understanding did become apparent with additional studies (vide infra).</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo xenograft activity of <b>8</b> when dosed orally in tumor bearing immune compromised mice at 10 and 5 mg/kg q.d.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With a selection of potent, wild type selective and efficacious compounds in hand, we investigated the in vivo toxicological profile of the most favored examples. The in vitro kinase selectivity testing had revealed a desirable selectivity profile albeit with inhibition of IGF1R and INSR as common hits. With this observation in mind, we designed bespoke rat toxicology studies to explore whether reversible inhibition of IGF1R-INSR would lead to hyperglycemia or impaired insulin signaling in vivo. Rats received a single oral dose of 200 mg/kg of each compound with assessment of blood glucose and insulin concentrations over a 24 h period (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). While all compounds were tolerated well, a single oral dose of <b>21</b> and <b>20</b> led to marked hyperglycemia and hyperinsulinemia (Figures <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>). At the same dose, <b>22</b> did not cause significant changes in blood glucose levels, but insulin levels were clearly increased, consistent with insulin being a more sensitive marker for perturbation of the glucose/insulin axis. In contrast, <b>8</b> did not impact measured levels of glucose or insulin. This is consistent with the observation that <b>8</b> was the only compound out of the four leading candidates that did not inhibit IGF1R (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>) or INSR (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>) with high potency.</div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound effects of blood glucose levels in the rat following a single 200 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, <b>22</b>, and <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0012.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound effects of blood insulin levels in the rat following a single 200 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, <b>22</b>, and <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Assessment of the toxicokinetics of the four compounds at 200 mg/kg in this study revealed that the free exposure of <b>8</b> was lower than the other three compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). Compounds <b>20</b>, <b>21</b>, and <b>22</b> were subsequently administered orally at the lower dose of 50 mg/kg, and despite a similar free exposure to compound <b>8</b>, they were still associated with hyperinsulinemia. The observed hyperinsulinemia with <b>20</b>, <b>21</b>, and <b>22</b> at both doses tested was consistent with the free exposure (<i>C</i><sub>ave</sub>) giving cover over the INSR IC<sub>50</sub> (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). In contrast, compound <b>8</b> did not provide cover over the INSR IC<sub>50</sub>, and furthermore at a dose of 200 mg/kg the INSR IC<sub>50</sub> was approximately 50-fold higher than the free exposure (<i>C</i><sub>ave</sub>). For compound <b>8</b>, pharmacological cover over the INSR IC<sub>50</sub> and perturbation of the insulin–glucose axis was considered extremely unlikely.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Exposure, INSR Potency/Fold Cover, and Effects on Blood Insulin Levels in the Rat after a Single 200 or 50 mg/kg po Dose of Compounds <b>20</b>, <b>21</b>, <b>22</b> and a Single 200 mg/kg Dose of <b>8</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">free <i>C</i><sub>ave</sub> over 24 h</th><th class="colsep0 rowsep0" align="center">INSR IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">free fold cover over INSR IC<sub>50</sub></th><th class="colsep0 rowsep0" align="center">mean insulin increase over 24 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">0.0169</td><td class="colsep0 rowsep0" align="left">0.912</td><td class="colsep0 rowsep0" align="left">0.018</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">0.1101</td><td class="colsep0 rowsep0" align="left">0.021</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">30.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">0.0358</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">0.0575</td><td class="colsep0 rowsep0" align="left">0.009</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left">33.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">0.0277</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">9.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">0.102</td><td class="colsep0 rowsep0" align="left">0.035</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">9.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">3.3</td></tr></tbody></table></div></div><div class="NLM_p">Although IGF1R inhibitors have been studied clinically in an oncology setting, hyperglycemia can be dose limiting.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Inhibition of IGF1R and INSR signaling and its associated pharmacology had the potential to limit maximal tolerated doses in the NSCLC EGFR sensitive patient setting. Furthermore, it could affect patient exclusion criteria and require additional monitoring during clinical trials. In light of these findings it was decided to focus remaining efforts on <b>8</b> and <b>22</b> which had no or minimal effects on the IGF1R–INSR axis, respectively.</div><div class="NLM_p">We subsequently performed a preliminary cardiovascular safety evaluation of the final two lead compounds. The compounds were assessed in an in vivo guinea pig model<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> to explore the effect of the compounds on hemodynamic, ECG, and contractility paramaters. Comparison of the cardiovascular profile revealed a major difference in the compounds with respect to QT prolongation. In contrast to <b>8</b>, <b>22</b> was associated with a pronounced QT prolongation at free <i>C</i><sub>max</sub> concentrations less than 30-fold predicted human free <i>C</i><sub>max</sub>. These data were consistent with the in vitro data for both compounds with <b>22</b> clearly having a higher affinity for the hERG ion channel than <b>8</b> (Ionworks hERG IC<sub>50</sub> for <b>22</b> and <b>8</b> is 4.3 and 16.2 μM, respectively). In view of the data package as a whole, <b>8</b> was considered to have a very desirable profile and was ultimately selected as a clinical candidate. The selectivity profile of <b>8</b> as determined in the Millipore kinase panel<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> of 270 kinases is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a> (complete data are available in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), and it can be seen that the compound displays a good overall profile with the majority of more active hits being other tyrosine kinases. Compound <b>8</b> both exploits and illustrates the SAR we have discussed above. The addition of the methyl group to the indole increases WT selectivity and reduces IGF1R potency (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Removing the 5-Cl group from the monoanilinopyrimidine scaffold reduces the IGF1R potency, WT selectivity, and to a lesser extent DM potency, but the last can be recovered by employing the inherently more potent indole rather than pyrazolopyridine headgroup, and indole N–H alkylation can be used to drive WT selectivity.</div><figure id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0013.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Millipore kinase selectivity profile for compound <b>8</b>. Colors are indicative of % inhibition at 1 μM as follows: dark green, 0–20% of control; light green, 20–40% of control; yellow, 40–60% of control; orange, 60–80% of control; red, 80–100% of control. Full % inhibition data are listed in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> including IC<sub>50</sub> data for those kinases with an analogous cysteine to C797.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although we are yet to obtain an X-ray crystal structure of <b>8</b> bound to the EGFR T790M mutant, we were able to employ a published structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> to model the binding mode of the inhibitor, and this is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>. Notable features include the covalent bond formed to C797, the hinge interaction at M793, and the orientation of the indole.</div><figure id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0014.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Modeled binding mode of compound (<b>8</b>). See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for further details. Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having selected <b>8</b> for further development, we wished to further understand its metabolic fate in vivo. Previously, when looking at in vivo metabolism in rat bile samples, little had been evident apart from glutathione conjugation to the acrylamide portion of the molecule. In contrast, when in vivo plasma samples from rat and mouse were examined in more detail, it became evident that loss of the indole <i>N</i>-methyl group was occurring, leading to small quantities of the metabolite <b>27</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">014</a>). In addition, dealkylation was also seen to occur to a small extent in the <i>N</i>,<i>N</i>,<i>N</i>′-trimethylethylenediamine side chain of <b>8</b>, yielding <b>28</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">014</a>). A small amount of the side chain <i>N</i>-oxide was also evident at low levels.</div><figure id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0015.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Compound <b>8</b> and identified circulating metabolites <b>27</b> and <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Shown in Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a> are the total levels for <b>8</b>, <b>27</b>, and <b>28</b> over a 12 h period following a 25 mg/kg oral dose in the nude mouse. As can be seen from Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a>, <b>28</b> appeared to offer a broadly similar potency and selectivity profile to the parent compound. In contrast, we had previously prepared and profiled <b>27</b> (see Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>), but despite its impressive double and activating mutant potency, we had not progressed the compound further, partly because of its modest in vitro wild type margin. In addition, oral dosing in the mouse led to only modest levels of exposure and low levels of free cover over the cellular IC<sub>50</sub> values. Nevertheless, we were now faced with the intriguing prospect that a degree of the observed efficacy in vivo for <b>8</b> was actually driven by the metabolite <b>27</b>.</div><figure id="fig15" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0016.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Total levels for <b>8</b>, <b>27</b>, and <b>28</b> over a 12 h period following a 25 mg/kg oral dose in the nude mouse. The markers are mean values ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Compound <b>28</b> in Vitro Profile</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>28</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AM cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT cell IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">786</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DM antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AM antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT antiproliferative cell GI<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">537</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">1.6 (<i>n</i> = 1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">min sol. pH 7.4 (μM)</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat HW % free</td><td class="colsep0 rowsep0" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human % free</td><td class="colsep0 rowsep0" align="left">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse % free</td><td class="colsep0 rowsep0" align="left">1.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup> cells)]</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human Heps Cl<sub>int</sub> [(μL/min)/(10<sup>6</sup> cells)]</td><td class="colsep0 rowsep0" align="left"><3</td></tr></tbody></table></div></div><div class="NLM_p">While <b>27</b> is present at lower concentrations in vivo than <b>8</b>, its higher cellular potency and lower protein binding equate to broadly similar free cover in vivo. A number of experiments were undertaken to try and establish the in vivo efficacy of <b>8</b> in the absence of <b>27</b>. These included co-dosing mice with <b>8</b> and the pan cytochrome P-450 inhibitor benzotriazol-1-amine (ABT)<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> in an attempt to reduce oxidative metabolism of the indole <i>N</i>-methyl group to give <b>27</b>. In addition, we undertook the preparation of an isotopically labeled version of <b>8</b>, where the indole <i>N</i>-methyl group was replaced by the <sup>13</sup>CD<sub>3</sub> equivalent. Our hypothesis here was that the kinetic isotope effect<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> might slow the deuterium atom extraction process relative to the corresponding hydrogen atom reaction and thus suppress formation of <b>27</b>, but neither of these measures were able to prevent the in vivo formation of <b>27</b> to an extent that its contribution to efficacy could be ignored.</div><div class="NLM_p">In order to try and understand the implications of the presence of the metabolite <b>27</b> in vivo, we elected to dose <b>27</b> in all three of the previously described efficacy models. Examination of the outcome from these studies (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>) showed that while substantial double and activating mutant efficacy is apparent, the level of wild type efficacy was also significant, reflecting the narrower in vitro margin as predicted from the in vitro cellular potency. It is also noteworthy that in the case of <b>27</b>, only very modest cover over the free cell IC<sub>50</sub> is needed to achieve significant efficacy, in contrast to other compounds profiled in this way. This is also apparent for <b>8</b>, but the presence of <b>27</b> in vivo makes this observation simpler to rationalize.</div><figure id="fig16" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0017.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. In vivo efficacy profiles (% tumor growth inhibition) of <b>8</b>, <b>27</b>, afatinib (<b>4</b>), and gefitinib (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Comparison of the efficacy profiles between the two compounds revealed significant differences, and while it is likely that <b>27</b> contributes to the observed in vivo efficacy of <b>8</b>, it does not appear to be the sole driver. It is apparent from Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a> that the efficacy profiles of <b>8</b> and <b>27</b> are quite different from both the reversible inhibitor gefitinib (<b>1</b>) and the irreversible compound afatinib (<b>4</b>) and that mutant selective inhibitors <b>8</b> and <b>27</b> offer a superior efficacy profile than these earlier agents. Clearly, the extent of formation of <b>27</b> in human patients would be a pivotal piece of information, as while its absence could possibly compromise the efficacy of the agent, more substantial levels could potentially lead to diminished margins to EGFRi driven wild type toxicity. Predicting an efficacious dose in patients for this agent presented challenges in terms of the irreversible inhibition mode of action, but the contribution of the metabolite to PD and efficacy also complicated the picture. The full details of these studies will be reported elsewhere, but basing human PK estimations on a metabolite <b>27</b> formation rate of 25% of parent (formation of <b>28</b> could not be quantified in vitro), the predicted efficacious dose in patients based on data from the PC9 model was approximately 20 and 10 mg based on the H1975 model.</div><div class="NLM_p">In silico modeling of human absorption<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> showed that <b>8</b> should not be solubility limited at clinically relevant doses with Fabs > 50% up to 330 mg. Although the free base properties of <b>8</b> were considered to offer a low biopharmaceutical risk, the mesylate salt was selected for further work because of manufacturing risks around the physical form of the free base. In vivo studies established that the pharmacokinetics of <b>8</b> mesylate were largely comparable to those of the free base.</div><div class="NLM_p">The mesylate salt of <b>8</b> was first dosed in March 2013 to patients with EGFRm+ advanced NSCLC who had disease progression following treatment with an EGFR TKI (including <b>1</b> or <b>2</b>). On the basis of the work described above, the initial dose selected for oral administration to patients was set at 20 mg, once a day. Pharmacokinetic data from this cohort of six patients are shown below.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> It can be seen that after a single dose, 7-day washout, and then 8 days of once daily dosing, exposure to <b>8</b>, <b>27</b>, and <b>28</b> was observed (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>). It is also evident that the formation rate of the <b>27</b> metabolite is largely consistent with the predicted levels and that interpatient variability is low. Clearly these data discharge to some extent the above-mentioned potential risks around the presence or absence of <b>27</b>.</div><figure id="fig17" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0018.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Preliminary plasma concentration versus time plots (mean + SD) of <b>8</b>, <b>27</b>, and <b>28</b> after 8 days of once daily 20 mg oral doses of <b>8</b> to patients with advanced EGFRm+ NSCLC in AURA phase 1 study (NCT01802632) (<i>n</i> = 6). Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Clinical testing with <b>8</b> is ongoing, with encouraging initial efficacy seen in NSCLC patients. Data from two patients have recently been reported<a onclick="showRef(event, 'cit21b ref22'); return false;" href="javascript:void(0);" class="ref cit21b ref22">(21b, 22)</a> and are discussed here. Serial CT scans from two patients who received <b>8</b> at a 20 mg once daily dose are shown (Figures <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">018</a> and <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">019</a>). Prior to commencing dosing, both patients’ tumors were known to exhibit T790M mutations according to local testing, as well as EGFR sensitizing mutations. The first patient was a 57 year old East Asian female from South Korea diagnosed with stage IV EGFR mutant (ex 19 del) NSCLC in May 2011. Tumor shrinkage on treatment with <b>8</b> was 39.7% at RECIST 1.1 (response evaluation criteria in solid tumors)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> scan 1, was 48.3% by scan 2 (Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">018</a>), remained at 48.3% at both scan 3 and scan 4, and was 51.7% at scan 5 (data not shown).</div><figure id="fig18" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0019.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Serial computed tomography scans of the chest from patients before and after treatment with <b>8</b> in a phase I trial: images from a 57-year old Korean female patient diagnosed with stage IV non-small-cell lung cancer in May 2011. Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second subject<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a> was a 57 year old white female from the United Kingdom, diagnosed with stage IV lung adenocarcinoma in December 2010. At the cycle 1 day 15 assessments on <b>8</b>, the patient reported full resolution of pre-existing persistent nocturnal cough. Tumor shrinkage was 38% at RECIST 1.1 scan 1, 39.3% by scan 2, 56.7% by scan 3 (Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">019</a>), 62% by scan 4, and 59.3% by scan 5 (data not shown). By cycle 7 day 1, the patient reported significant improvement in pre-existing hair and eyelash abnormalities which had developed during the immediately prior gefitinib therapy. Both patients had a duration of response of approximately 9 months and were progression-free on 20 mg/day of compound <b>8</b> mesylate salt for approximately 11 months until disease progression by RECIST 1.1. Both patients continue to receive compound <b>8</b> treatment on study as per protocol, as they continue to derive clinical benefit according to their treating physicians. Consistent with <b>8</b> being less active against wild-type EGFR, in these two cases there were no rash events and only one reported CTCAE (common terminology criteria for adverse events)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> grade 1 diarrhea. No significant aberration of blood glucose levels were noted in either patient during the study.</div><figure id="fig19" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0020.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Serial computed tomography scans of the chest from patients before and after treatment with <b>8</b> in a phase I trial: images from a 57-year old British female never smoker diagnosed with stage IV lung adenocarcinoma in December 2010. Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described herein the evolution of a chemical series from lead selection to candidate nomination and the initial clinical findings with this novel agent. During the course of this work, a number of key challenges were addressed including off-target kinase selectivity and cardiovascular safety. Compound <b>8</b> offers a number of advantages over earlier EGFR TKI agents including high cellular potency, superior efficacy in relevant disease models, and selectivity over the wild type form of the receptor. The promising data package for <b>8</b> strongly supported its selection as a clinical candidate, and first dose in patients was achieved in March 2013. To date, encouraging and reproducible drug exposure has been achieved in humans, and of particular significance is the early evidence of tumor responses in patients who had previously progressed on earlier treatments, accompanied by good tolerability.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Additional safety, pharmacokinetic, and clinical data for <b>8</b> will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General</h3><div class="NLM_p last">All solvents and chemical used were reagent grade. Purity and characterization of compounds were established by a combination of LCMS and NMR. LCMS spectra were obtained using a Waters liquid chromatography mass spectrometry system, where purity was determined by UV absorption at a wavelength of 254 nm, and the mass ion was determined by electrospray ionization (Micromass instrument). All test compounds were >95% pure as assessed by LCMS and <sup>1</sup>H NMR. <sup>1</sup>H NMR spectra were recorded using a Bruker Avance 400 FT spectrometer or via flow NMR process using an AVANCE 500 FT spectrometer and using DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> with the data expressed as chemical shifts in ppm from internal standard TMS. Preparative HPLC was performed on a Waters or Phenomenex column using decreasingly polar mixtures of water (containing 1% formic acid or 1% aqueous NH<sub>4</sub>OH) and MeCN. Purification by column chromatography (FCC) was typically performed using silica gel (Merck 7734 grade), and solvent mixtures and gradients are recorded herein. Water present in compounds was quantified by Karl Fischer analysis. All reactions were performed under nitrogen unless otherwise stated. All IC<sub>50</sub> data are quoted as geometric mean values, and statistical analysis is availble in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of Representative Key Examples (Compounds <b>20</b>, <b>21</b>, <b>22</b>, and <b>8</b>). <i>N</i>-[5-[(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide (<b>20</b>)</h3><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 5-Chloro-<i>N</i>-[4-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-2-methoxy-5-nitrophenyl]-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0032.gif" alt="" id="GRAPHIC-d1307e3775-autogenerated" /></img><div class="NLM_p last">(<i>R</i>)-(+)-3-(Dimethylamino)pyrrolidine dihydrochloride (90 mg, 0.48 mmol) was added to a suspension of 5-chloro-<i>N</i>-(4-fluoro-2-methoxy-5-nitrophenyl)-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (<b>11</b>, 200 mg, 0.48 mmol) and DIPEA (0.250 mL, 1.45 mmol) in DMA (3 mL). The mixture was heated at 140 °C in a microwave for 0.5 h. The mixture was diluted with MeOH and absorbed onto an SCX column, washed with MeOH, and eluted with 1:1 DCM/NH<sub>3</sub> in MeOH. Product-containing fractions were concentrated. The crude product was purified by flash silica chromatography, eluting with 1.5% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford 5-chloro-<i>N</i>-[4-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-2-methoxy-5-nitrophenyl]-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine (149 mg, 61%) as an orange foam. <sup>1</sup>H NMR (400 MHz, DMSO, 21 °C) δ 1.76–1.89 (1H, m), 2.14–2.25 (7H, m), 2.69–2.84 (1H, m), 3.12–3.27 (3H, m), 3.41–3.53 (1H, m), 3.89 (3H, s), 6.56 (1H, s), 7.13 (1H, td), 7.26–7.38 (1H, m), 8.06 (1H, s), 8.40–8.43 (2H, m), 8.73 (1H, s), 8.85 (1H, d), 8.95 (1H, s); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 509.5.</div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-4-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-6-methoxybenzene-1,3-diamine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0033.gif" alt="" id="GRAPHIC-d1307e3832-autogenerated" /></img><div class="NLM_p last">5-Chloro-<i>N</i>-[4-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-2-methoxy-5-nitrophenyl]-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine (145 mg, 0.28 mmol), iron (95 mg, 1.71 mmol), and ammonium chloride (11.43 mg, 0.21 mmol) were heated in ethanol (6 mL) and water (2 mL) at reflux for 1.5 h. The mixture was cooled and concentrated. The residue was triturated in 10% MeOH/DCM (15 mL) for 15 min and filtered. The residues were retriturated with 10% MeOH/DCM (15 mL) and filtered. The combined filtrates were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was purified by flash silica chromatography, eluting with 2% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford <i>N</i>-(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-4-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-6-methoxybenzene-1,3-diamine (112 mg, 82%) as a yellow gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 21 °C) δ 1.83–1.96 (1H, m), 2.08–2.23 (1H, m), 2.30 (6H, s), 2.82–2.92 (1H, m), 2.99–3.13 (2H, m), 3.17–3.28 (2H, m), 3.65 (2H, s), 3.84 (3H, s), 6.72 (1H, s), 6.96 (1H, td), 7.38 (1H, ddd), 7.52 (1H, s), 7.90 (1H, s), 8.36 (1H, s), 8.55–8.60 (1H, m), 8.65 (1H, dd), 8.94 (1H, s); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 479.5.</div></div><div id="sec4_2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N-</i>[5-[(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0034.gif" alt="" id="GRAPHIC-d1307e3890-autogenerated" /></img><div class="NLM_p last">Acryloyl chloride (0.042 mL, 0.51 mmol) in DCM (1 mL) was added dropwise to <i>N-</i>(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-4-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-6-methoxybenzene-1,3-diamine (245 mg, 0.51 mmol) and DIPEA (0.097 mL, 0.56 mmol) in DCM (10 mL), cooled in an ice/water bath. The mixture was stirred for 2 h and then washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was purified by flash silica chromatography, eluting with 2% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to give a foam. This was triturated with DCM/Et<sub>2</sub>O and concentrated. The solid was triturated with Et<sub>2</sub>O and filtered to afford <i>N-</i>[5-[(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-[(3<i>R</i>)-3-dimethylaminopyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide (157 mg, 58%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO, 22 °C) δ 1.68–1.83 (1H, m), 2.05–2.16 (1H, m), 2.18 (6H, s), 2.64–2.76 (1H, m), 3.18–3.29 (3H, m), 3.36–3.47 (1H, m), 3.77 (3H, s), 5.67 (1H, dd), 6.16 (1H, dd), 6.48 (1H, dd), 6.54 (1H, s), 7.12 (1H, t), 7.37 (1H, t), 7.43 (1H, s), 8.28–8.46 (2H, m), 8.55 (1H, s), 8.83 (1H, d), 8.94 (1H, s), 9.37 (1H, s); <sup>13</sup>C NMR (176 MHz, DMSO, 22 °C) δ 29.4, 43.8, 49.2, 54.8, 55.6, 65.1, 99.3, 107.1, 113.8, 114.2, 117.7, 119.0, 120.6, 125.5, 125.7, 126.9, 129.3, 131.9, 139.3, 142.8, 143.2, 151.5, 155.4, 157.8, 159.4. CHN analysis, C<sub>27</sub>H<sub>29</sub>O<sub>2</sub>N<sub>8</sub>Cl requires C = 60.84%, H = 5.48%, N = 21.02%. Found: C = 60.7%, H = 5.6%, N = 21.0%. <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 533.5. HRMS: (M + H)<sup>+</sup> = C<sub>27</sub>H<sub>30</sub>O<sub>2</sub>N<sub>8</sub>Cl = 533.21747, found 533.21747.</div></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N-</i>[5-[(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-(2-dimethylaminoethylmethylamino)-4-methoxyphenyl]prop-2-enamide (<b>21</b>)</h3><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N-</i>(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-<i>N</i>′-(2-dimethylaminoethyl)-2-methoxy-<i>N</i>′-methyl-5-nitrobenzene-1,4-diamine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0035.gif" alt="" id="GRAPHIC-d1307e3997-autogenerated" /></img><div class="NLM_p last"><i>N</i>,<i>N</i>,<i>N</i>′-Trimethylethylenediamine (0.188 mL, 1.45 mmol) was added to a suspension of 5-chloro-<i>N-</i>(4-fluoro-2-methoxy-5-nitrophenyl)-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine (<b>11</b>, 500 mg, 1.21 mmol) and <i>N</i>-ethyldiisopropylamine (0.250 mL, 1.45 mmol) in DMA (5 mL). The mixture was heated at 140 °C in a microwave for 30 min. The mixture was diluted with MeOH and absorbed onto an SCX column, washed with MeOH, and eluted with 1:1 DCM/NH<sub>3</sub> in MeOH. Product containing fractions were evaporated to dryness to afford <i>N-</i>(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-<i>N</i>′-(2-dimethylaminoethyl)-2-methoxy-<i>N</i>′-methyl-5-nitrobenzene-1,4-diamine (624 mg, 104%) as an orange solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 2.17 (6H, d), 2.89 (3H, d), 3.87–3.93 (3H, m), 6.84 (1H, s), 7.14 (1H, td), 7.31–7.38 (1H, m), 8.15 (1H, s), 8.39 (1H, d), 8.44 (1H, d), 8.69 (1H, s), 8.85 (1H, d), 8.95 (1H, s); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 497.</div></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>4-(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-<i>N</i>1-(2-dimethylaminoethyl)-5-methoxy-<i>N</i>1-methylbenzene-1,2,4-triamine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0036.gif" alt="" id="GRAPHIC-d1307e4063-autogenerated" /></img><div class="NLM_p last">A solution of ammonium chloride (45.2 mg, 0.85 mmol) in water (10 mL) was added in one portion to a stirred mixture of <i>N-</i>(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-<i>N</i>′-(2-dimethylaminoethyl)-2-methoxy-<i>N</i>′-methyl-5-nitrobenzene-1,4-diamine (600 mg, 1.21 mmol) and iron (405 mg, 7.24 mmol) in ethanol (30 mL). The resulting mixture was stirred at 105 °C for 3 h. The mixture was evaporated to dryness and the residue triturated with DMF (10 mL). The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 0.35 M NH<sub>3</sub>/MeOH/DCM, and pure fractions were evaporated to dryness to afford <i>N</i>4-(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-<i>N</i>1-(2-dimethylaminoethyl)-5-methoxy-<i>N</i>1-methylbenzene-1,2,4-triamine (530 mg, 94%) as a brown gum. <sup>1</sup>H NMR (400 MHz, DMSO, 22 °C) δ 2.16 (6H, d), 2.38 (2H, t), 2.66 (3H, d), 2.92 (2H, t), 3.66 (3H, s), 4.60 (2H, s), 6.78 (1H, s), 6.92 (1H, s), 7.12 (1H, t), 7.27–7.4 (1H, m), 8.38 (1H, s), 8.43 (1H, d), 8.49 (1H, s), 8.83 (1H, d), 8.95 (1H, s); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 467.</div></div><div id="sec4_2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N-</i>[5-[(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-(2-dimethylaminoethylmethylamino)-4-methoxyphenyl]prop-2-enamide</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0037.gif" alt="" id="GRAPHIC-d1307e4115-autogenerated" /></img><div class="NLM_p last">Acryloyl chloride (1.248 mL, 1M, THF, 1.25 mmol) was added dropwise to <i>N</i>4-(5-chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-yl)-<i>N</i>1-(2-(dimethylamino)ethyl)-5-methoxy-<i>N</i>1-methylbenzene-1,2,4-triamine (530 mg, 1.13 mmol) and DIPEA (0.244 mL, 1.36 mmol) in THF (20 mL) cooled to 0 °C. The resulting mixture was stirred at 0 °C for 2 h. The reaction mixture was evaporated to dryness and redissolved in DCM (100 mL) and washed sequentially with saturated NaHCO<sub>3</sub> (25 mL), water (25 mL), and saturated brine (25 mL). The organic layer was evaporated to afford crude product. The crude product was purified by flash silica chromatography, with elution gradient 0–20% 2 M NH<sub>3</sub>/methanol in DCM. This gave product still containing impurities. The crude product was purified by flash silica chromatography, with elution gradient 0–20% MeOH in DCM. Pure fractions were evaporated to dryness to afford a brown gum. Again this showed impurities by LCMS. The crude product was purified by flash silica chromatography, with elution gradient 0–20% MeOH in DCM to yield <i>N-</i>[5-[(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-(2-dimethylaminoethylmethylamino)-4-methoxyphenyl]prop-2-enamide (191 mg, 32%) as a brown gum. Lyophilization from MeOH/water gave a brown semisolid. Trituration of the semisolid with ether followed by evaporation of the ether gave <i>N-</i>[5-[(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-(2-dimethylaminoethylmethylamino)-4-methoxyphenyl]prop-2-enamide (191 mg, 32%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 22 °C) δ 2.28 (6H, s), 2.32 (2H, t), 2.71 (3H, s), 2.84–2.92 (2H, m), 3.87 (3H, s), 5.67 (1H, dd), 6.29 (1H, dd), 6.37 (1H, dd), 6.80 (1H, s), 6.89 (1H, td), 7.23–7.33 (1H, m), 7.46 (1H, s), 8.45 (1H, s), 8.52 (1H, d), 8.56 (1H, d), 8.94 (1H, s), 9.39 (1H, s), 10.09 (1H, s); <sup>13</sup>C NMR (176 MHz, DMSO, 22 °C) δ 29.4, 41.8, 44.9, 45.0, 55.7, 56.7, 105.8, 106.9, 113.8, 114.3, 117.7, 120.3, 124.0, 126.2, 127.1, 129.0, 132.0, 139.0, 140.0, 143.0, 148.9, 155.3, 157.5, 158.9. CHN analysis, C<sub>26</sub>H<sub>29</sub> N<sub>8</sub>O<sub>2</sub>Cl requires C = 59.94%, H = 5.61%, N = 21.51%. Found: C = 60.2%, H = 5.7%, N = 21.7%; <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 521.29; HRMS: (M + H)<sup>+</sup> = C<sub>26</sub>H<sub>30</sub> N<sub>8</sub>O<sub>2</sub>Cl = 521.217 47, found 521.217 59.</div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N-</i>[5-[(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-(3-dimethylaminoazetidin-1-yl)-4-methoxyphenyl]prop-2-enamide (<b>22</b>)</h3><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 5-Chloro-<i>N-</i>[4-(3-dimethylaminoazetidin-1-yl)-2-methoxy-5-nitrophenyl]-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0038.gif" alt="" id="GRAPHIC-d1307e4217-autogenerated" /></img><div class="NLM_p">DIPEA (0.341 mL, 1.96 mmol) was added to a mixture of 5-chloro-<i>N-</i>(4-fluoro-2-methoxy-5-nitrophenyl)-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-amine (<b>11</b>, 254 mg, 0.61 mmol) and <i>N</i>,<i>N</i>-dimethylazetidin-3-amine dihydrochloride (106 mg, 0.61 mmol) in DMA (4 mL). The mixture was heated at 100 °C for 30 min. The reaction was incomplete and further <i>N</i>,<i>N</i>-dimethylazetidin-3-amine (35 mg, 0.19 mmol) was added. The mixture was stirred at 100 °C for a further 2 h and then sat at room temperature overnight.</div><div class="NLM_p last">The reaction mixture was purified directly by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7 M NH<sub>3</sub>/MeOH and evaporated onto silica for purification by flash silica chromatography. The crude product was purified by flash silica chromatography, with elution gradient 0–4% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford 5-chloro-<i>N-</i>[4-(3-dimethylaminoazetidin-1-yl)-2-methoxy-5-nitrophenyl]-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine (310 mg, 102%) as an orange solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 2.14 (6H, s), 3.08–3.18 (1H, m), 3.76 (2H, dd), 3.89 (3H, s), 4.02–4.11 (2H, m), 6.28 (1H, s), 7.12 (1H, td), 7.3–7.39 (1H, m), 8.12 (1H, s), 8.37 (1H, br s), 8.42 (1H, s), 8.68 (1H, s), 8.83 (1H, d), 8.94 (1H, d); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 495.56.</div></div><div id="sec4_2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N-</i>(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-4-(3-dimethylaminoazetidin-1-yl)-6-methoxybenzene-1,3-diamine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0039.gif" alt="" id="GRAPHIC-d1307e4277-autogenerated" /></img><div class="NLM_p last">5-Chloro-<i>N-</i>[4-(3-dimethylaminoazetidin-1-yl)-2-methoxy-5-nitrophenyl]-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-amine (265 mg, 0.54 mmol), iron (179 mg, 3.21 mmol), and ammonium chloride (20.05 mg, 0.37 mmol) were heated in ethanol (6 mL) and water (2 mL) at reflux for 1 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7 M NH<sub>3</sub>/MeOH and evaporated to dryness. Analysis showed clean product, <i>N-</i>(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-4-(3-dimethylaminoazetidin-1-yl)-6-methoxybenzene-1,3-diamine (235 mg, 94%) as a yellow solid which was used directly with no further purification. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 2.13 (6H, s), 3.07 (1H, s), 3.50 (2H, t), 3.66 (3H, s), 4.00 (3H, t), 4.05 (2H, s), 6.28 (1H, s), 6.79 (1H, s), 7.10 (1H, t), 7.3–7.39 (1H, m), 8.33 (1H, s), 8.37 (1H, s), 8.80 (1H, d), 8.93 (1H, s); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 465.25.</div></div><div id="sec4_2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N-</i>[5-[(5-Chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-(3-dimethylaminoazetidin-1-yl)-4-methoxyphenyl]prop-2-enamide</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0040.gif" alt="" id="GRAPHIC-d1307e4316-autogenerated" /></img><div class="NLM_p last">Acryloyl chloride (0.038 mL, 0.47 mmol) in DCM (1 mL) was added dropwise to a stirred solution of <i>N-</i>(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)-4-(3-dimethylaminoazetidin-1-yl)-6-methoxybenzene-1,3-diamine (220 mg, 0.47 mmol) and DIPEA (0.090 mL, 0.52 mmol) in DCM (5 mL), cooled in an ice/water bath. The mixture was stirred for 3 h and then washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was purified by flash silica chromatography, eluting with 0–5% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford <i>N-</i>[5-[(5-chloro-4-pyrazolo[1,5-<i>a</i>]pyridin-3-ylpyrimidin-2-yl)amino]-2-(3-dimethylaminoazetidin-1-yl)-4-methoxyphenyl]prop-2-enamide (221 mg, 90%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 2.09 (6H, s), 3.08 (1H, p), 3.55–3.62 (2H, m), 3.76 (3H, s), 3.97 (2H, t), 5.66 (1H, dd), 6.16 (1H, dd), 6.25 (1H, s), 6.45 (1H, dd), 7.10 (1H, dd), 7.35 (1H, s), 7.39 (1H, dd), 8.25–8.4 (1H, m), 8.35 (1H, s), 8.45 (1H, s), 8.81 (1H, d), 8.92 (1H, s), 9.24 (1H, s); <sup>13</sup>C NMR (176 MHz, DMSO, 22 °C) δ 41.1, 55.5, 55.5, 56.9, 56.9, 97.2, 106.9, 113.8, 113.8, 115.8, 118.5, 120.2, 124.9, 125.1, 126.5, 128.9, 131.7, 139.1, 142.8, 144.4, 151.4, 155.2, 157.4, 159.2, 163.5. CHN analysis, C<sub>26</sub>H<sub>27</sub>ClN<sub>8</sub>O<sub>2</sub> requires C = 60.17%, H = 5.24%, N = 21.59%. Found: C = 60.3%, H = 5.3%, N = 21.7%. <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 519.56. HRMS: (M + H)<sup>+</sup> = C<sub>26</sub>H<sub>28</sub> N<sub>8</sub>O<sub>2</sub>Cl = 519.201 82, found 519.201 90.</div></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N-</i>[2-(2-Dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide (<b>8</b>)</h3><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-(2-Chloropyrimidin-4-yl)-1<i>H</i>-indole</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0041.gif" alt="" id="GRAPHIC-d1307e4399-autogenerated" /></img><div class="NLM_p last">Methylmagnesium bromide (3 M in diethyl ether) (22.68 mL, 68.03 mmol) was added dropwise over a period of 10 min to a stirred solution of 1<i>H</i>-indole (7.97 g, 68.03 mmol) in 1,2-dichloroethane (250 mL) at 0 °C under nitrogen. The resulting solution was stirred for 15 min. 2,4-Dichloropyrimidine (15 g, 100.69 mmol) was added in one portion. The resulting solution was allowed to warm to ambient temperature and stirred for 16 h. The reaction was quenched by the addition of MeOH (25 mL). The mixture was evaporated to dryness, absorbed onto silica, and purified by flash silica chromatography, with elution gradient 0–20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 3-(2-chloropyrimidin-4-yl)-1<i>H</i>-indole (7.17 g, 46%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 7.2–7.28 (2H, m), 7.49–7.53 (1H, m), 7.91 (1H, d), 8.42 (1H, dd), 8.50 (1H, d), 8.53 (1H, d), 12.06 (1H, s); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 230.</div></div><div id="sec4_2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(2-Chloropyrimidin-4-yl)-1-methylindole</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0043.gif" alt="" id="GRAPHIC-d1307e4424-autogenerated" /></img><div class="NLM_p last">Sodium hydride (1.707 g, 42.68 mmol) was added portionwise to 3-(2-chloropyrimidin-4-yl)-1<i>H</i>-indole (8.1684 g, 35.57 mmol) in THF (250 mL) cooled to 0 °C. The resulting mixture was stirred at 0 °C for 30 min before iodomethane (2.67 mL, 42.68 mmol) was added. The mixture was stirred at 0 °C for 3 h. The reaction was quenched by the addition of saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The reaction mixture was diluted with EtOAc (100 mL) and washed sequentially with saturated NaHCO<sub>3</sub> (50 mL), water (50 mL), and saturated brine (50 mL). The organic layer was evaporated to afford crude product. The crude product was purified by flash silica chromatography, with elution gradient 0–20% MeOH in DCM. Pure fractions were evaporated to dryness to afford 3-(2-chloropyrimidin-4-yl)-1-methylindole (8.35 g, 96%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 3.90 (3H, s), 7.30 (2H, pd), 7.54–7.6 (1H, m), 7.82 (1H, d), 8.38–8.44 (1H, m), 8.49 (1H, s), 8.53 (1H, d); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 244.</div></div><div id="sec4_2_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Alternative Synthesis of 3-(2-Chloropyrimidin-4-yl)-1-methylindole</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0044.gif" alt="" id="GRAPHIC-d1307e4452-autogenerated" /></img><div class="NLM_p">A suspension of 2,4-dichloropyrimidine (0.5 g, 3.36 mmol) and aluminum chloride (0.183 mL, 3.36 mmol) in DME (5 mL) was stirred at ambient temperature for 5 min. To this was added 1-methylindole (0.429 mL, 3.36 mmol), and the mixture was heated to 80 °C for 2 h.</div><div class="NLM_p">The cool reaction mixture was added dropwise to vigorously stirring water (50 mL) over 5 min. Upon complete addition the mixture was stirred for 30 min, filtered and the solid washed with water (50 mL).</div><div class="NLM_p last">The crude product was purified by flash silica chromatography, eluting with DCM. Pure fractions were evaporated to dryness to afford 3-(2-chloropyrimidin-4-yl)-1-methylindole (0.515 g, 63%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 3.96 (3H, s), 7.36 (2H, dqd), 7.64 (1H, dd), 7.88 (1H, d), 8.45–8.5 (1H, m), 8.56 (1H, s), 8.59 (1H, d); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 244.54.</div></div><div id="sec4_2_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0045.gif" alt="" id="GRAPHIC-d1307e4476-autogenerated" /></img><div class="NLM_p last">4-Methylbenzenesulfonic acid hydrate (22.73 g, 119.50 mmol) was added in one portion to 3-(2-chloropyrimidin-4-yl)-1-methylindole (24.2679 g, 99.58 mmol) and 4-fluoro-2-methoxy-5-nitroaniline<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (18.54 g, 99.58 mmol) in 2-pentanol (500 mL). The resulting mixture was stirred at 105 °C for 2.5 h. The mixture was cooled to room temperature. The precipitate was collected by filtration, washed with 2-pentanol (50 mL), and dried under vacuum to afford <i>N-</i>(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine as a yellow solid. The filtrate was cooled, and the precipitate was collected by filtration and washed with 2-pentanol (10 mL). The two crops were combined and triturated with MeCN to give a solid which was collected by filtration and dried under vacuum to give <i>N-</i>(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine (37.4 g, 95%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO, 30 °C) δ 3.92 (3H, s), 4.01 (3H, s), 7.13 (1H, dd), 7.27–7.36 (1H, m), 7.4–7.51 (2H, m), 7.59 (1H, d), 8.26 (1H, t), 8.35 (1H, d), 8.61 (1H, s), 8.85 (1H, d), 9.46 (1H, s); <i>m</i>/<i>z</i> (ES−) M<sup>–</sup> = 392.</div></div><div id="sec4_2_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>′-(2-Dimethylaminoethyl)-2-methoxy-<i>N</i>′-methyl-<i>N-</i>[4-(1-methylindol-3-yl)pyrimidin-2-yl]-5-nitrobenzene-1,4-diamine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0046.gif" alt="" id="GRAPHIC-d1307e4511-autogenerated" /></img><div class="NLM_p"><i>N</i>1,<i>N</i>1,<i>N</i>2-Trimethylethane-1,2-diamine (80 mg, 0.79 mmol) was added to a suspension of <i>N-</i>(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine (350 mg, 0.79 mmol) and DIPEA (0.342 mL, 1.97 mmol) in 2,2,2-trifluoroethanol (5 mL). The mixture was heated in a microwave at 140 °C for 60 min.</div><div class="NLM_p last">The cooled reaction mixture was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7 M NH<sub>3</sub>/MeOH and evaporated onto silica for silica chromatography. The crude product was purified by flash silica chromatography, with elution gradient 0–4% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford <i>N</i>′-(2-dimethylaminoethyl)-2-methoxy-<i>N</i>′-methyl-<i>N</i>-[4-(1-methylindol-3-yl)pyrimidin-2-yl]-5-nitrobenzene-1,4-diamine (230 mg, 62%) as an orange solid. <sup>1</sup>H NMR (400 MHz, DMSO, 22 °C) δ 2.16 (6H, s), 2.45–2.49 (2H, t), 2.86 (3H, s), 3.26 (2H, t), 3.87 (3H, s), 3.95 (3H, s), 6.85 (1H, s), 7.11 (1H, t), 7.21 (1H, d), 7.25 (1H, t), 7.52 (1H, d), 8.10 (1H, s), 8.31 (1H, d), 8.33 (1H, s), 8.36 (1H, d), 8.62 (1H, s); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 476.40.</div></div><div id="sec4_2_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>1-(2-Dimethylaminoethyl)-5-methoxy-<i>N</i>1-methyl-<i>N</i>4-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0047.gif" alt="" id="GRAPHIC-d1307e4566-autogenerated" /></img><div class="NLM_p"><i>N</i>′-(2-Dimethylaminoethyl)-2-methoxy-<i>N</i>′<i>-</i>methyl-<i>N-</i>[4-(1-methylindol-3-yl)pyrimidin-2-yl]-5-nitrobenzene-1,4-diamine (220 mg, 0.46 mmol), iron (155 mg, 2.78 mmol), and ammonium chloride (17.32 mg, 0.32 mmol) were heated in ethanol (12 mL) and water (4 mL) at reflux for 2 h. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7 M NH<sub>3</sub>/MeOH and evaporated onto silica for chromatographic purification.</div><div class="NLM_p last">The crude product was purified by flash silica chromatography, with elution gradient 0–5% 7N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness to afford <i>N</i>1-(2-dimethylaminoethyl)-5-methoxy-<i>N</i>1-methyl-<i>N</i>4-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine (175 mg, 85%) as a beige foam. <sup>1</sup>H NMR (400 MHz, DMSO, 22 °C) δ 2.17 (6H, s), 2.36 (2H, t), 2.63 (3H, s), 2.88 (2H, t), 3.74 (3H, s), 3.88 (3H, s), 4.58 (2H, br s), 6.76 (1H, s), 7.12–7.19 (2H, m), 7.21–7.27 (1H, m), 7.48 (1H, s), 7.51 (1H, d), 7.78 (1H, s), 8.27 (1H, d), 8.30 (1H, s), 8.42 (1H, d); <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 446.32.</div></div><div id="sec4_2_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N-</i>[2-(2-Dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0048.gif" alt="" id="GRAPHIC-d1307e4615-autogenerated" /></img><div class="NLM_p last">Acryloyl chloride (34.5 mg, 0.38 mmol) in DCM (1 mL) was added dropwise to a stirred solution of <i>N</i>1-(2-dimethylaminoethyl)-5-methoxy-<i>N</i>1-methyl-<i>N</i>4-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine (170 mg, 0.38 mmol) and DIPEA (0.073 mL, 0.42 mmol) in DCM (5 mL), cooled in an ice/water bath. The mixture was stirred for 90 min and then diluted with DCM (25 mL) and washed with saturated aqueous NaHCO<sub>3</sub> solution (50 mL). The organics were removed, and the aqueous portion was further extracted with DCM (2 × 25 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated onto silica for purification. The crude product was purified by flash silica chromatography, with elution gradient 0–4% 7 N NH<sub>3</sub>/MeOH in DCM. Pure fractions were evaporated to dryness and triturated with ether to afford <i>N-</i>[2-(2-dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide (75 mg, 39%) as a cream solid. <sup>1</sup>H NMR (400 MHz, DMSO, 22 °C) δ 2.21 (6H, s), 2.29 (2H, t), 2.72 (3H, s), 2.89 (2H, t), 3.86 (3H, s), 3.92 (3H, s), 5.77 (1H, dd), 6.27 (1H, dd), 6.43 (1H, dd), 7.04 (1H, s), 7.15 (1H, t), 7.2–7.27 (2H, m), 7.53 (1H, d), 7.91 (1H, s), 8.24 (1H, d), 8.33 (1H, d), 8.68 (1H, s), 9.14 (1H, s), 10.22 (1H, s); <sup>13</sup>C NMR (176 MHz, DMSO, 22 °C) δ 32.8, 42.6, 45.1, 55.7, 56.0, 56.8, 105.3, 107.1, 110.4, 112.4, 113.3, 120.8, 121.2, 121.9, 125.3, 125.5, 125.9, 127.7, 132.4, 133.8, 137.3, 137.7, 145.8, 157.6, 158.9, 159.8, 161.5, 162.3. CHN analysis, C<sub>28</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub>·H<sub>2</sub>O requires C = 64.97%, H = 6.82%, N = 18.94%. Found: C = 64.6%, H = 6.7%, N = 18.8%. <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 500.42. HRMS: (M + H)<sup>+</sup> = C<sub>28</sub>H<sub>34</sub>N<sub>7</sub>O<sub>2</sub> = 500.276 84, found 500.276 86.</div></div><div id="sec4_2_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N-</i>[2-(2-Dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Mesylate Salt</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0049.gif" alt="" id="GRAPHIC-d1307e4692-autogenerated" /></img><div class="NLM_p last">To a stirred solution of <i>N-</i>[2-(2-dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide (5g, 9.11 mmol) in acetone (45.5 mL) and water (4.55 mL) at 50 °C was added methanesulfonic acid (0.893g, 9.11 mmol) as a solution in acetone (4.55 mL). The resulting mixture was stirred for 1.5 h. The resulting solid was collected by filtration and dried at 80 °C under vacuum to give the title salt (4.9 g, 94%) as a solid (mp(DSC) = 246–259 °C). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>, 22 °C) δ 2.72 (3H, s), 2.96 (3H, s), 3.01 (6H, s), 3.58 (3H, t), 3.87–3.90 (7H, m), 5.76 (1H, dd), 6.38–6.53 (2H, m), 7.12 (1H, t), 7.20 (1H, t), 7.29 (1H, s), 7.40 (2H, t), 8.07–8.16 (3H, m), 8.56 (1H, s), 9.30 (1H, s), 9.60 (1H, s), 9.66 (1H, s); <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>, 22 °C) δ 34.3, 39.9, 44, 45.5, 50.1, 55.2, 57, 105.9, 107.7, 112, 113.4, 123.4, 123.9, 124.4, 124.9, 125.1, 125.2, 126.9, 129.4, 131.5, 139.9, 140.2, 142.3, 144, 152.8, 153.7, 167.1, 169.3. CHN analysis, C<sub>29</sub>H<sub>37</sub>O<sub>5</sub>N<sub>7</sub>S (0.1% w/w H<sub>2</sub>O) requires C = 58.41%, H = 6.27%, N = 16.44%, S = 5.38%. Found: C = 58.6%, H = 6.3%, N = 16.5%, S = 5.2%. <i>m</i>/<i>z</i> (ES+) (M + H)<sup>+</sup> = 500.26. HRMS: (M + H)<sup>+</sup> = C<sub>28</sub>H<sub>34</sub>N<sub>7</sub>O<sub>2</sub> = 500.27684, found 500.2759.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Cellular Assays</h3><div class="NLM_p last">Cellular phosphorylation and proliferation assays were performed as reported previously by ourselves.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> In Vivo Antitumor Efficacy Studies</h3><div class="NLM_p last">All in vivo efficacy studies were performed as reported previously by ourselves.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Rat in Vivo Toxicology Studies</h3><div class="NLM_p last">Studies were carried out in accordance with U.K. Home Office legislation (Animals [Scientific Procedures] Act 1986) and AstraZeneca’s institutional policies. The animals used were 10-week-old male RccHan:WIST rats obtained from Harlan, U.K. Animals (<i>n</i> = 3/compound) received a single oral dose of compound as a suspension in 0.5% w/v HPMC/0.1% w/v Tween in deionized water at a concentration of 20 mg/mL. Blood glucose levels were measured using an Accuchek Active meter (ACCU-CHEK Active; Roche, Basel, Switzerland). Serum insulin concentrations were determined using a commercial rat ELISA kit (Mercodia, Upsala, Sweden). Water and food were available ad libitum.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44"><a href="/doi/suppl/10.1021/jm500973a">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66675" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66675" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Preparation and characterization for additional final compounds, cell assay statistical analyses, pharmacodynamic assay procedure, kinase selectivty data, binding mode computational modeling, and enzyme/cell correlations. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm500973a/suppl_file/jm500973a_si_001.pdf">jm500973a_si_001.pdf (629.35 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm500973a" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Raymond V. Finlay</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6a180b13440c0304060b132a0b191e180b100f040f090b44090507"><span class="__cf_email__" data-cfemail="3f4d5e4611595651535e467f5e4c4b4d5e455a515a5c5e115c5052">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Anderton</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Ashton</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Ballard</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Bethel</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Box</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert H. Bradbury</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon J. Brown</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sam Butterworth</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Campbell</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Chorley</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola Colclough</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darren A. E. Cross</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gordon S. Currie</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Grist</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lorraine Hassall</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George B. Hill</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel James</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael James</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Kemmitt</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teresa Klinowska</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gillian Lamont</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott G. Lamont</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathaniel Martin</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heather L. McFarland</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martine J. Mellor</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathon P. Orme</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Perkins</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paula Perkins</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graham Richmond</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Smith</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Ward</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Waring</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Whittaker</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stuart Wells</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gail L. Wrigley</span> - <span class="hlFld-Affiliation affiliation">†Oncology Innovative Medicines, ‡Drug Safety and
Metabolism, §Global Medicines Development, and ∥Discovery Sciences, AstraZeneca, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1307e4792-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Didier Danillion, Gareth Hughes, Cath Eberlein, and Scott Martin for expert technical assistance. We are also grateful to Anne Galer and Paula Daunt for project team leadership. We also acknowldege Susan Galbraith for her support of the AZD9291 program. Jamie Scott, Jason Kettle, and Kevin Foote are also gratefully acknowledged for their helpful comments during the preparation of this manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> Abbreviations Used</h2><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">AM</td><td class="NLM_def"><p class="first last">activating mutant</p></td></tr><tr><td class="NLM_term">DM</td><td class="NLM_def"><p class="first last">double mutant</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetra-<i>N</i>-butylammonium fluoride</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35482" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35482" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruvka, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span> <span class="citation_source-journal">J. Clin. Oncol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1200%2FJCO.2012.43.3912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=23401451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1070-1080&author=K.+Ohashiauthor=Y.+E.+Maruvkaauthor=F.+Michorauthor=W.+Pao&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor-resistant+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span></div><div class="casAuthors">Ohashi, Kadoaki; Maruvka, Yosef E.; Michor, Franziska; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose EGFR-mutant lung cancer was first described as a new clin. entity in 2004.  Here, we present an update on new controversies and conclusions regarding the disease.  Methods This article reviews the clin. implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.  Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC).  Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.  Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC.  Efforts should now conc. on making EGFR-mutant lung cancer a chronic rather than fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FJbVyt6ydLVg90H21EOLACvtfcHk0lgIDVFb3FrgAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D&md5=dfda1563a90ce24bc51e55ebbf47d981</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3912%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMaruvka%26aufirst%3DY.%2BE.%26aulast%3DMichor%26aufirst%3DF.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor-resistant%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol%26date%3D2013%26volume%3D31%26spage%3D1070%26epage%3D1080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0lgIDVFb3FrgAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span> </span><span class="NLM_article-title">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lgQ2S38gZCC_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DGefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Jaenneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lgQ2S38gZCC_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span> </span><span class="NLM_article-title">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.critrevonc.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=22257651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=407-421&author=S.-H.+I.+Ou&title=Second-generation+irreversible+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29%3A+A+better+mousetrap%3F+A+review+of+the+clinical+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence</span></div><div class="casAuthors">Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC.  First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations.  However, resistance to gefitinib and erlotinib invariably develops after prolonged clinical use.  Two second-generation irreversible EGFR TKIs, afatinib (BIBW 2992) and dacomitinib (PF-00299804), that can potentially overcome the majority of these resistances are in late stage clinical development.  Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB3Zud0oX1WCM8MEzWGjS9fW6udTcc2eaggd-ZqUnFWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D&md5=df9e3f1fe1c2bb8f328f925725024d40</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DSecond-generation%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%253A%2520A%2520better%2520mousetrap%253F%2520A%2520review%2520of%2520the%2520clinical%2520evidence%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2012%26volume%3D83%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0lgw_3YT6u2phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgw_3YT6u2phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgw_3YT6u2phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span>International Centre for Kinase Profiling. <a href="http://www.kinase-screen.mrc.ac.uk/" class="extLink">http://www.kinase-screen.mrc.ac.uk/</a> (accessed August 12,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International+Centre+for+Kinase+Profiling.+http%3A%2F%2Fwww.kinase-screen.mrc.ac.uk%2F+%28accessed+August+12%2C+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Compounds were screened in the Millipore kinase panel. Full data are described in ref <a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">20</a>.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compounds+were+screened+in+the+Millipore+kinase+panel.+Full+data+are+described+in+ref+20."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yee, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor receptor inhibitors: baby or the bathwater?</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1093%2Fjnci%2Fdjs258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=22761272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=975-981&author=D.+Yee&title=Insulin-like+growth+factor+receptor+inhibitors%3A+baby+or+the+bathwater%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?</span></div><div class="casAuthors">Yee, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The success of targeted therapies for cancer is undisputed; strong preclin. evidence has resulted in the approval of several new agents for cancer treatment.  The type I insulin-like growth factor receptor (IGF1R) appeared to be one of these promising new targets.  Substantial population and preclin. data have all pointed toward this pathway as an important regulator of tumor cell biol.  Although early results from clin. trials that targeted the IGF1R showed some evidence of response, larger randomized phase III trials have not shown clear clin. benefit of targeting this pathway in combination with conventional strategies.  These disappointing results have resulted in the discontinuation of several anti-IGF1R programs.  However, the conduct of these trials has brought to the forefront several important factors that need to be considered in the conduct of future clin. trials.  The need to develop biomarkers, a clearer understanding of insulin receptor function, and defining rational combination regimens all require further consideration.  In this commentary, the current state of IGF1R inhibitors in cancer therapy is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2brv9Teud4rVg90H21EOLACvtfcHk0litR8kENkV8qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOjsLrM&md5=9a474634c9cbb43ce2a1cd0d576f522a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjs258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjs258%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%2520receptor%2520inhibitors%253A%2520baby%2520or%2520the%2520bathwater%253F%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D975%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Clarke, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenhow, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D.</span><span> </span><span class="NLM_article-title">Metabolism-related assays and their application to agrochemical research: reactivity of pesticides with glutathione and glutathione transferases</span> <span class="citation_source-journal">Pestic. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=385-393&author=E.+D.+Clarkeauthor=D.+T.+Greenhowauthor=D.+Adams&title=Metabolism-related+assays+and+their+application+to+agrochemical+research%3A+reactivity+of+pesticides+with+glutathione+and+glutathione+transferases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-related assays and their application to agrochemical research: reactivity of pesticides with glutathione and glutathione transferases</span></div><div class="casAuthors">Clarke, Eric D.; Greenhow, Daren T.; Adams, David</div><div class="citationInfo"><span class="NLM_cas:title">Pesticide Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-393</span>CODEN:
                <span class="NLM_cas:coden">PSSCBG</span>;
        ISSN:<span class="NLM_cas:issn">0031-613X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An HPLC-based assay system has been developed to measure the reactivity of agrochems. with glutathione (GSH) with and without catalysis by glutathione transferases (GSTs).  Metab.-related parameters based on second-order related rate consts. from nonenzymic GSH and enzymic GSH + GST assays have been derived for use in structure-activity and structure-reactivity relationship studies of exploratory agrochems.  The versatility and sensitivity of the assay system has been established using a diverse range of agrochems. and model compds., e.g. 4-nitrobenzyl chloride, 1-chloro-2,4-dinitrobenzene, atrazine, acetochlor, fluorodifen, fluazifop-Bu, tridiphane, fluazinam, chlorothalonil and diazinon.  For the enzymic GSH + GST assay, second-order related rate consts., ratioed to the assay std., 4-nitrobenzyl chloride to provide a parameter independent of assay conditions, spanned 5 orders of magnitude, fluazinam being the most reactive and atrazine the least.  Within chem. classes, significant variations in reactivity were obsd., alachlor being c. 15-fold more reactive than pretilachlor.  Applications of this assay system based on comparative measures of reactivity across and within chem. classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozE9JcsswrNbVg90H21EOLACvtfcHk0litR8kENkV8qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D&md5=5de37b3f68e5df660d917bc17fb4fb16</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-9063%2528199812%252954%253A4%253C385%253A%253AAID-PS842%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DE.%2BD.%26aulast%3DGreenhow%26aufirst%3DD.%2BT.%26aulast%3DAdams%26aufirst%3DD.%26atitle%3DMetabolism-related%2520assays%2520and%2520their%2520application%2520to%2520agrochemical%2520research%253A%2520reactivity%2520of%2520pesticides%2520with%2520glutathione%2520and%2520glutathione%2520transferases%26jtitle%3DPestic.%2520Sci.%26date%3D1998%26volume%3D54%26spage%3D385%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morley, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span> </span><span class="NLM_article-title">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1136</span><span class="NLM_x">–</span> <span class="NLM_lpage">1138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.bmcl.2008.12.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=19168354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1136-1138&author=P.+A.+MacFaulauthor=A.+D.+Morleyauthor=J.+J.+Crawford&title=A+simple+in+vitro+assay+for+assessing+the+reactivity+of+nitrile+containing+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span></div><div class="casAuthors">MacFaul, Philip A.; Morley, Andrew D.; Crawford, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1136-1138</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A quant. assay involving the reaction of nitriles with glutathione and cysteine has been used as a simple in vitro screen to assess potential toxicity risk of candidate compds. in drug discovery.  Studies have indicated that, when benchmarked with selected compds., the reaction of the nitriles with glutathione can provide a useful tool for deciding whether or not to progress compds. in the absence of radiolabelling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro23j0VCklM7Vg90H21EOLACvtfcHk0litR8kENkV8qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D&md5=d949b5d0e76c6d268f3f57cc4584f0b9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.105%26sid%3Dliteratum%253Aachs%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DMorley%26aufirst%3DA.%2BD.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520simple%2520in%2520vitro%2520assay%2520for%2520assessing%2520the%2520reactivity%2520of%2520nitrile%2520containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1136%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Schwobel, J. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madden, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T. D.</span><span> </span><span class="NLM_article-title">Examination of Michael addition reactivity towards glutathione by transition-state calculations</span> <span class="citation_source-journal">SAR QSAR Environ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=693-710&author=J.+A.+H.+Schwobelauthor=J.+C.+Maddenauthor=M.+T.+D.+Cronin&title=Examination+of+Michael+addition+reactivity+towards+glutathione+by+transition-state+calculations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwobel%26aufirst%3DJ.%2BA.%2BH.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DCronin%26aufirst%3DM.%2BT.%2BD.%26atitle%3DExamination%2520of%2520Michael%2520addition%2520reactivity%2520towards%2520glutathione%2520by%2520transition-state%2520calculations%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D2010%26volume%3D21%26spage%3D693%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Mah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span> </span><span class="NLM_article-title">Drug discovery considerations in the development of covalent inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.bmcl.2013.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=24314671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=33-39&author=R.+Mahauthor=J.+R.+Thomasauthor=C.+M.+Shafer&title=Drug+discovery+considerations+in+the+development+of+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery considerations in the development of covalent inhibitors</span></div><div class="casAuthors">Mah, Robert; Thomas, Jason R.; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the no. of drug candidates with a covalent mechanism of action progressing through clin. trials or being approved by the FDA has increased significantly.  And as interest in covalent inhibitors has increased, the tech. challenges for characterizing and optimizing these inhibitors have become evident.  A no. of new tools have been developed to aid this process, but these have not gained wide-spread use.  This review will highlight a no. of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dY63LHbEhLVg90H21EOLACvtfcHk0lgBPrxB3tOfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O&md5=9407bcb76e83065f5a56a97b63547ede</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDrug%2520discovery%2520considerations%2520in%2520the%2520development%2520of%2520covalent%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D33%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Marks, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewart, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainée, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentin, J. P.</span><span> </span><span class="NLM_article-title">The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.taap.2012.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=22714037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2012&pages=171-83&author=L.+Marksauthor=S.+Borlandauthor=K.+Philipauthor=L.+Ewartauthor=P.+Lain%C3%A9eauthor=M.+Skinnerauthor=S.+Kirkauthor=J.+P.+Valentin&title=The+role+of+the+anaesthetised+guinea-pig+in+the+preclinical+cardiac+safety+evaluation+of+drug+candidate+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds</span></div><div class="casAuthors">Marks, Louise; Borland, Samantha; Philp, Karen; Ewart, Lorna; Lainee, Pierre; Skinner, Matthew; Kirk, Sarah; Valentin, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-183</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite rigorous preclin. and clin. safety evaluation, adverse cardiac effects remain a leading cause of drug attrition and post-approval drug withdrawal.  A no. of cardiovascular screens exist within preclin. development.  These screens do not, however, provide a thorough cardiac liability profile and, in many cases, are not preventing the progression of high risk compds.  We evaluated the suitability of the anesthetized guinea-pig for the assessment of drug-induced changes in cardiovascular parameters.  Sodium pentobarbitone anesthetized male guinea-pigs received three 15 min i.v. infusions of ascending doses of amoxicillin, atenolol, clonidine, dobutamine, dofetilide, flecainide, isoprenaline, levosimendan, milrinone, moxifloxacin, nifedipine, paracetamol, verapamil or vehicle, followed by a 30 min washout.  Dose levels were targeted to cover clin. exposure and above, with plasma samples obtained to evaluate effect/exposure relationships.  Arterial blood pressure, heart rate, contractility function (left ventricular dP/dtmax and QA interval) and lead II ECG were recorded throughout.  In general, the expected ref. compd. induced effects on hemodynamic, contractility and electrocardiog. parameters were detected confirming that all three endpoints can be measured accurately and simultaneously in one small animal.  Plasma exposures obtained were within, or close to the expected clin. range of therapeutic plasma levels.  Concn.-effect curves were produced which allowed a more complete understanding of the margins for effects at different plasma exposures.  This single in vivo screen provides a significant amt. of information pertaining to the cardiovascular risk of drug candidates, ultimately strengthening strategies addressing cardiovascular-mediated compd. attrition and drug withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiPhG6sCLHrLVg90H21EOLACvtfcHk0lgBPrxB3tOfFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCks7g%253D&md5=cbbd8f21bb3c17986d08ab65b91f1dd1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2012.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2012.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DL.%26aulast%3DBorland%26aufirst%3DS.%26aulast%3DPhilip%26aufirst%3DK.%26aulast%3DEwart%26aufirst%3DL.%26aulast%3DLain%25C3%25A9e%26aufirst%3DP.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DS.%26aulast%3DValentin%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520the%2520anaesthetised%2520guinea-pig%2520in%2520the%2520preclinical%2520cardiac%2520safety%2520evaluation%2520of%2520drug%2520candidate%2520compounds%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2012%26volume%3D263%26spage%3D171%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span>Eurofins. Discovery Series. KinaseProfiler Services. <a href="http://www.eurofins.com/pharma-services/pharma-discovery-services/eurofins-discovery-services/kinases-phosphatases/kinaseprofiler-services.aspx" class="extLink">http://www.eurofins.com/pharma-services/pharma-discovery-services/eurofins-discovery-services/kinases-phosphatases/kinaseprofiler-services.aspx</a> (accessed August 12,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eurofins.+Discovery+Series.+KinaseProfiler+Services.+http%3A%2F%2Fwww.eurofins.com%2Fpharma-services%2Fpharma-discovery-services%2Feurofins-discovery-services%2Fkinases-phosphatases%2Fkinaseprofiler-services.aspx+%28accessed+August+12%2C+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleasby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magriotis, P. A.</span><span> </span><span class="NLM_article-title">Importance of mechanistic drug metabolism studies in support of drug discovery: a case study with N-sulfonylated dipeptide VLA-4 antagonists in rats</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=223-237&author=W.+Tangauthor=R.+A.+Stearnsauthor=Q.+Chenauthor=K.+Bleasbyauthor=Y.+Tefferaauthor=A.+Collettiauthor=M.+Hafeyauthor=R.+Eversauthor=D.+C.+Deanauthor=P.+A.+Magriotis&title=Importance+of+mechanistic+drug+metabolism+studies+in+support+of+drug+discovery%3A+a+case+study+with+N-sulfonylated+dipeptide+VLA-4+antagonists+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DBleasby%26aufirst%3DK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DColletti%26aufirst%3DA.%26aulast%3DHafey%26aufirst%3DM.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DMagriotis%26aufirst%3DP.%2BA.%26atitle%3DImportance%2520of%2520mechanistic%2520drug%2520metabolism%2520studies%2520in%2520support%2520of%2520drug%2520discovery%253A%2520a%2520case%2520study%2520with%2520N-sulfonylated%2520dipeptide%2520VLA-4%2520antagonists%2520in%2520rats%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D223%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, A.</span><span> </span><span class="NLM_article-title">The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: a case study</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.2174%2F187231208784041004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1ajsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=120-124&author=A.+F.+El-Kattanauthor=J.+Poeauthor=L.+Buchholzauthor=H.+V.+Thomasauthor=J.+Brodfuehrerauthor=A.+Clark&title=The+use+of+1-aminobenzotriazole+in+differentiating+the+role+of+CYP-mediated+first+pass+metabolism+and+absorption+in+limiting+drug+oral+bioavailability%3A+a+case+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting Drug oral bioavailability: a case study</span></div><div class="casAuthors">El-Kattan, Ayman F.; Poe, Julie; Buchholz, Lisa; Thomas, Hayden V.; Brodfuehrer, Joanne; Clark, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-124</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Preliminary studies in our lab. demonstrated low oral bioavailability of Drug X in male Sprague Dawley rats.  However, the factors responsible for the obsd. poor bioavailability were not well understood.  The objective of this study was to investigate the contribution of cytochrome P 4501(s) metab. to the obsd. poor oral bioavailability of Drug X in male Sprague-Dawley rats in the presence of 1-aminobenzotriazole, a non-specific irreversible inhibitor of cytochrome P450s.  Male Sprague-Dawley rats were pre-treated with or without oral 1-aminobenzotriazole (50 mg/kg) 2 h prior to receiving a single i.v. or oral dose of Drug X (3 mg/kg).  Blood samples were collected from animals at different time points over 6 h following Drug X dosing.  Plasma concns. of Drug X were detd. using LC/MS/MS.  Pharmacokinetic data obtained from an i.v. dose study in rats suggested that Drug X exhibited a high clearance (55 mL/min/kg) and moderate vol. of distribution (1.3 L/kg) with short half-life in rats (0.7 h).  Oral dosing of Drug X to rats resulted in low oral bioavailability (19%).  1-Aminobenzotriazole pre-treatment of male Sprague Dawley rats followed by an i.v. dose of Drug X resulted in a decrease in plasma clearance by 71% and an increase in half-life by 100%, without affecting the vol. of distribution.  Furthermore, the oral bioavailability of Drug X increased markedly with 1-aminobenzotriazole pre-treatment.  However, the fraction absorbed of Drug X did not significantly change with 1-aminobenzotriazole pre-treatment.  The results of this study indicated that CYP-mediated metab. played a major role in limiting the oral bioavailability of Drug X in rats.  The data suggests that 1-aminobenzotriazole can be used as an effective tool in assessing the factors contributing to the poor oral bioavailability of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmldBUJ-PF3rVg90H21EOLACvtfcHk0liclZbNLxm-aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1ajsLs%253D&md5=04def10dee094365b7d9c5e470927eab</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F187231208784041004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231208784041004%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DPoe%26aufirst%3DJ.%26aulast%3DBuchholz%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DH.%2BV.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DA.%26atitle%3DThe%2520use%2520of%25201-aminobenzotriazole%2520in%2520differentiating%2520the%2520role%2520of%2520CYP-mediated%2520first%2520pass%2520metabolism%2520and%2520absorption%2520in%2520limiting%2520drug%2520oral%2520bioavailability%253A%2520a%2520case%2520study%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2008%26volume%3D2%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aicholz, R.</span><span> </span><span class="NLM_article-title">The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite CGP74588</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3231</span><span class="NLM_x">–</span> <span class="NLM_lpage">3239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=3231-3239&author=P.+W.+Manleyauthor=F.+Blascoauthor=J.+Mestanauthor=R.+Aicholz&title=The+kinetic+deuterium+isotope+effect+as+applied+to+metabolic+deactivation+of+imatinib+to+the+des-methyl+metabolite+CGP74588"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DAicholz%26aufirst%3DR.%26atitle%3DThe%2520kinetic%2520deuterium%2520isotope%2520effect%2520as%2520applied%2520to%2520metabolic%2520deactivation%2520of%2520imatinib%2520to%2520the%2520des-methyl%2520metabolite%2520CGP74588%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D3231%26epage%3D3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Sjogren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westergren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanish, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindfors, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennernas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannergren, C.</span><span> </span><span class="NLM_article-title">In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=679-698&author=E.+Sjogrenauthor=J.+Westergrenauthor=I.+Grantauthor=G.+Hanishauthor=L.+Lindforsauthor=H.+Lennernasauthor=B.+Abrahamssonauthor=C.+Tannergren&title=In+silico+predictions+of+gastrointestinal+drug+absorption+in+pharmaceutical+product+development%3A+application+of+the+mechanistic+absorption+model+GI-Sim"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSjogren%26aufirst%3DE.%26aulast%3DWestergren%26aufirst%3DJ.%26aulast%3DGrant%26aufirst%3DI.%26aulast%3DHanish%26aufirst%3DG.%26aulast%3DLindfors%26aufirst%3DL.%26aulast%3DLennernas%26aufirst%3DH.%26aulast%3DAbrahamsson%26aufirst%3DB.%26aulast%3DTannergren%26aufirst%3DC.%26atitle%3DIn%2520silico%2520predictions%2520of%2520gastrointestinal%2520drug%2520absorption%2520in%2520pharmaceutical%2520product%2520development%253A%2520application%2520of%2520the%2520mechanistic%2520absorption%2520model%2520GI-Sim%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D49%26spage%3D679%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimelow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J.</span><span> </span><span class="NLM_article-title">Integrating the pre-clinical pharmacokinetic, pharmacodynamic and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating (EGFRm+) and resistant (EGFRm+/T790M) mutations and an active metabolite to predict the human pharmacokinetics and potential efficacious dose in patients</span> <span class="citation_source-journal">Mol. Cancer Ther</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">11 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">B212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=B212&issue=11+Suppl.&author=P.+Ballardauthor=S.+Ashtonauthor=D.+Crossauthor=R.+Dimelowauthor=J.+Yates&title=Integrating+the+pre-clinical+pharmacokinetic%2C+pharmacodynamic+and+efficacy+data+for+AZD9291%2C+an+oral%2C+irreversible+inhibitor+of+EGFR+activating+%28EGFRm%2B%29+and+resistant+%28EGFRm%2B%2FT790M%29+mutations+and+an+active+metabolite+to+predict+the+human+pharmacokinetics+and+potential+efficacious+dose+in+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDimelow%26aufirst%3DR.%26aulast%3DYates%26aufirst%3DJ.%26atitle%3DIntegrating%2520the%2520pre-clinical%2520pharmacokinetic%252C%2520pharmacodynamic%2520and%2520efficacy%2520data%2520for%2520AZD9291%252C%2520an%2520oral%252C%2520irreversible%2520inhibitor%2520of%2520EGFR%2520activating%2520%2528EGFRm%252B%2529%2520and%2520resistant%2520%2528EGFRm%252B%252FT790M%2529%2520mutations%2520and%2520an%2520active%2520metabolite%2520to%2520predict%2520the%2520human%2520pharmacokinetics%2520and%2520potential%2520efficacious%2520dose%2520in%2520patients%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2013%26volume%3D12%26issue%3D11%2520Suppl%26spage%3DB212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Red Brewer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+Nebhanauthor=P.+Spitzlerauthor=J.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0liclZbNLxm-aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%26aulast%3DSpitzler%26aufirst%3DP.%26aulast%3DOrme%26aufirst%3DJ.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span> </span><span class="NLM_article-title">Preliminary results from a phase I study with AZD9291: an irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span><div class="note"><p class="first last">(Abstract LBA33)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S15&issue=Suppl.+3&author=M.+Ransonauthor=W.+Paoauthor=D.+Planchardauthor=Y.+Oheauthor=S.-W.+Kimauthor=D.+W.+Kimauthor=E.+Felipauthor=S.+Ghiorghiuauthor=M.+Cantariniauthor=P.+Janne&title=Preliminary+results+from+a+phase+I+study+with+AZD9291%3A+an+irreversible+inhibitor+of+epidermal+growth+factor+receptor+%28EGFR%29+activating+and+resistance+mutations+in+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%2520I%2520study%2520with%2520AZD9291%253A%2520an%2520irreversible%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520activating%2520and%2520resistance%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26issue%3DSuppl.%25203%26spage%3DS15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Eisenhauer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therasse, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaerts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dancey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwyther, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span> </span><span class="NLM_article-title">New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=228-247&author=E.+A.+Eisenhauerauthor=P.+Therasseauthor=J.+Bogaertsauthor=L.+H.+Schwartzauthor=D.+Sargentauthor=R.+Fordauthor=J.+Danceyauthor=S.+Arbuckauthor=S.+Gwytherauthor=M.+Mooneyauthor=L.+Rubinsteinauthor=L.+Shankarauthor=L.+Doddauthor=R.+Kaplanauthor=D.+Lacombeauthor=J.+Verweij&title=New+response+evaluation+criteria+in+solid+tumours%3A+Revised+RECIST+guideline+%28version+1.1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEisenhauer%26aufirst%3DE.%2BA.%26aulast%3DTherasse%26aufirst%3DP.%26aulast%3DBogaerts%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DL.%2BH.%26aulast%3DSargent%26aufirst%3DD.%26aulast%3DFord%26aufirst%3DR.%26aulast%3DDancey%26aufirst%3DJ.%26aulast%3DArbuck%26aufirst%3DS.%26aulast%3DGwyther%26aufirst%3DS.%26aulast%3DMooney%26aufirst%3DM.%26aulast%3DRubinstein%26aufirst%3DL.%26aulast%3DShankar%26aufirst%3DL.%26aulast%3DDodd%26aufirst%3DL.%26aulast%3DKaplan%26aufirst%3DR.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DNew%2520response%2520evaluation%2520criteria%2520in%2520solid%2520tumours%253A%2520Revised%2520RECIST%2520guideline%2520%2528version%25201.1%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D228%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span>Common Terminology Criteria for Adverse Events (CTCAE). <a href="http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf" class="extLink">http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</a> (accessed August 12,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Common+Terminology+Criteria+for+Adverse+Events+%28CTCAE%29.+http%3A%2F%2Fevs.nci.nih.gov%2Fftp1%2FCTCAE%2FCTCAE_4.03_2010-06-14_QuickReference_5x7.pdf+%28accessed+August+12%2C+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaligam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin Oncol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 5</span><span class="NLM_x">) </span> <span class="NLM_fpage">8009</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&issue=Suppl.+5&author=P.+A.+Janneauthor=S.+S.+Ramaligamauthor=J.+C.+H.+Yangauthor=M.-J.+Ahnauthor=D.-W.+Kimauthor=S.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+activity+of+the+mutant-selective+EGFR+inhibitor+AZD9291+in+patients+%28pts%29+with+EGFR+inhibitor%E2%80%93resistant+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRamaligam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520activity%2520of%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520AZD9291%2520in%2520patients%2520%2528pts%2529%2520with%2520EGFR%2520inhibitor%25E2%2580%2593resistant%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin%2520Oncol%26date%3D2014%26volume%3D32%26issue%3DSuppl.%25205%26spage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 292 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Islam Al-Khawaldeh, Mohammed J. Al Yasiri, Gregory G. Aldred, Christine Basmadjian, Cinzia Bordoni, Suzannah J. Harnor, Amy B. Heptinstall, Stephen J. Hobson, Claire E. Jennings, Shaimaa Khalifa, Honorine Lebraud, Mathew P. Martin, Duncan C. Miller, Harry J. Shrives, João V. de Souza, Hannah L. Stewart, Max Temple, Huw D. Thomas, Jane Totobenazara, Julie A. Tucker, Susan J. Tudhope, Lan Z. Wang, Agnieszka K. Bronowska, Céline Cano, Jane A. Endicott, Bernard T. Golding, Ian R. Hardcastle, Ian Hickson, Stephen R. Wedge, Elaine Willmore, Martin E. M. Noble, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Waring</span>. </span><span class="cited-content_cbyCitation_article-title">An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 10001-10018. <a href="https://doi.org/10.1021/acs.jmedchem.0c01249" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01249%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252BAlkynylpyrimidine-Based%252BCovalent%252BInhibitor%252BThat%252BTargets%252Ba%252BUnique%252BCysteine%252Bin%252BNF-%2525CE%2525BAB-Inducing%252BKinase%26aulast%3DAl-Khawaldeh%26aufirst%3DIslam%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D17022021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D10001%26epage%3D10018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias P. Müller, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2484-2490. <a href="https://doi.org/10.1021/acsmedchemlett.0c00472" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00472%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DComplex%252BCrystal%252BStructures%252Bof%252BEGFR%252Bwith%252BThird-Generation%252BKinase%252BInhibitors%252Band%252BSimultaneously%252BBound%252BAllosteric%252BLigands%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26082020%26date%3D28092020%26date%3D05112020%26volume%3D11%26issue%3D12%26spage%3D2484%26epage%3D2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Keisuke Tokunaga, Mami Sato, Keiko Kuwata, Chizuru Miura, Hirokazu Fuchida, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Naoya Shindo, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclobutane Carboxylic Amide as a Cysteine-Directed Strained Electrophile for Selective Targeting of Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (43)
                                     , 18522-18531. <a href="https://doi.org/10.1021/jacs.0c07490" title="DOI URL">https://doi.org/10.1021/jacs.0c07490</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c07490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c07490%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DBicyclobutane%252BCarboxylic%252BAmide%252Bas%252Ba%252BCysteine-Directed%252BStrained%252BElectrophile%252Bfor%252BSelective%252BTargeting%252Bof%252BProteins%26aulast%3DTokunaga%26aufirst%3DKeisuke%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12072020%26date%3D13102020%26volume%3D142%26issue%3D43%26spage%3D18522%26epage%3D18531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adam Birkholz, David J. Kopecky, Laurie P. Volak, Michael D. Bartberger, Yuping Chen, Christopher M. Tegley, Tara Arvedson, John D. McCarter, Christopher Fotsch, <span class="NLM_string-name hlFld-ContribAuthor">Victor J. Cee</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11602-11614. <a href="https://doi.org/10.1021/acs.jmedchem.0c00749" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00749%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BStudy%252Bof%252Bthe%252BGlutathione%252BReactivity%252Bof%252BN-Phenylacrylamides%25253A%252B2.%252BEffects%252Bof%252BAcrylamide%252BSubstitution%26aulast%3DBirkholz%26aufirst%3DAdam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04052020%26date%3D09102020%26date%3D23092020%26volume%3D63%26issue%3D20%26spage%3D11602%26epage%3D11614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Manuel Köckinger, Benjamin Wyler, Christof Aellig, Dominique M. Roberge, Christopher A. Hone, <span class="NLM_string-name hlFld-ContribAuthor">C. Oliver Kappe</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization and Scale-Up of the Continuous Flow Acetylation and Nitration of 4-Fluoro-2-methoxyaniline to Prepare a Key Building Block of Osimertinib. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (10)
                                     , 2217-2227. <a href="https://doi.org/10.1021/acs.oprd.0c00254" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00254%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DOptimization%252Band%252BScale-Up%252Bof%252Bthe%252BContinuous%252BFlow%252BAcetylation%252Band%252BNitration%252Bof%252B4-Fluoro-2-methoxyaniline%252Bto%252BPrepare%252Ba%252BKey%252BBuilding%252BBlock%252Bof%252BOsimertinib%26aulast%3DK%25C3%25B6ckinger%26aufirst%3DManuel%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D06102020%26volume%3D24%26issue%3D10%26spage%3D2217%26epage%3D2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mami Sato, Hirokazu Fuchida, Naoya Shindo, Keiko Kuwata, Keisuke Tokunaga, Guo Xiao-Lin, Ryo Inamori, Keitaro Hosokawa, Kosuke Watari, Tomohiro Shibata, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Mayumi Ono, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1137-1144. <a href="https://doi.org/10.1021/acsmedchemlett.9b00574" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00574%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSelective%252BCovalent%252BTargeting%252Bof%252BMutated%252BEGFR%252528T790M%252529%252Bwith%252BChlorofluoroacetamide-Pyrimidines%26aulast%3DSato%26aufirst%3DMami%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D04122019%26date%3D08042020%26date%3D10042020%26date%3D08042020%26volume%3D11%26issue%3D6%26spage%3D1137%26epage%3D1144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kirsten McAulay, Emily A. Hoyt, Morgan Thomas, Marianne Schimpl, Michael S. Bodnarchuk, Hilary J. Lewis, Derek Barratt, Deepa Bhavsar, David M. Robinson, Michael J. Deery, Derek J. Ogg, Gonçalo J. L. Bernardes, Richard A. Ward, Michael J. Waring, <span class="NLM_string-name hlFld-ContribAuthor">Jason G. Kettle</span>. </span><span class="cited-content_cbyCitation_article-title">Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (23)
                                     , 10358-10372. <a href="https://doi.org/10.1021/jacs.9b13391" title="DOI URL">https://doi.org/10.1021/jacs.9b13391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b13391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b13391%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAlkynyl%252BBenzoxazines%252Band%252BDihydroquinazolines%252Bas%252BCysteine%252BTargeting%252BCovalent%252BWarheads%252Band%252BTheir%252BApplication%252Bin%252BIdentification%252Bof%252BSelective%252BIrreversible%252BKinase%252BInhibitors%26aulast%3DMcAulay%26aufirst%3DKirsten%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D12122019%26date%3D02062020%26date%3D15052020%26volume%3D142%26issue%3D23%26spage%3D10358%26epage%3D10372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F. Borenstein, Huawei Chen, Claudio E. Chuaqui, Nanhua Deng, Andrew D. Ferguson, Sameer Kawatkar, Neil P. Grimster, Linette Ruston, Paul D. Lyne, Jon A. Read, Xianyou Peng, Xiaohui Pei, Stephen Fawell, Zhanlei Tang, Scott Throner, Melissa M. Vasbinder, Haoyu Wang, Jon Winter-Holt, Richard Woessner, Allan Wu, Wenzhan Yang, Michael Zinda, <span class="NLM_string-name hlFld-ContribAuthor">Jason G. Kettle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4517-4527. <a href="https://doi.org/10.1021/acs.jmedchem.9b01392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%2525282R%252529-N-%25255B3-%25255B2-%25255B%2525283-Methoxy-1-methyl-pyrazol-4-yl%252529amino%25255Dpyrimidin-4-yl%25255D-1H-indol-7-yl%25255D-2-%2525284-methylpiperazin-1-yl%252529propenamide%252B%252528AZD4205%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252B1%252BInhibitor%26aulast%3DSu%26aufirst%3DQibin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22082019%26date%3D28042020%26date%3D16042020%26volume%3D63%26issue%3D9%26spage%3D4517%26epage%3D4527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jason G. Kettle, Sharan K. Bagal, Sue Bickerton, Michael S. Bodnarchuk, Jason Breed, Rodrigo J. Carbajo, Doyle J. Cassar, Atanu Chakraborty, Sabina Cosulich, Iain Cumming, Michael Davies, Andrew Eatherton, Laura Evans, Lyman Feron, Shaun Fillery, Emma S. Gleave, Frederick W. Goldberg, Stephanie Harlfinger, Lyndsey Hanson, Martin Howard, Rachel Howells, Anne Jackson, Paul Kemmitt, Jennifer K. Kingston, Scott Lamont, Hilary J. Lewis, Songlei Li, Libin Liu, Derek Ogg, Christopher Phillips, Radek Polanski, Graeme Robb, David Robinson, Sarah Ross, James M. Smith, Michael Tonge, Rebecca Whiteley, Junsheng Yang, Longfei Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiliang Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4468-4483. <a href="https://doi.org/10.1021/acs.jmedchem.9b01720" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01720%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Band%252BPharmacokinetic%252BOptimization%252Bof%252BCovalent%252BAllosteric%252BInhibitors%252Bof%252Bthe%252BMutant%252BGTPase%252BKRASG12C%26aulast%3DKettle%26aufirst%3DJason%2BG.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18102019%26date%3D13022020%26date%3D05022020%26volume%3D63%26issue%3D9%26spage%3D4468%26epage%3D4483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiang Zhai, Richard A. Ward, Peter Doig, <span class="NLM_string-name hlFld-ContribAuthor">Argyrides Argyrou</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2020,</strong> <em>59 </em>
                                    (14)
                                     , 1428-1441. <a href="https://doi.org/10.1021/acs.biochem.0c00104" title="DOI URL">https://doi.org/10.1021/acs.biochem.0c00104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.0c00104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.0c00104%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DInsight%252Binto%252Bthe%252BTherapeutic%252BSelectivity%252Bof%252Bthe%252BIrreversible%252BEGFR%252BTyrosine%252BKinase%252BInhibitor%252BOsimertinib%252Bthrough%252BEnzyme%252BKinetic%252BStudies%26aulast%3DZhai%26aufirst%3DXiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05022020%26date%3D20032020%26date%3D31032020%26date%3D24032020%26volume%3D59%26issue%3D14%26spage%3D1428%26epage%3D1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sayumi Yamazoe, Jeffrey Tom, Yue Fu, Wenqiong Wu, Liang Zeng, Changlei Sun, Qi Liu, Jie Lin, Kui Lin, Wayne J. Fairbrother, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 2807-2813. <a href="https://doi.org/10.1021/acs.jmedchem.9b01167" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01167%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeterobifunctional%252BMolecules%252BInduce%252BDephosphorylation%252Bof%252BKinases%2525E2%252580%252593A%252BProof%252Bof%252BConcept%252BStudy%26aulast%3DYamazoe%26aufirst%3DSayumi%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D24072019%26date%3D14012020%26date%3D24122019%26volume%3D63%26issue%3D6%26spage%3D2807%26epage%3D2813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Julia Hardick, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 40-51. <a href="https://doi.org/10.1021/acs.jmedchem.9b00964" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BDefines%252BFunction%25253A%252BClinically%252BRelevant%252BMutations%252Bin%252BErbB%252BKinases%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D17062019%26date%3D28082019%26date%3D15082019%26volume%3D63%26issue%3D1%26spage%3D40%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shu-Yu Lin, Yung Chang Hsu, Yi-Hui Peng, Yi-Yu Ke, Wen-Hsing Lin, Hsu-Yi Sun, Hui-Yi Shiao, Fu-Ming Kuo, Pei-Yi Chen, Tzu-Wen Lien, Chun-Hwa Chen, Chang-Ying Chu, Sing-Yi Wang, Kai-Chia Yeh, Ching-Ping Chen, Tsu-An Hsu, Su-Ying Wu, Teng-Kuang Yeh, Chiung-Tong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Hsing-Pang Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10108-10123. <a href="https://doi.org/10.1021/acs.jmedchem.9b00722" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00722</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00722%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BFuranopyrimidine-Based%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252B%252528DBPR112%252529%252Bas%252Ba%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DLin%26aufirst%3DShu-Yu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03052019%26date%3D15112019%26date%3D27092019%26volume%3D62%26issue%3D22%26spage%3D10108%26epage%3D10123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiannan Li, Tao Zhang, Shiliang Li, Linjiang Tong, Junyu Li, Zhicheng Su, Fang Feng, Deheng Sun, Yi Tong, Xia Wang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Honglin Li, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Yufang Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (6)
                                     , 869-873. <a href="https://doi.org/10.1021/acsmedchemlett.8b00564" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00564%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BNoncovalent%252BReversible%252BEGFR%252BKinase%252BInhibitors%252Bof%252BEGFRL858R%25252FT790M%25252FC797S%26aulast%3DLi%26aufirst%3DQiannan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D21052019%26date%3D29052019%26date%3D22052019%26volume%3D10%26issue%3D6%26spage%3D869%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Helen L. Lightfoot, Frederick W. Goldberg, <span class="NLM_string-name hlFld-ContribAuthor">Joerg Sedelmeier</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of Small Molecule Kinase Drugs. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (2)
                                     , 153-160. <a href="https://doi.org/10.1021/acsmedchemlett.8b00445" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00445%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEvolution%252Bof%252BSmall%252BMolecule%252BKinase%252BDrugs%26aulast%3DLightfoot%26aufirst%3DHelen%2BL.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27092018%26date%3D17122018%26date%3D10012019%26date%3D18122018%26volume%3D10%26issue%3D2%26spage%3D153%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuming Wang, Lijun Li, Jun Fan, Yang Dai, Alan Jiang, Meiyu Geng, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9085-9104. <a href="https://doi.org/10.1021/acs.jmedchem.7b01843" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01843%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252BIrreversible%252BPan-Fibroblast%252BGrowth%252BFactor%252BReceptor%252B%252528FGFR%252529%252BInhibitors%26aulast%3DWang%26aufirst%3DYuming%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D14122017%26date%3D16032018%26date%3D09032018%26volume%3D61%26issue%3D20%26spage%3D9085%26epage%3D9104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew T. Parsons, Michele Kubryk, Simon J. Hedley, Oliver R. Thiel, David Bauer, Matthew S. Potter-Racine, <span class="NLM_string-name hlFld-ContribAuthor">Zhenxin Lin</span>. </span><span class="cited-content_cbyCitation_article-title">An Improved Process for the Preparation of a Covalent Kinase Inhibitor through a C–N Bond-Forming SNAr Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (7)
                                     , 898-902. <a href="https://doi.org/10.1021/acs.oprd.8b00080" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00080%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DAn%252BImproved%252BProcess%252Bfor%252Bthe%252BPreparation%252Bof%252Ba%252BCovalent%252BKinase%252BInhibitor%252Bthrough%252Ba%252BC%2525E2%252580%252593N%252BBond-Forming%252BSNAr%252BReaction%26aulast%3DParsons%26aufirst%3DAndrew%2BT.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20032018%26date%3D12062018%26volume%3D22%26issue%3D7%26spage%3D898%26epage%3D902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ye Ding, Dengfeng Li, Chunyong Ding, Pingyuan Wang, Zhiqing Liu, Eric A. Wold, Na Ye, Haiying Chen, Mark A. White, Qiang Shen, <span class="NLM_string-name hlFld-ContribAuthor">Jia Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2737-2752. <a href="https://doi.org/10.1021/acs.jmedchem.7b01514" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01514%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRegio-%252Band%252BStereospecific%252BSynthesis%252Bof%252BOridonin%252BD-Ring%252BAziridinated%252BAnalogues%252Bfor%252Bthe%252BTreatment%252Bof%252BTriple-Negative%252BBreast%252BCancer%252Bvia%252BMediated%252BIrreversible%252BCovalent%252BWarheads%26aulast%3DDing%26aufirst%3DYe%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D11102017%26date%3D20032018%26date%3D12032018%26volume%3D61%26issue%3D7%26spage%3D2737%26epage%3D2752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nanyi  Wang</span>, <span class="hlFld-ContribAuthor ">Lirong  Wang</span>, and <span class="hlFld-ContribAuthor ">Xiang-Qun  Xie</span>  . </span><span class="cited-content_cbyCitation_article-title">ProSelection: A Novel Algorithm to Select Proper Protein Structure Subsets for in Silico Target Identification and Drug Discovery Research. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (11)
                                     , 2686-2698. <a href="https://doi.org/10.1021/acs.jcim.7b00277" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00277</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00277%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DProSelection%25253A%252BA%252BNovel%252BAlgorithm%252Bto%252BSelect%252BProper%252BProtein%252BStructure%252BSubsets%252Bfor%252Bin%252BSilico%252BTarget%252BIdentification%252Band%252BDrug%252BDiscovery%252BResearch%26aulast%3DWang%26aufirst%3DNanyi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17052017%26date%3D26102017%26date%3D27112017%26date%3D10102017%26volume%3D57%26issue%3D11%26spage%3D2686%26epage%3D2698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter W.  Kenny</span>  . </span><span class="cited-content_cbyCitation_article-title">Comment on The Ecstasy and Agony of Assay Interference Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (11)
                                     , 2640-2645. <a href="https://doi.org/10.1021/acs.jcim.7b00313" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00313</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00313%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Ecstasy%2520and%2520Agony%2520of%2520Assay%2520Interference%2520Compounds%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D387%26epage%3D390%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComment%252Bon%252BThe%252BEcstasy%252Band%252BAgony%252Bof%252BAssay%252BInterference%252BCompounds%26aulast%3DKenny%26aufirst%3DPeter%2BW.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D28052017%26date%3D07112017%26date%3D27112017%26date%3D19102017%26volume%3D57%26issue%3D11%26spage%3D2640%26epage%3D2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew C.  Flick</span>, <span class="hlFld-ContribAuthor ">Hong X.  Ding</span>, <span class="hlFld-ContribAuthor ">Carolyn A.  Leverett</span>, <span class="hlFld-ContribAuthor ">Robert E.  Kyne, Jr.</span>, <span class="hlFld-ContribAuthor ">Kevin K. -C.  Liu</span>, <span class="hlFld-ContribAuthor ">Sarah J.  Fink</span>, and <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved During 2015. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (15)
                                     , 6480-6515. <a href="https://doi.org/10.1021/acs.jmedchem.7b00010" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252BDuring%252B2015%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D03012017%26date%3D03052017%26date%3D10082017%26date%3D19042017%26volume%3D60%26issue%3D15%26spage%3D6480%26epage%3D6515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Juchum</span>, <span class="hlFld-ContribAuthor ">Marcel  Günther</span>, <span class="hlFld-ContribAuthor ">Eva  Döring</span>, <span class="hlFld-ContribAuthor ">Adrian  Sievers-Engler</span>, <span class="hlFld-ContribAuthor ">Michael  Lämmerhofer</span>, and <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>  . </span><span class="cited-content_cbyCitation_article-title">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (11)
                                     , 4636-4656. <a href="https://doi.org/10.1021/acs.jmedchem.7b00178" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTrisubstituted%252BImidazoles%252Bwith%252Ba%252BRigidized%252BHinge%252BBinding%252BMotif%252BAct%252BAs%252BSingle%252BDigit%252BnM%252BInhibitors%252Bof%252BClinically%252BRelevant%252BEGFR%252BL858R%25252FT790M%252Band%252BL858R%25252FT790M%25252FC797S%252BMutants%25253A%252BAn%252BExample%252Bof%252BTarget%252BHopping%26aulast%3DJuchum%26aufirst%3DMichael%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D02022017%26date%3D23052017%26date%3D08062017%26date%3D08052017%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Behenna</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Theodore O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">T. Eric  Ballard</span>, <span class="hlFld-ContribAuthor ">Louise  Bernier</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle  Hemkens</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">James  Solowiej</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Paolo  Vicini</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Longqing  Liu</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Chengyi  Zhang</span>, and <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 3002-3019. <a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%252528%2525283R%25252C4R%252529-4-Fluoro-1-%2525286-%252528%2525283-methoxy-1-methyl-1H-pyrazol-4-yl%252529amino%252529-9-methyl-9H-purin-2-yl%252529pyrrolidine-3-yl%252529acrylamide%252B%252528PF-06747775%252529%252Bthrough%252BStructure-Based%252BDrug%252BDesign%25253A%252BA%252BHigh%252BAffinity%252BIrreversible%252BInhibitor%252BTargeting%252BOncogenic%252BEGFR%252BMutants%252Bwith%252BSelectivity%252Bover%252BWild-Type%252BEGFR%26aulast%3DPlanken%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11012017%26date%3D29032017%26date%3D13042017%26date%3D13032017%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Tomassi</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Hannah L.  Tumbrink</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Matthias  Baumann</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (6)
                                     , 2361-2372. <a href="https://doi.org/10.1021/acs.jmedchem.6b01626" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndazole-Based%252BCovalent%252BInhibitors%252BTo%252BTarget%252BDrug-Resistant%252BEpidermal%252BGrowth%252BFactor%252BReceptor%26aulast%3DTomassi%26aufirst%3DStefano%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D02112016%26date%3D10032017%26date%3D23032017%26date%3D22022017%26volume%3D60%26issue%3D6%26spage%3D2361%26epage%3D2372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David L.  Hughes</span>  . </span><span class="cited-content_cbyCitation_article-title">Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (12)
                                     , 2028-2042. <a href="https://doi.org/10.1021/acs.oprd.6b00374" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00374%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DPatent%252BReview%252Bof%252BManufacturing%252BRoutes%252Bto%252BOncology%252BDrugs%25253A%252BCarfilzomib%25252C%252BOsimertinib%25252C%252Band%252BVenetoclax%26aulast%3DHughes%26aufirst%3DDavid%2BL.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D08112016%26date%3D09122016%26date%3D16122016%26date%3D07122016%26volume%3D20%26issue%3D12%26spage%3D2028%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (12)
                                     , 1050-1055. <a href="https://doi.org/10.1021/acsmedchemlett.6b00235" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00235%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitors%252BBearing%252Ba%252BN%25252C9-Diphenyl-9H-purin-2-amine%252BScaffold%26aulast%3DGe%26aufirst%3DYang%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11062016%26date%3D21092016%26date%3D27092016%26date%3D08122016%26date%3D21092016%26volume%3D7%26issue%3D12%26spage%3D1050%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gérald  Lelais</span>, <span class="hlFld-ContribAuthor ">Robert  Epple</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Marsilje</span>, <span class="hlFld-ContribAuthor ">Yun O.  Long</span>, <span class="hlFld-ContribAuthor ">Matthew  McNeill</span>, <span class="hlFld-ContribAuthor ">Bei  Chen</span>, <span class="hlFld-ContribAuthor ">Wenshuo  Lu</span>, <span class="hlFld-ContribAuthor ">Jaganmohan  Anumolu</span>, <span class="hlFld-ContribAuthor ">Sangamesh  Badiger</span>, <span class="hlFld-ContribAuthor ">Badry  Bursulaya</span>, <span class="hlFld-ContribAuthor ">Michael  DiDonato</span>, <span class="hlFld-ContribAuthor ">Rina  Fong</span>, <span class="hlFld-ContribAuthor ">Jose  Juarez</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>, <span class="hlFld-ContribAuthor ">Mari  Manuia</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Mason</span>, <span class="hlFld-ContribAuthor ">Perry  Gordon</span>, <span class="hlFld-ContribAuthor ">Todd  Groessl</span>, <span class="hlFld-ContribAuthor ">Kevin  Johnson</span>, <span class="hlFld-ContribAuthor ">Yong  Jia</span>, <span class="hlFld-ContribAuthor ">Shailaja  Kasibhatla</span>, <span class="hlFld-ContribAuthor ">Chun  Li</span>, <span class="hlFld-ContribAuthor ">John  Isbell</span>, <span class="hlFld-ContribAuthor ">Glen  Spraggon</span>, <span class="hlFld-ContribAuthor ">Steven  Bender</span>, and <span class="hlFld-ContribAuthor ">Pierre-Yves  Michellys</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6671-6689. <a href="https://doi.org/10.1021/acs.jmedchem.5b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%25252CE%252529-N-%2525287-Chloro-1-%2525281-%25255B4-%252528dimethylamino%252529but-2-enoyl%25255Dazepan-3-yl%252529-1H-benzo%25255Bd%25255Dimidazol-2-yl%252529-2-methylisonicotinamide%252B%252528EGF816%252529%25252C%252Ba%252BNovel%25252C%252BPotent%25252C%252Band%252BWT%252BSparing%252BCovalent%252BInhibitor%252Bof%252BOncogenic%252B%252528L858R%25252C%252Bex19del%252529%252Band%252BResistant%252B%252528T790M%252529%252BEGFR%252BMutants%252Bfor%252Bthe%252BTreatment%252Bof%252BEGFR%252BMutant%252BNon-Small-Cell%252BLung%252BCancers%26aulast%3DLelais%26aufirst%3DG%25C3%25A9rald%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D22122015%26date%3D19072016%26date%3D28072016%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sung-Han  Hsiao</span>, <span class="hlFld-ContribAuthor ">Yu-Jen  Lu</span>, <span class="hlFld-ContribAuthor ">Yan-Qing  Li</span>, <span class="hlFld-ContribAuthor ">Yang-Hui  Huang</span>, <span class="hlFld-ContribAuthor ">Chia-Hung  Hsieh</span>, and <span class="hlFld-ContribAuthor ">Chung-Pu  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (6)
                                     , 2117-2125. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00249" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00249%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DOsimertinib%252B%252528AZD9291%252529%252BAttenuates%252Bthe%252BFunction%252Bof%252BMultidrug%252BResistance-Linked%252BATP-Binding%252BCassette%252BTransporter%252BABCB1%252Bin%252BVitro%26aulast%3DHsiao%26aufirst%3DSung-Han%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D18032016%26date%3D12052016%26date%3D06052016%26date%3D19052016%26date%3D06062016%26date%3D12052016%26volume%3D13%26issue%3D6%26spage%3D2117%26epage%3D2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sébastien L.  Degorce</span>, <span class="hlFld-ContribAuthor ">Scott  Boyd</span>, <span class="hlFld-ContribAuthor ">Jon O.  Curwen</span>, <span class="hlFld-ContribAuthor ">Richard  Ducray</span>, <span class="hlFld-ContribAuthor ">Christopher T.  Halsall</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Jones</span>, <span class="hlFld-ContribAuthor ">Franck  Lach</span>, <span class="hlFld-ContribAuthor ">Eva M.  Lenz</span>, <span class="hlFld-ContribAuthor ">Martin  Pass</span>, <span class="hlFld-ContribAuthor ">Sarah  Pass</span>, and <span class="hlFld-ContribAuthor ">Catherine  Trigwell</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4859-4866. <a href="https://doi.org/10.1021/acs.jmedchem.6b00203" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00203</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00203%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%25252C%252BSelective%25252C%252BOrally%252BBioavailable%25252C%252Band%252BEfficacious%252BNovel%252B2-%252528Pyrazol-4-ylamino%252529-pyrimidine%252BInhibitor%252Bof%252Bthe%252BInsulin-like%252BGrowth%252BFactor-1%252BReceptor%252B%252528IGF-1R%252529%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D07022016%26date%3D22042016%26date%3D26052016%26date%3D14042016%26volume%3D59%26issue%3D10%26spage%3D4859%26epage%3D4866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward J.  Hennessy</span>, <span class="hlFld-ContribAuthor ">Claudio  Chuaqui</span>, <span class="hlFld-ContribAuthor ">Susan  Ashton</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Darren A. E.  Cross</span>, <span class="hlFld-ContribAuthor ">Judit É.  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Cath  Eberlein</span>, <span class="hlFld-ContribAuthor ">Lakshmaiah  Gingipalli</span>, <span class="hlFld-ContribAuthor ">Teresa C. M.  Klinowska</span>, <span class="hlFld-ContribAuthor ">Jonathan P.  Orme</span>, <span class="hlFld-ContribAuthor ">Li  Sha</span>, and <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (5)
                                     , 514-519. <a href="https://doi.org/10.1021/acsmedchemlett.6b00058" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00058%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DUtilization%252Bof%252BStructure-Based%252BDesign%252Bto%252BIdentify%252BNovel%25252C%252BIrreversible%252BInhibitors%252Bof%252BEGFR%252BHarboring%252Bthe%252BT790M%252BMutation%26aulast%3DHennessy%26aufirst%3DEdward%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D09022016%26date%3D21032016%26date%3D24032016%26date%3D12052016%26date%3D21032016%26volume%3D7%26issue%3D5%26spage%3D514%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Sangita  Baxi</span>, <span class="hlFld-ContribAuthor ">Doug  Behenna</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Jun Li  Feng</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Hemkens</span>, <span class="hlFld-ContribAuthor ">Amy  Jackson-Fisher</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Ted O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Susan  Kephart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>, <span class="hlFld-ContribAuthor ">Beth  Lunney</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Liu</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Martha A.  Ornelas</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Shijian  Ren</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neal  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Jim  Solowiej</span>, <span class="hlFld-ContribAuthor ">Scott  Sutton</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">William  Vernier</span>, <span class="hlFld-ContribAuthor ">Marlena  Walls</span>, <span class="hlFld-ContribAuthor ">Shuiwang  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>, <span class="hlFld-ContribAuthor ">Min-Jean  Yin</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, and <span class="hlFld-ContribAuthor ">John C.  Kath</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 2005-2024. <a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25257B%2525283R%25252C4R%252529-3-%25255B%252528%25257B5-Chloro-2-%25255B%2525281-methyl-1H-pyrazol-4-yl%252529amino%25255D-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%25257Doxy%252529methyl%25255D-4-methoxypyrrolidin-1-yl%25257Dprop-2-en-1-one%252B%252528PF-06459988%252529%25252C%252Ba%252BPotent%25252C%252BWT%252BSparing%25252C%252BIrreversible%252BInhibitor%252Bof%252BT790M-Containing%252BEGFR%252BMutants%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17102015%26date%3D28012016%26date%3D10032016%26date%3D12012016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Heald</span>, <span class="hlFld-ContribAuthor ">Krista K.  Bowman</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">Daniel  Burdick</span>, <span class="hlFld-ContribAuthor ">Bryan  Chan</span>, <span class="hlFld-ContribAuthor ">Emily  Chan</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Saundra  Clausen</span>, <span class="hlFld-ContribAuthor ">Belen  Dominguez-Fernandez</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Richard  Elliott</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Philip  Jackson</span>, <span class="hlFld-ContribAuthor ">Jamie  Knight</span>, <span class="hlFld-ContribAuthor ">Hank  La</span>, <span class="hlFld-ContribAuthor ">Michael  Lainchbury</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Sam  Mann</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Kyle  Mortara</span>, <span class="hlFld-ContribAuthor ">Hans  Purkey</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Stephen  Schmidt</span>, <span class="hlFld-ContribAuthor ">Eileen  Seward</span>, <span class="hlFld-ContribAuthor ">Steve  Sideris</span>, <span class="hlFld-ContribAuthor ">Lily  Shao</span>, <span class="hlFld-ContribAuthor ">Shumei  Wang</span>, <span class="hlFld-ContribAuthor ">Kuen  Yeap</span>, <span class="hlFld-ContribAuthor ">Ivana  Yen</span>, <span class="hlFld-ContribAuthor ">Christine  Yu</span>, and <span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (22)
                                     , 8877-8895. <a href="https://doi.org/10.1021/acs.jmedchem.5b01412" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01412</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01412%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNoncovalent%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%25253A%252BA%252BLead%252BOptimization%252BCase%252BStudy%26aulast%3DHeald%26aufirst%3DRobert%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D30062015%26date%3D12112015%26date%3D25112015%26date%3D10102015%26volume%3D58%26issue%3D22%26spage%3D8877%26epage%3D8895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">André  Richters</span>, <span class="hlFld-ContribAuthor ">Matthäus  Getlik</span>, <span class="hlFld-ContribAuthor ">Stefano  Tomassi</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Martin  Termathe</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Christian  Becker</span>, <span class="hlFld-ContribAuthor ">Svenja  Mayer-Wrangowski</span>, <span class="hlFld-ContribAuthor ">Christian  Grütter</span>, <span class="hlFld-ContribAuthor ">Niklas  Uhlenbrock</span>, <span class="hlFld-ContribAuthor ">Jasmin  Krüll</span>, <span class="hlFld-ContribAuthor ">Niklas  Schaumann</span>, <span class="hlFld-ContribAuthor ">Simone  Eppmann</span>, <span class="hlFld-ContribAuthor ">Patrick  Kibies</span>, <span class="hlFld-ContribAuthor ">Franziska  Hoffgaard</span>, <span class="hlFld-ContribAuthor ">Jochen  Heil</span>, <span class="hlFld-ContribAuthor ">Sascha  Menninger</span>, <span class="hlFld-ContribAuthor ">Sandra  Ortiz-Cuaran</span>, <span class="hlFld-ContribAuthor ">Johannes M.  Heuckmann</span>, <span class="hlFld-ContribAuthor ">Verena  Tinnefeld</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Martin L.  Sos</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Roman K.  Thomas</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Kast</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (17)
                                     , 6844-6863. <a href="https://doi.org/10.1021/acs.jmedchem.5b01082" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BDrug%252BResistance%252Bin%252BEGFR%252Bwith%252BCovalent%252BInhibitors%25253A%252BA%252BStructure-Based%252BDesign%252BApproach%26aulast%3DEngel%26aufirst%3DJulian%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D16042015%26date%3D31082015%26date%3D10092015%26date%3D14082015%26volume%3D58%26issue%3D17%26spage%3D6844%26epage%3D6863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Kate  Ashton</span>, <span class="hlFld-ContribAuthor ">James  Brown</span>, <span class="hlFld-ContribAuthor ">Jian Jeffrey  Chen</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Fang-Tsao  Hong</span>, <span class="hlFld-ContribAuthor ">Essa  Hu-Harrington</span>, <span class="hlFld-ContribAuthor ">Tom  Nguyen</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean, Jr.</span>, <span class="hlFld-ContribAuthor ">Seifu  Tadesse</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Michele  Kubryk</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhan</span>, <span class="hlFld-ContribAuthor ">Keegan  Cooke</span>, <span class="hlFld-ContribAuthor ">Petia  Mitchell</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Faye  Hsieh</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Nataraj  Kalyanaraman</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Edward K.  Lobenhofer</span>, <span class="hlFld-ContribAuthor ">Dina A.  Andrews</span>, <span class="hlFld-ContribAuthor ">Nancy  Everds</span>, <span class="hlFld-ContribAuthor ">Roberto  Guzman</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Parsons</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hedley</span>, <span class="hlFld-ContribAuthor ">Jason  Tedrow</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Thiel</span>, <span class="hlFld-ContribAuthor ">Matthew  Potter</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Pedro J.  Beltran</span>, and <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 987-992. <a href="https://doi.org/10.1021/acsmedchemlett.5b00193" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00193%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOxopyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08052015%26date%3D27072015%26date%3D31072015%26date%3D10092015%26date%3D27072015%26volume%3D6%26issue%3D9%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Mairi  Challinor</span>, <span class="hlFld-ContribAuthor ">Judit E.  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Kay  Eckersley</span>, <span class="hlFld-ContribAuthor ">Gary  Fairley</span>, <span class="hlFld-ContribAuthor ">Lyman  Feron</span>, <span class="hlFld-ContribAuthor ">Vikki  Flemington</span>, <span class="hlFld-ContribAuthor ">Mark A.  Graham</span>, <span class="hlFld-ContribAuthor ">Ryan  Greenwood</span>, <span class="hlFld-ContribAuthor ">Philip  Hopcroft</span>, <span class="hlFld-ContribAuthor ">Tina D.  Howard</span>, <span class="hlFld-ContribAuthor ">Michael  James</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Jones</span>, <span class="hlFld-ContribAuthor ">Christopher R.  Jones</span>, <span class="hlFld-ContribAuthor ">Jonathan  Renshaw</span>, <span class="hlFld-ContribAuthor ">Karen  Roberts</span>, <span class="hlFld-ContribAuthor ">Lindsay  Snow</span>, <span class="hlFld-ContribAuthor ">Michael  Tonge</span>, and <span class="hlFld-ContribAuthor ">Kay  Yeung</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4790-4801. <a href="https://doi.org/10.1021/acs.jmedchem.5b00466" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Guided%252BDesign%252Bof%252BHighly%252BSelective%252Band%252BPotent%252BCovalent%252BInhibitors%252Bof%252BERK1%25252F2%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D22032015%26date%3D28052015%26date%3D11062015%26date%3D15052015%26volume%3D58%26issue%3D11%26spage%3D4790%26epage%3D4801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tereza  Vaclova</span>, <span class="hlFld-ContribAuthor ">Ursula  Grazini</span>, <span class="hlFld-ContribAuthor ">Lewis  Ward</span>, <span class="hlFld-ContribAuthor ">Daniel  O’Neill</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Markovets</span>, <span class="hlFld-ContribAuthor ">Xiangning  Huang</span>, <span class="hlFld-ContribAuthor ">Juliann  Chmielecki</span>, <span class="hlFld-ContribAuthor ">Ryan  Hartmaier</span>, <span class="hlFld-ContribAuthor ">Kenneth S.  Thress</span>, <span class="hlFld-ContribAuthor ">Paul D.  Smith</span>, <span class="hlFld-ContribAuthor ">J. Carl  Barrett</span>, <span class="hlFld-ContribAuthor ">Julian  Downward</span>, <span class="hlFld-ContribAuthor ">Elza C.  de Bruin</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-22057-8" title="DOI URL">https://doi.org/10.1038/s41467-021-22057-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-22057-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-22057-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DClinical%252Bimpact%252Bof%252Bsubclonal%252BEGFR%252BT790M%252Bmutations%252Bin%252Badvanced-stage%252BEGFR-mutant%252Bnon-small-cell%252Blung%252Bcancers%26aulast%3DVaclova%26aufirst%3DTereza%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lixue  Chen</span>, <span class="hlFld-ContribAuthor ">Yunhao  Zhang</span>, <span class="hlFld-ContribAuthor ">Liangliang  Tian</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Tuo  Deng</span>, <span class="hlFld-ContribAuthor ">Xu  Zheng</span>, <span class="hlFld-ContribAuthor ">Tong  Wang</span>, <span class="hlFld-ContribAuthor ">Zhen  Li</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Youjun  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113626. <a href="https://doi.org/10.1016/j.ejmech.2021.113626" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113626%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNoncovalent%252BEGFR%252BT790M%25252FL858R%252Binhibitors%252Bbased%252Bon%252Bdiphenylpyrimidine%252Bscaffold%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bbioactivity%252Bevaluation%252Bfor%252Bthe%252Btreatment%252Bof%252BNSCLC%26aulast%3DChen%26aufirst%3DLixue%26date%3D2021%26volume%3D223%26spage%3D113626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Camilo  Serrano-Sterling</span>, <span class="hlFld-ContribAuthor ">Diana  Becerra</span>, <span class="hlFld-ContribAuthor ">Jaime  Portilla</span>, <span class="hlFld-ContribAuthor ">Hugo  Rojas</span>, <span class="hlFld-ContribAuthor ">Mario  Macías</span>, <span class="hlFld-ContribAuthor ">Juan-Carlos  Castillo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluation and X-ray crystallographic analysis of novel (E)-2-cyano-3-(het)arylacrylamides as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1244 </em>, 130944. <a href="https://doi.org/10.1016/j.molstruc.2021.130944" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130944</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130944%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252BX-ray%252Bcrystallographic%252Banalysis%252Bof%252Bnovel%252B%252528E%252529-2-cyano-3-%252528het%252529arylacrylamides%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DSerrano-Sterling%26aufirst%3DCamilo%26date%3D2021%26volume%3D1244%26spage%3D130944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sai-Jie  Zuo</span>, <span class="hlFld-ContribAuthor ">Xiao-Liang  Cheng</span>, <span class="hlFld-ContribAuthor ">Dong-Zheng  Liu</span>, <span class="hlFld-ContribAuthor ">Wei-Yi  Feng</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative analysis and pharmacokinetic study of a novel diarylurea EGFR inhibitor (ZCJ14) in rat plasma using a validated LC-MS/MS method. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica</span><span> <strong>2021,</strong> <em>71 </em>
                                    (3)
                                     , 415-428. <a href="https://doi.org/10.2478/acph-2021-0024" title="DOI URL">https://doi.org/10.2478/acph-2021-0024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2478/acph-2021-0024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2478%2Facph-2021-0024%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%26atitle%3DQuantitative%252Banalysis%252Band%252Bpharmacokinetic%252Bstudy%252Bof%252Ba%252Bnovel%252Bdiarylurea%252BEGFR%252Binhibitor%252B%252528ZCJ14%252529%252Bin%252Brat%252Bplasma%252Busing%252Ba%252Bvalidated%252BLC-MS%25252FMS%252Bmethod%26aulast%3DZuo%26aufirst%3DSai-Jie%26date%3D2021%26date%3D2020%26volume%3D71%26issue%3D3%26spage%3D415%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lixue  Chen</span>, <span class="hlFld-ContribAuthor ">Yunhao  Zhang</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Hunjun  Sun</span>, <span class="hlFld-ContribAuthor ">Yan  Qi</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Youjun  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105045. <a href="https://doi.org/10.1016/j.bioorg.2021.105045" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bhydroxamic%252Bacid-substituted%252B2%25252C4-diaryl%252Baminopyrimidines%252Bas%252Bpotent%252BEGFRT790M%25252FL858R%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BNSCLC%26aulast%3DChen%26aufirst%3DLixue%26date%3D2021%26volume%3D114%26spage%3D105045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ismail M.M.  Othman</span>, <span class="hlFld-ContribAuthor ">Zahra M.  Alamshany</span>, <span class="hlFld-ContribAuthor ">Nada Y.  Tashkandi</span>, <span class="hlFld-ContribAuthor ">Mohamed A.M.  Gad-Elkareem</span>, <span class="hlFld-ContribAuthor ">Manal M.  Anwar</span>, <span class="hlFld-ContribAuthor ">Eman S.  Nossier</span>. </span><span class="cited-content_cbyCitation_article-title">New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105078. <a href="https://doi.org/10.1016/j.bioorg.2021.105078" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNew%252Bpyrimidine%252Band%252Bpyrazole-based%252Bcompounds%252Bas%252Bpotential%252BEGFR%252Binhibitors%25253A%252BSynthesis%25252C%252Banticancer%25252C%252Bantimicrobial%252Bevaluation%252Band%252Bcomputational%252Bstudies%26aulast%3DOthman%26aufirst%3DIsmail%2BM.M.%26date%3D2021%26volume%3D114%26spage%3D105078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114643. <a href="https://doi.org/10.1016/j.bcp.2021.114643" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114643%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFighting%252Btertiary%252Bmutations%252Bin%252BEGFR-driven%252Blung-cancers%25253A%252BCurrent%252Badvances%252Band%252Bfuture%252Bperspectives%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DScalvini%26aufirst%3DLaura%26date%3D2021%26volume%3D190%26spage%3D114643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Funeng  Xu</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>113 </em>, 105011. <a href="https://doi.org/10.1016/j.bioorg.2021.105011" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bsynthesis%252Breview%252Bof%252Bthe%252Bapproved%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Banticancer%252Btherapy%252Bin%252B2015%2525E2%252580%2525932020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D113%26spage%3D105011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Yunyu  Xie</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">An update of new small-molecule anticancer drugs approved from 2015 to 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113473. <a href="https://doi.org/10.1016/j.ejmech.2021.113473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bof%252Bnew%252Bsmall-molecule%252Banticancer%252Bdrugs%252Bapproved%252Bfrom%252B2015%252Bto%252B2020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D220%26spage%3D113473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atsushi  Osoegawa</span>, <span class="hlFld-ContribAuthor ">Masafumi  Yamaguchi</span>, <span class="hlFld-ContribAuthor ">Tomomi  Nakamura</span>, <span class="hlFld-ContribAuthor ">Ryotaro  Morinaga</span>, <span class="hlFld-ContribAuthor ">Kentaro  Tanaka</span>, <span class="hlFld-ContribAuthor ">Kosuke  Kashiwabara</span>, <span class="hlFld-ContribAuthor ">Takashi  Miura</span>, <span class="hlFld-ContribAuthor ">Takayuki  Suetsugu</span>, <span class="hlFld-ContribAuthor ">Taishi  Harada</span>, <span class="hlFld-ContribAuthor ">Tatsuma  Asoh</span>, <span class="hlFld-ContribAuthor ">Kenichi  Taguchi</span>, <span class="hlFld-ContribAuthor ">Kazuki  Nabeshima</span>, <span class="hlFld-ContribAuthor ">Junji  Kishimoto</span>, <span class="hlFld-ContribAuthor ">Kazuko  Sakai</span>, <span class="hlFld-ContribAuthor ">Kazuto  Nishio</span>, <span class="hlFld-ContribAuthor ">Kenji  Sugio</span>. </span><span class="cited-content_cbyCitation_article-title">High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. </span><span class="cited-content_cbyCitation_journal-name">JTO Clinical and Research Reports</span><span> <strong>2021,</strong> <em>2 </em>
                                    (7)
                                     , 100191. <a href="https://doi.org/10.1016/j.jtocrr.2021.100191" title="DOI URL">https://doi.org/10.1016/j.jtocrr.2021.100191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtocrr.2021.100191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtocrr.2021.100191%26sid%3Dliteratum%253Aachs%26jtitle%3DJTO%2520Clinical%2520and%2520Research%2520Reports%26atitle%3DHigh%252BIncidence%252Bof%252BC797S%252BMutation%252Bin%252BPatients%252BWith%252BLong%252BTreatment%252BHistory%252Bof%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%252BIncluding%252BOsimertinib%26aulast%3DOsoegawa%26aufirst%3DAtsushi%26date%3D2021%26volume%3D2%26issue%3D7%26spage%3D100191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Ming  Cai</span>, <span class="hlFld-ContribAuthor ">Liang  Shao</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein Kinases Degradation by PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.679120" title="DOI URL">https://doi.org/10.3389/fchem.2021.679120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.679120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.679120%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DTargeting%252BProtein%252BKinases%252BDegradation%252Bby%252BPROTACs%26aulast%3DYu%26aufirst%3DFei%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Wittlinger</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>40 </em>, 1-13. <a href="https://doi.org/10.1080/17460441.2021.1936496" title="DOI URL">https://doi.org/10.1080/17460441.2021.1936496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1936496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1936496%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DThe%252Bpre-clinical%252Bdiscovery%252Band%252Bdevelopment%252Bof%252Bosimertinib%252Bused%252Bto%252Btreat%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DWittlinger%26aufirst%3DFlorian%26date%3D2021%26date%3D2021%26volume%3D40%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elise  Bouffard</span>, <span class="hlFld-ContribAuthor ">Balyn W.  Zaro</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Dix</span>, <span class="hlFld-ContribAuthor ">Benjamin  Cravatt</span>, <span class="hlFld-ContribAuthor ">Chi-Huey  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Refinement of covalent EGFR inhibitor AZD9291 to eliminate off-target activity. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>74 </em>, 153178. <a href="https://doi.org/10.1016/j.tetlet.2021.153178" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.153178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.153178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.153178%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DRefinement%252Bof%252Bcovalent%252BEGFR%252Binhibitor%252BAZD9291%252Bto%252Beliminate%252Boff-target%252Bactivity%26aulast%3DBouffard%26aufirst%3DElise%26date%3D2021%26volume%3D74%26spage%3D153178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Wang</span>, <span class="hlFld-ContribAuthor ">Xiangping  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Kong</span>, <span class="hlFld-ContribAuthor ">Qiuyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Honglei  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a sensitive UHPLC–MS/MS method for the pharmacokinetics study of a novel tyrosine kinase inhibitors, 1‐[4‐(4‐{5‐Chloro‐4‐[2‐(propane‐2‐sulfonyl)‐phenylamino]‐pyrimidin‐2‐ylamino}‐phenyl)‐piperazin‐1‐yl]‐propenone in rats. </span><span class="cited-content_cbyCitation_journal-name">Biomedical Chromatography</span><span> <strong>2021,</strong> <em>35 </em>
                                    (5)
                                     <a href="https://doi.org/10.1002/bmc.5059" title="DOI URL">https://doi.org/10.1002/bmc.5059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bmc.5059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbmc.5059%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Chromatography%26atitle%3DDevelopment%252Bof%252Ba%252Bsensitive%252BUHPLC%2525E2%252580%252593MS%25252FMS%252Bmethod%252Bfor%252Bthe%252Bpharmacokinetics%252Bstudy%252Bof%252Ba%252Bnovel%252Btyrosine%252Bkinase%252Binhibitors%25252C%252B1%2525E2%252580%252590%25255B4%2525E2%252580%252590%2525284%2525E2%252580%252590%25257B5%2525E2%252580%252590Chloro%2525E2%252580%2525904%2525E2%252580%252590%25255B2%2525E2%252580%252590%252528propane%2525E2%252580%2525902%2525E2%252580%252590sulfonyl%252529%2525E2%252580%252590phenylamino%25255D%2525E2%252580%252590pyrimidin%2525E2%252580%2525902%2525E2%252580%252590ylamino%25257D%2525E2%252580%252590phenyl%252529%2525E2%252580%252590piperazin%2525E2%252580%2525901%2525E2%252580%252590yl%25255D%2525E2%252580%252590propenone%252Bin%252Brats%26aulast%3DWang%26aufirst%3DLin%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yueyu  Dai</span>, <span class="hlFld-ContribAuthor ">Fangyuan  Zhong</span>, <span class="hlFld-ContribAuthor ">Wenbin  Liu</span>, <span class="hlFld-ContribAuthor ">Qibin  Song</span>, <span class="hlFld-ContribAuthor ">Weiguo  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Research and Clinical Oncology</span><span> <strong>2021,</strong> <em>147 </em>
                                    (5)
                                     , 1379-1388. <a href="https://doi.org/10.1007/s00432-021-03547-0" title="DOI URL">https://doi.org/10.1007/s00432-021-03547-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00432-021-03547-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00432-021-03547-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Clinical%2520Oncology%26atitle%3DMycoplasma%252Bhyorhinis%252Binfection%252Bpromotes%252Btyrosine%252Bkinase%252Binhibitor%252B%252528TKI%252529%252Bresistance%252Bin%252Blung%252Badenocarcinoma%252Bpatients%26aulast%3DDai%26aufirst%3DYueyu%26date%3D2021%26date%3D2021%26volume%3D147%26issue%3D5%26spage%3D1379%26epage%3D1388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Si-Qi  Feng</span>, <span class="hlFld-ContribAuthor ">An-Qi  Li</span>, <span class="hlFld-ContribAuthor ">Jia-Hui  Zuo</span>, <span class="hlFld-ContribAuthor ">Dan-Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Jie  Xing</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Xie</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of new indole containing biaryl derivatives as potent antiproliferative agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104821. <a href="https://doi.org/10.1016/j.bioorg.2021.104821" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104821%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnew%252Bindole%252Bcontaining%252Bbiaryl%252Bderivatives%252Bas%252Bpotent%252Bantiproliferative%252Bagents%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2021%26volume%3D110%26spage%3D104821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Bo  Cheng</span>, <span class="hlFld-ContribAuthor ">Zisheng  Chen</span>, <span class="hlFld-ContribAuthor ">Jianfu  Li</span>, <span class="hlFld-ContribAuthor ">Hengrui  Liang</span>, <span class="hlFld-ContribAuthor ">Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>, <span class="hlFld-ContribAuthor ">Caichen  Li</span>, <span class="hlFld-ContribAuthor ">Ke  Xu</span>, <span class="hlFld-ContribAuthor ">Shan  Xiong</span>, <span class="hlFld-ContribAuthor ">Weixiang  Lu</span>, <span class="hlFld-ContribAuthor ">Zhuxing  Chen</span>, <span class="hlFld-ContribAuthor ">Ran  Zhong</span>, <span class="hlFld-ContribAuthor ">Shen  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhanhong  Xie</span>, <span class="hlFld-ContribAuthor ">Jun  Liu</span>, <span class="hlFld-ContribAuthor ">Wenhua  Liang</span>, <span class="hlFld-ContribAuthor ">Jianxing  He</span>. </span><span class="cited-content_cbyCitation_article-title">Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Oncology/Hematology</span><span> <strong>2021,</strong> <em>160 </em>, 103305. <a href="https://doi.org/10.1016/j.critrevonc.2021.103305" title="DOI URL">https://doi.org/10.1016/j.critrevonc.2021.103305</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.critrevonc.2021.103305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.critrevonc.2021.103305%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Oncology%252FHematology%26atitle%3DToxicity%252Bprofile%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Bpatients%252Bwith%252Blung%252Bcancer%25253A%252BA%252Bsystematic%252Breview%252Band%252Bnetwork%252Bmeta-analysis%26aulast%3DZhao%26aufirst%3DYi%26date%3D2021%26volume%3D160%26spage%3D103305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiao  Liu</span>, <span class="hlFld-ContribAuthor ">Yanli  Luo</span>, <span class="hlFld-ContribAuthor ">Zerui  Li</span>, <span class="hlFld-ContribAuthor ">Chen  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>, 116094. <a href="https://doi.org/10.1016/j.bmc.2021.116094" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116094%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Bmodifications%252Bon%252Bindole%252Band%252Bpyrimidine%252Brings%252Bof%252Bosimertinib%252Blead%252Bto%252Bhigh%252Bselectivity%252Btowards%252BL858R%25252FT790M%252Bdouble%252Bmutant%252Benzyme%252Band%252Bpotent%252Bantitumor%252Bactivity%26aulast%3DLiu%26aufirst%3DQiao%26date%3D2021%26volume%3D36%26spage%3D116094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naoyuki  Nishiya</span>, <span class="hlFld-ContribAuthor ">Yusuke  Oku</span>, <span class="hlFld-ContribAuthor ">Chie  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Tsutomu  Fukuda</span>, <span class="hlFld-ContribAuthor ">Shingo  Dan</span>, <span class="hlFld-ContribAuthor ">Tetsuo  Mashima</span>, <span class="hlFld-ContribAuthor ">Masaru  Ushijima</span>, <span class="hlFld-ContribAuthor ">Yoko  Furukawa</span>, <span class="hlFld-ContribAuthor ">Yuka  Sasaki</span>, <span class="hlFld-ContribAuthor ">Keishi  Otsu</span>, <span class="hlFld-ContribAuthor ">Tomoko  Sakyo</span>, <span class="hlFld-ContribAuthor ">Masanori  Abe</span>, <span class="hlFld-ContribAuthor ">Honami  Yonezawa</span>, <span class="hlFld-ContribAuthor ">Fumito  Ishibashi</span>, <span class="hlFld-ContribAuthor ">Masaaki  Matsuura</span>, <span class="hlFld-ContribAuthor ">Akihiro  Tomida</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Seimiya</span>, <span class="hlFld-ContribAuthor ">Takao  Yamori</span>, <span class="hlFld-ContribAuthor ">Masatomo  Iwao</span>, <span class="hlFld-ContribAuthor ">Yoshimasa  Uehara</span>. </span><span class="cited-content_cbyCitation_article-title">Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2021,</strong> <em>304 </em><a href="https://doi.org/10.1111/cas.14839" title="DOI URL">https://doi.org/10.1111/cas.14839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.14839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.14839%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DLamellarin%252B14%25252C%252Ba%252Bderivative%252Bof%252Bmarine%252Balkaloids%25252C%252Binhibits%252Bthe%252BT790M%25252FC797S%252Bmutant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DNishiya%26aufirst%3DNaoyuki%26date%3D2021%26date%3D2021%26volume%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaowei  Wu</span>, <span class="hlFld-ContribAuthor ">Mengdi  Dai</span>, <span class="hlFld-ContribAuthor ">Rongrong  Cui</span>, <span class="hlFld-ContribAuthor ">Yulan  Wang</span>, <span class="hlFld-ContribAuthor ">Chunpu  Li</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Jihui  Zhao</span>, <span class="hlFld-ContribAuthor ">Bao  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Dan  Feng</span>, <span class="hlFld-ContribAuthor ">Tianbiao  Yang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zheng</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 781-794. <a href="https://doi.org/10.1016/j.apsb.2020.09.002" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.09.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.09.002%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252Bderivatives%252Bas%252Bcovalent%252BFGFR%252Binhibitors%26aulast%3DWu%26aufirst%3DXiaowei%26date%3D2021%26volume%3D11%26issue%3D3%26spage%3D781%26epage%3D794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>165 </em>, 105422. <a href="https://doi.org/10.1016/j.phrs.2021.105422" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105422%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DOrally%252Beffective%252BFDA-approved%252Bprotein%252Bkinase%252Btargeted%252Bcovalent%252Binhibitors%252B%252528TCIs%252529%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2021%26volume%3D165%26spage%3D105422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew J.  Goldstein</span>, <span class="hlFld-ContribAuthor ">Malte  Peters</span>, <span class="hlFld-ContribAuthor ">Barbara L.  Weber</span>, <span class="hlFld-ContribAuthor ">Charles B.  Davis</span>. </span><span class="cited-content_cbyCitation_article-title">Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency‐Guided First‐in‐Human Studies. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Science</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     , 536-543. <a href="https://doi.org/10.1111/cts.12902" title="DOI URL">https://doi.org/10.1111/cts.12902</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cts.12902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcts.12902%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Science%26atitle%3DOptimizing%252Bthe%252BTherapeutic%252BWindow%252Bof%252BTargeted%252BDrugs%252Bin%252BOncology%25253A%252BPotency%2525E2%252580%252590Guided%252BFirst%2525E2%252580%252590in%2525E2%252580%252590Human%252BStudies%26aulast%3DGoldstein%26aufirst%3DMatthew%2BJ.%26date%3D2021%26date%3D2020%26volume%3D14%26issue%3D2%26spage%3D536%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianheng  Li</span>, <span class="hlFld-ContribAuthor ">Baijiao  An</span>, <span class="hlFld-ContribAuthor ">Xianheng  Song</span>, <span class="hlFld-ContribAuthor ">Qianzhong  Zhang</span>, <span class="hlFld-ContribAuthor ">Chun  Chen</span>, <span class="hlFld-ContribAuthor ">Shuxian  Wei</span>, <span class="hlFld-ContribAuthor ">Runzhu  Fan</span>, <span class="hlFld-ContribAuthor ">Xingshu  Li</span>, <span class="hlFld-ContribAuthor ">Yong  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFRL858R/T790M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113019. <a href="https://doi.org/10.1016/j.ejmech.2020.113019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-diaryl%252Bpyrimidine%252Bderivatives%252Bas%252Bselective%252BEGFRL858R%25252FT790M%252Binhibitors%26aulast%3DLi%26aufirst%3DJianheng%26date%3D2021%26volume%3D212%26spage%3D113019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fushun  Fan</span>, <span class="hlFld-ContribAuthor ">Minhua  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaolan  Ye</span>, <span class="hlFld-ContribAuthor ">Zhenxian  Mo</span>, <span class="hlFld-ContribAuthor ">Yaru  Ma</span>, <span class="hlFld-ContribAuthor ">Liying  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaotong  Liang</span>, <span class="hlFld-ContribAuthor ">Haiqi  Liu</span>, <span class="hlFld-ContribAuthor ">Yunwo  Weng</span>, <span class="hlFld-ContribAuthor ">Mingsheng  Lin</span>, <span class="hlFld-ContribAuthor ">Xinjian  Liu</span>, <span class="hlFld-ContribAuthor ">Xiong  Cai</span>, <span class="hlFld-ContribAuthor ">Changgeng  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     , 100961. <a href="https://doi.org/10.1016/j.tranon.2020.100961" title="DOI URL">https://doi.org/10.1016/j.tranon.2020.100961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2020.100961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2020.100961%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DBEBT-109%25252C%252Ba%252Bpan-mutant-selective%252BEGFR%252Binhibitor%252Bwith%252Bpotent%252Bantitumor%252Bactivity%252Bin%252BEGFR-mutant%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DFan%26aufirst%3DFushun%26date%3D2021%26volume%3D14%26issue%3D2%26spage%3D100961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Kuojun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yiwu  Yao</span>, <span class="hlFld-ContribAuthor ">Yunyao  Liu</span>, <span class="hlFld-ContribAuthor ">Yong  Ni</span>, <span class="hlFld-ContribAuthor ">Chenzhong  Liao</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yatao  Qiu</span>, <span class="hlFld-ContribAuthor ">Dexiang  Wang</span>, <span class="hlFld-ContribAuthor ">Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Qiang</span>, <span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113022. <a href="https://doi.org/10.1016/j.ejmech.2020.113022" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113022%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bnicotinamide%252Bphosphoribosyltransferase%252Band%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DZhang%26aufirst%3DWanheng%26date%3D2021%26volume%3D211%26spage%3D113022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kjell  Jorner</span>, <span class="hlFld-ContribAuthor ">Tore  Brinck</span>, <span class="hlFld-ContribAuthor ">Per-Ola  Norrby</span>, <span class="hlFld-ContribAuthor ">David  Buttar</span>. </span><span class="cited-content_cbyCitation_article-title">Machine learning meets mechanistic modelling for accurate prediction of experimental activation energies. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 1163-1175. <a href="https://doi.org/10.1039/D0SC04896H" title="DOI URL">https://doi.org/10.1039/D0SC04896H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC04896H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC04896H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DMachine%252Blearning%252Bmeets%252Bmechanistic%252Bmodelling%252Bfor%252Baccurate%252Bprediction%252Bof%252Bexperimental%252Bactivation%252Benergies%26aulast%3DJorner%26aufirst%3DKjell%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D3%26spage%3D1163%26epage%3D1175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiu-Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Jie  Han</span>, <span class="hlFld-ContribAuthor ">Yin-Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yun-Fang  Li</span>, <span class="hlFld-ContribAuthor ">Xiang-Cong  Wang</span>, <span class="hlFld-ContribAuthor ">Jian-Xiong  Ran</span>, <span class="hlFld-ContribAuthor ">Zhong-Hua  Wang</span>, <span class="hlFld-ContribAuthor ">Fan-Hong  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Study on the mild, rapid and selective difluorocarbene-mediated triclassification of iododifluoroacetophenone with secondary amines and tree model for product classification. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>78 </em>, 131762. <a href="https://doi.org/10.1016/j.tet.2020.131762" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131762%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DStudy%252Bon%252Bthe%252Bmild%25252C%252Brapid%252Band%252Bselective%252Bdifluorocarbene-mediated%252Btriclassification%252Bof%252Biododifluoroacetophenone%252Bwith%252Bsecondary%252Bamines%252Band%252Btree%252Bmodel%252Bfor%252Bproduct%252Bclassification%26aulast%3DChen%26aufirst%3DXiu-Ping%26date%3D2021%26volume%3D78%26spage%3D131762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Kan  Chen</span>, <span class="hlFld-ContribAuthor ">Peter  Johnström</span>, <span class="hlFld-ContribAuthor ">Nicole  Strittmatter</span>, <span class="hlFld-ContribAuthor ">Yumei  Yan</span>, <span class="hlFld-ContribAuthor ">Gail L.  Wrigley</span>, <span class="hlFld-ContribAuthor ">Magnus  Schou</span>, <span class="hlFld-ContribAuthor ">Richard  Goodwin</span>, <span class="hlFld-ContribAuthor ">Katarina  Varnäs</span>, <span class="hlFld-ContribAuthor ">Sally J.  Adua</span>, <span class="hlFld-ContribAuthor ">Minghui  Zhao</span>, <span class="hlFld-ContribAuthor ">Don X.  Nguyen</span>, <span class="hlFld-ContribAuthor ">Gareth  Maglennon</span>, <span class="hlFld-ContribAuthor ">Peter  Barton</span>, <span class="hlFld-ContribAuthor ">James  Atkinson</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Annika  Janefeldt</span>, <span class="hlFld-ContribAuthor ">Joanne  Wilson</span>, <span class="hlFld-ContribAuthor ">Aaron  Smith</span>, <span class="hlFld-ContribAuthor ">Akihiro  Takano</span>, <span class="hlFld-ContribAuthor ">Ryosuke  Arakawa</span>, <span class="hlFld-ContribAuthor ">Mikhail  Kondrashov</span>, <span class="hlFld-ContribAuthor ">Jonas  Malmquist</span>, <span class="hlFld-ContribAuthor ">Evgeny  Revunov</span>, <span class="hlFld-ContribAuthor ">Ana  Vazquez-Romero</span>, <span class="hlFld-ContribAuthor ">Mohammad Mahdi  Moein</span>, <span class="hlFld-ContribAuthor ">Albert D.  Windhorst</span>, <span class="hlFld-ContribAuthor ">Natasha A.  Karp</span>, <span class="hlFld-ContribAuthor ">M. Raymond V.  Finlay</span>, <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">James W.T.  Yates</span>, <span class="hlFld-ContribAuthor ">Paul D.  Smith</span>, <span class="hlFld-ContribAuthor ">Lars  Farde</span>, <span class="hlFld-ContribAuthor ">Zack  Cheng</span>, <span class="hlFld-ContribAuthor ">Darren A.E.  Cross</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2021,</strong> <em>27 </em>
                                    (1)
                                     , 189-201. <a href="https://doi.org/10.1158/1078-0432.CCR-19-1871" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-19-1871</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-19-1871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-19-1871%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DPreclinical%252BComparison%252Bof%252Bthe%252BBlood%2525E2%252580%252593brain%252Bbarrier%252BPermeability%252Bof%252BOsimertinib%252Bwith%252BOther%252BEGFR%252BTKIs%26aulast%3DColclough%26aufirst%3DNicola%26date%3D2021%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D189%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gan  Qiao</span>, <span class="hlFld-ContribAuthor ">Kangping  Bi</span>, <span class="hlFld-ContribAuthor ">Junhong  Liu</span>, <span class="hlFld-ContribAuthor ">Shousong  Cao</span>, <span class="hlFld-ContribAuthor ">Minghua  Liu</span>, <span class="hlFld-ContribAuthor ">Milica  Pešić</span>, <span class="hlFld-ContribAuthor ">Xiukun  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Protein kinases as targets for developing anticancer agents from marine organisms. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - General Subjects</span><span> <strong>2021,</strong> <em>1865 </em>
                                    (1)
                                     , 129759. <a href="https://doi.org/10.1016/j.bbagen.2020.129759" title="DOI URL">https://doi.org/10.1016/j.bbagen.2020.129759</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbagen.2020.129759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbagen.2020.129759%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520General%2520Subjects%26atitle%3DProtein%252Bkinases%252Bas%252Btargets%252Bfor%252Bdeveloping%252Banticancer%252Bagents%252Bfrom%252Bmarine%252Borganisms%26aulast%3DQiao%26aufirst%3DGan%26date%3D2021%26volume%3D1865%26issue%3D1%26spage%3D129759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chuan-dong  Cheng</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Zuo-wei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Zong-ru  Jiang</span>, <span class="hlFld-ContribAuthor ">Ao-li  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Yong-fei  Dong</span>, <span class="hlFld-ContribAuthor ">Wan-xiang  Niu</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Zi-ping  Qi</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-chao  Wang</span>, <span class="hlFld-ContribAuthor ">Chao-shi  Niu</span>, <span class="hlFld-ContribAuthor ">Qing-song  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2021,</strong> <em>42 </em>
                                    (1)
                                     , 108-114. <a href="https://doi.org/10.1038/s41401-020-0418-2" title="DOI URL">https://doi.org/10.1038/s41401-020-0418-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-020-0418-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-020-0418-2%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DOsimertinib%252Bsuccessfully%252Bcombats%252BEGFR-negative%252Bglioblastoma%252Bcells%252Bby%252Binhibiting%252Bthe%252BMAPK%252Bpathway%26aulast%3DChen%26aufirst%3DCheng%26date%3D2021%26date%3D2020%26volume%3D42%26issue%3D1%26spage%3D108%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neil P.  Grimster</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent PROTACs: the best of both worlds?. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.1039/D1MD00191D" title="DOI URL">https://doi.org/10.1039/D1MD00191D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00191D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00191D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252BPROTACs%25253A%252Bthe%252Bbest%252Bof%252Bboth%252Bworlds%25253F%26aulast%3DGrimster%26aufirst%3DNeil%2BP.%26date%3D2021%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-di  Dai</span>, <span class="hlFld-ContribAuthor ">Yue-liang  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Fan</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Yin-chun  Ji</span>, <span class="hlFld-ContribAuthor ">Yi-ming  Sun</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Lan-lan  Li</span>, <span class="hlFld-ContribAuthor ">Yu-ming  Wang</span>, <span class="hlFld-ContribAuthor ">Wen-hu  Duan</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>. </span><span class="cited-content_cbyCitation_article-title">DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.1038/s41401-020-00567-3" title="DOI URL">https://doi.org/10.1038/s41401-020-00567-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-020-00567-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-020-00567-3%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DDW14383%252Bis%252Ban%252Birreversible%252Bpan-FGFR%252Binhibitor%252Bthat%252Bsuppresses%252BFGFR-dependent%252Btumor%252Bgrowth%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DDai%26aufirst%3DMeng-di%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Fang</span>, <span class="hlFld-ContribAuthor ">Victoria  Izumi</span>, <span class="hlFld-ContribAuthor ">Lily L. Remsing  Rix</span>, <span class="hlFld-ContribAuthor ">Eric  Welsh</span>, <span class="hlFld-ContribAuthor ">Ian  Pike</span>, <span class="hlFld-ContribAuthor ">Gary W.  Reuther</span>, <span class="hlFld-ContribAuthor ">Eric B.  Haura</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>, <span class="hlFld-ContribAuthor ">John M.  Koomen</span>. </span><span class="cited-content_cbyCitation_article-title">Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach. </span><span class="cited-content_cbyCitation_journal-name">PROTEOMICS</span><span> <strong>2020,</strong> <em>20 </em>
                                    (24)
                                     , 2000116. <a href="https://doi.org/10.1002/pmic.202000116" title="DOI URL">https://doi.org/10.1002/pmic.202000116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pmic.202000116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpmic.202000116%26sid%3Dliteratum%253Aachs%26jtitle%3DPROTEOMICS%26atitle%3DLowering%252BSample%252BRequirements%252Bto%252BStudy%252BTyrosine%252BKinase%252BSignaling%252BUsing%252BPhosphoproteomics%252Bwith%252Bthe%252BTMT%252BCalibrator%252BApproach%26aulast%3DFang%26aufirst%3DBin%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D24%26spage%3D2000116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mennatallah A.  Shaheen</span>, <span class="hlFld-ContribAuthor ">Ali A.  El-Emam</span>, <span class="hlFld-ContribAuthor ">Nadia S.  El-Gohary</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>105 </em>, 104274. <a href="https://doi.org/10.1016/j.bioorg.2020.104274" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104274%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252Bseries%252Bof%252Bhexahydroquinoline%252Band%252Bfused%252Bquinoline%252Bderivatives%252Bas%252Bpotent%252Binhibitors%252Bof%252Bwild-type%252BEGFR%252Band%252Bmutant%252BEGFR%252B%252528L858R%252Band%252BT790M%252529%26aulast%3DShaheen%26aufirst%3DMennatallah%2BA.%26date%3D2020%26volume%3D105%26spage%3D104274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Wang</span>, <span class="hlFld-ContribAuthor ">Tadaaki  Yamada</span>, <span class="hlFld-ContribAuthor ">Kenji  Kita</span>, <span class="hlFld-ContribAuthor ">Hirokazu  Taniguchi</span>, <span class="hlFld-ContribAuthor ">Sachiko  Arai</span>, <span class="hlFld-ContribAuthor ">Koji  Fukuda</span>, <span class="hlFld-ContribAuthor ">Minoru  Terashima</span>, <span class="hlFld-ContribAuthor ">Akihiko  Ishimura</span>, <span class="hlFld-ContribAuthor ">Akihiro  Nishiyama</span>, <span class="hlFld-ContribAuthor ">Azusa  Tanimoto</span>, <span class="hlFld-ContribAuthor ">Shinji  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Koshiro  Ohtsubo</span>, <span class="hlFld-ContribAuthor ">Kaname  Yamashita</span>, <span class="hlFld-ContribAuthor ">Tomoyoshi  Yamano</span>, <span class="hlFld-ContribAuthor ">Akihiro  Yoshimura</span>, <span class="hlFld-ContribAuthor ">Koichi  Takayama</span>, <span class="hlFld-ContribAuthor ">Kyoichi  Kaira</span>, <span class="hlFld-ContribAuthor ">Yoshihiko  Taniguchi</span>, <span class="hlFld-ContribAuthor ">Shinji  Atagi</span>, <span class="hlFld-ContribAuthor ">Hisanori  Uehara</span>, <span class="hlFld-ContribAuthor ">Rikinari  Hanayama</span>, <span class="hlFld-ContribAuthor ">Isao  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Xujun  Han</span>, <span class="hlFld-ContribAuthor ">Kunio  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Takeshi  Suzuki</span>, <span class="hlFld-ContribAuthor ">Seiji  Yano</span>. </span><span class="cited-content_cbyCitation_article-title">Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-18442-4" title="DOI URL">https://doi.org/10.1038/s41467-020-18442-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-18442-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-18442-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DTransient%252BIGF-1R%252Binhibition%252Bcombined%252Bwith%252Bosimertinib%252Beradicates%252BAXL-low%252Bexpressing%252BEGFR%252Bmutated%252Blung%252Bcancer%26aulast%3DWang%26aufirst%3DRong%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iqrar  Ahmad</span>, <span class="hlFld-ContribAuthor ">Matin  Shaikh</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>, <span class="hlFld-ContribAuthor ">Arabinda  Ghosh</span>, <span class="hlFld-ContribAuthor ">Harun  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>3 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2020.1844801" title="DOI URL">https://doi.org/10.1080/07391102.2020.1844801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1844801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1844801%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3Dp38%2525CE%2525B1%252BMAP%252Bkinase%252Binhibitors%252Bto%252Bovercome%252BEGFR%252Btertiary%252BC797S%252Bpoint%252Bmutation%252Bassociated%252Bwith%252Bosimertinib%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%25253A%252Bemergence%252Bof%252Bfourth-generation%252BEGFR%252Binhibitor%26aulast%3DAhmad%26aufirst%3DIqrar%26date%3D2020%26date%3D2020%26volume%3D3%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Biersack</span>, <span class="hlFld-ContribAuthor ">Sibel  Polat</span>, <span class="hlFld-ContribAuthor ">Michael  Höpfner</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer properties of chimeric HDAC and kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2020,</strong> <em>184 </em><a href="https://doi.org/10.1016/j.semcancer.2020.11.005" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAnticancer%252Bproperties%252Bof%252Bchimeric%252BHDAC%252Band%252Bkinase%252Binhibitors%26aulast%3DBiersack%26aufirst%3DBernhard%26date%3D2020%26volume%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Floc'h</span>, <span class="hlFld-ContribAuthor ">Sangbin  Lim</span>, <span class="hlFld-ContribAuthor ">Sue  Bickerton</span>, <span class="hlFld-ContribAuthor ">Afshan  Ahmed</span>, <span class="hlFld-ContribAuthor ">Jonathan  Orme</span>, <span class="hlFld-ContribAuthor ">Jelena  Urosevic</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Martin</span>, <span class="hlFld-ContribAuthor ">Darren A.E.  Cross</span>, <span class="hlFld-ContribAuthor ">Byoung Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Paul D.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (11)
                                     , 2298-2307. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0103" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0103%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DOsimertinib%25252C%252Ban%252BIrreversible%252BNext-Generation%252BEGFR%252BTyrosine%252BKinase%252BInhibitor%25252C%252BExerts%252BAntitumor%252BActivity%252Bin%252BVarious%252BPreclinical%252BNSCLC%252BModels%252BHarboring%252Bthe%252BUncommon%252BEGFR%252BMutations%252BG719X%252Bor%252BL861Q%252Bor%252BS768I%26aulast%3DFloc%2527h%26aufirst%3DNicolas%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D11%26spage%3D2298%26epage%3D2307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed Karam  Farag</span>, <span class="hlFld-ContribAuthor ">Ahmed H.E.  Hassan</span>, <span class="hlFld-ContribAuthor ">Kyung-Sook  Chung</span>, <span class="hlFld-ContribAuthor ">Jeong-Hun  Lee</span>, <span class="hlFld-ContribAuthor ">Hyo-Sun  Gil</span>, <span class="hlFld-ContribAuthor ">Kyung-Tae  Lee</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Diarylurea derivatives comprising 2,4-diarylpyrimidines: Discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>103 </em>, 104121. <a href="https://doi.org/10.1016/j.bioorg.2020.104121" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104121%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiarylurea%252Bderivatives%252Bcomprising%252B2%25252C4-diarylpyrimidines%25253A%252BDiscovery%252Bof%252Bnovel%252Bpotential%252Banticancer%252Bagents%252Bvia%252Bcombined%252Bfailed-ligands%252Brepurposing%252Band%252Bmolecular%252Bhybridization%252Bapproaches%26aulast%3DFarag%26aufirst%3DAhmed%2BKaram%26date%3D2020%26volume%3D103%26spage%3D104121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paulina  Sobierajska</span>, <span class="hlFld-ContribAuthor ">Anna  Serwotka-Suszczak</span>, <span class="hlFld-ContribAuthor ">Damian  Szymanski</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Marycz</span>, <span class="hlFld-ContribAuthor ">Rafal J.  Wiglusz</span>. </span><span class="cited-content_cbyCitation_article-title">Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (20)
                                     , 4602. <a href="https://doi.org/10.3390/molecules25204602" title="DOI URL">https://doi.org/10.3390/molecules25204602</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25204602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25204602%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNanohydroxyapatite-Mediated%252BImatinib%252BDelivery%252Bfor%252BSpecific%252BAnticancer%252BApplications%26aulast%3DSobierajska%26aufirst%3DPaulina%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D20%26spage%3D4602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Indranil  Chattopadhyay</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Circulating Cell‐free DNA for Personalized Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 83-97. <a href="https://doi.org/10.1002/9781119432487.ch3" title="DOI URL">https://doi.org/10.1002/9781119432487.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119432487.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119432487.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DApplication%252Bof%252BCirculating%252BCell%2525E2%252580%252590free%252BDNA%252Bfor%252BPersonalized%252BCancer%252BTherapy%26aulast%3DChattopadhyay%26aufirst%3DIndranil%26date%3D2020%26date%3D2020%26spage%3D83%26epage%3D97%26pub%3DWiley%26atitle%3DPrecision%252BMedicine%252Bin%252BOncology%26aulast%3DAydogan%26aufirst%3DBulent%26date%3D2020%26date%3D2020%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zichao  Yang</span>, <span class="hlFld-ContribAuthor ">Haikui  Yang</span>, <span class="hlFld-ContribAuthor ">Yangcheng  Ai</span>, <span class="hlFld-ContribAuthor ">Lishun  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Xuan  Xu</span>, <span class="hlFld-ContribAuthor ">Huiwu  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaoyu  Wu</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>152 </em>, 105463. <a href="https://doi.org/10.1016/j.ejps.2020.105463" title="DOI URL">https://doi.org/10.1016/j.ejps.2020.105463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2020.105463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2020.105463%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DComputational%252Bstudies%252Bof%252Bpotent%252Bcovalent%252Binhibitors%252Bon%252Bwild%252Btype%252Bor%252BT790M%25252FL858R%252Bmutant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DYang%26aufirst%3DZichao%26date%3D2020%26volume%3D152%26spage%3D105463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaebong  Jang</span>, <span class="hlFld-ContribAuthor ">Ciric  To</span>, <span class="hlFld-ContribAuthor ">Dries J. H.  De Clercq</span>, <span class="hlFld-ContribAuthor ">Eunyoung  Park</span>, <span class="hlFld-ContribAuthor ">Charles M.  Ponthier</span>, <span class="hlFld-ContribAuthor ">Bo Hee  Shin</span>, <span class="hlFld-ContribAuthor ">Mierzhati  Mushajiang</span>, <span class="hlFld-ContribAuthor ">Radosław P.  Nowak</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (34)
                                     , 14589-14597. <a href="https://doi.org/10.1002/ange.202003500" title="DOI URL">https://doi.org/10.1002/ange.202003500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202003500%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DMutant%2525E2%252580%252590Selective%252BAllosteric%252BEGFR%252BDegraders%252Bare%252BEffective%252BAgainst%252Ba%252BBroad%252BRange%252Bof%252BDrug%2525E2%252580%252590Resistant%252BMutations%26aulast%3DJang%26aufirst%3DJaebong%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D34%26spage%3D14589%26epage%3D14597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaebong  Jang</span>, <span class="hlFld-ContribAuthor ">Ciric  To</span>, <span class="hlFld-ContribAuthor ">Dries J. H.  De Clercq</span>, <span class="hlFld-ContribAuthor ">Eunyoung  Park</span>, <span class="hlFld-ContribAuthor ">Charles M.  Ponthier</span>, <span class="hlFld-ContribAuthor ">Bo Hee  Shin</span>, <span class="hlFld-ContribAuthor ">Mierzhati  Mushajiang</span>, <span class="hlFld-ContribAuthor ">Radosław P.  Nowak</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (34)
                                     , 14481-14489. <a href="https://doi.org/10.1002/anie.202003500" title="DOI URL">https://doi.org/10.1002/anie.202003500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202003500%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DMutant%2525E2%252580%252590Selective%252BAllosteric%252BEGFR%252BDegraders%252Bare%252BEffective%252BAgainst%252Ba%252BBroad%252BRange%252Bof%252BDrug%2525E2%252580%252590Resistant%252BMutations%26aulast%3DJang%26aufirst%3DJaebong%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D34%26spage%3D14481%26epage%3D14489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanshu  Jia</span>, <span class="hlFld-ContribAuthor ">Xiaoyue  Wen</span>, <span class="hlFld-ContribAuthor ">Yufeng  Gong</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Current scenario of indole derivatives with potential anti-drug-resistant cancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112359. <a href="https://doi.org/10.1016/j.ejmech.2020.112359" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112359%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Bscenario%252Bof%252Bindole%252Bderivatives%252Bwith%252Bpotential%252Banti-drug-resistant%252Bcancer%252Bactivity%26aulast%3DJia%26aufirst%3DYanshu%26date%3D2020%26volume%3D200%26spage%3D112359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huijuan  Chen</span>, <span class="hlFld-ContribAuthor ">Aiqin  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Zeming  He</span>, <span class="hlFld-ContribAuthor ">Yanqiu  Mao</span>, <span class="hlFld-ContribAuthor ">Liming  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Research and Clinical Oncology</span><span> <strong>2020,</strong> <em>146 </em>
                                    (7)
                                     , 1867-1876. <a href="https://doi.org/10.1007/s00432-020-03192-z" title="DOI URL">https://doi.org/10.1007/s00432-020-03192-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00432-020-03192-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00432-020-03192-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Clinical%2520Oncology%26atitle%3DTarget-based%252Bgenomic%252Bprofiling%252Bof%252BctDNA%252Bfrom%252BChinese%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bpatients%25253A%252Ba%252Bresult%252Bof%252Breal-world%252Bdata%26aulast%3DChen%26aufirst%3DHuijuan%26date%3D2020%26date%3D2020%26volume%3D146%26issue%3D7%26spage%3D1867%26epage%3D1876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koji  Fukuda</span>, <span class="hlFld-ContribAuthor ">Shinji  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Sachiko  Arai</span>, <span class="hlFld-ContribAuthor ">Kenji  Kita</span>, <span class="hlFld-ContribAuthor ">Azusa  Tanimoto</span>, <span class="hlFld-ContribAuthor ">Akihiro  Nishiyama</span>, <span class="hlFld-ContribAuthor ">Seiji  Yano</span>. </span><span class="cited-content_cbyCitation_article-title">Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in
              EGFR
              ‐mutant lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2020,</strong> <em>111 </em>
                                    (7)
                                     , 2374-2384. <a href="https://doi.org/10.1111/cas.14454" title="DOI URL">https://doi.org/10.1111/cas.14454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.14454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.14454%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DGlycogen%252Bsynthase%252Bkinase%2525E2%252580%2525903%252Binhibition%252Bovercomes%252Bepithelial%2525E2%252580%252590mesenchymal%252Btransition%2525E2%252580%252590associated%252Bresistance%252Bto%252Bosimertinib%252Bin%252BEGFR%252B%2525E2%252580%252590mutant%252Blung%252Bcancer%26aulast%3DFukuda%26aufirst%3DKoji%26date%3D2020%26date%3D2020%26volume%3D111%26issue%3D7%26spage%3D2374%26epage%3D2384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Han</span>, <span class="hlFld-ContribAuthor ">Jiahong  Ren</span>, <span class="hlFld-ContribAuthor ">Feng  Su</span>, <span class="hlFld-ContribAuthor ">Xiaoqin  Hu</span>, <span class="hlFld-ContribAuthor ">Mengyao  Li</span>, <span class="hlFld-ContribAuthor ">Zhijun  Wang</span>, <span class="hlFld-ContribAuthor ">Lintao  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (6)
                                     , 724-733. <a href="https://doi.org/10.2174/1871520620666200302113206" title="DOI URL">https://doi.org/10.2174/1871520620666200302113206</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520620666200302113206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520620666200302113206%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DHybrids%252Bof%252BQuinoline%252Band%252BAnilinopyrimidine%25253A%252BNovel%252BEGFRT790M%252BInhibitors%252Bwith%252BAntiproliferative%252BActivity%252Bagainst%252BNon-Small%252BCell%252BLung%252BCancer%252BCell%252BLines%26aulast%3DHan%26aufirst%3DChun%26date%3D2020%26volume%3D20%26issue%3D6%26spage%3D724%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long  Mao</span>, <span class="hlFld-ContribAuthor ">Wei  Tang</span>, <span class="hlFld-ContribAuthor ">Xiaoying  Zhang</span>, <span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Yile  Chen</span>, <span class="hlFld-ContribAuthor ">Yuning  Hua</span>, <span class="hlFld-ContribAuthor ">Bojie  Weng</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Mo</span>, <span class="hlFld-ContribAuthor ">Yimei  Bao</span>, <span class="hlFld-ContribAuthor ">Li  Teng</span>, <span class="hlFld-ContribAuthor ">Lijun  Xu</span>, <span class="hlFld-ContribAuthor ">Yuren  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Wu</span>, <span class="hlFld-ContribAuthor ">Guanglin  Zhou</span>, <span class="hlFld-ContribAuthor ">Bin  Liang</span>, <span class="hlFld-ContribAuthor ">Changxu  Xu</span>, <span class="hlFld-ContribAuthor ">Biao  Xi</span>, <span class="hlFld-ContribAuthor ">Li  Zhao</span>, <span class="hlFld-ContribAuthor ">Rongda  Xu</span>, <span class="hlFld-ContribAuthor ">Che  Fang</span>, <span class="hlFld-ContribAuthor ">Wanhong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Medicine in Drug Discovery</span><span> <strong>2020,</strong> <em>6 </em>, 100035. <a href="https://doi.org/10.1016/j.medidd.2020.100035" title="DOI URL">https://doi.org/10.1016/j.medidd.2020.100035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medidd.2020.100035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medidd.2020.100035%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%2520in%2520Drug%2520Discovery%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%25252C%252BSelective%252Band%252BIrreversible%252BInhibitor%252B%252528Abivertinib%252529%252Bof%252BMutated%252BEGFR%252Band%252BT790M-induced%252BResistance%252Bfor%252Bthe%252BTreatment%252Bof%252BNSCLC%26aulast%3DMao%26aufirst%3DLong%26date%3D2020%26volume%3D6%26spage%3D100035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riyaz  Shah</span>, <span class="hlFld-ContribAuthor ">Jason F.  Lester</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lung Cancer</span><span> <strong>2020,</strong> <em>21 </em>
                                    (3)
                                     , e216-e228. <a href="https://doi.org/10.1016/j.cllc.2019.12.003" title="DOI URL">https://doi.org/10.1016/j.cllc.2019.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cllc.2019.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cllc.2019.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lung%2520Cancer%26atitle%3DTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BEGFR%252BMutation-Positive%252BNon%2525E2%252580%252593Small-Cell%252BLung%252BCancer%25253A%252BA%252BClash%252Bof%252Bthe%252BGenerations%26aulast%3DShah%26aufirst%3DRiyaz%26date%3D2020%26volume%3D21%26issue%3D3%26spage%3De216%26epage%3De228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Byoungsan  Choi</span>, <span class="hlFld-ContribAuthor ">Minkwon  Cha</span>, <span class="hlFld-ContribAuthor ">Gee Sung  Eun</span>, <span class="hlFld-ContribAuthor ">Dae Hee  Lee</span>, <span class="hlFld-ContribAuthor ">Seul  Lee</span>, <span class="hlFld-ContribAuthor ">Muhammad  Ehsan</span>, <span class="hlFld-ContribAuthor ">Pil Seok  Chae</span>, <span class="hlFld-ContribAuthor ">Won Do  Heo</span>, <span class="hlFld-ContribAuthor ">YongKeun  Park</span>, <span class="hlFld-ContribAuthor ">Tae-Young  Yoon</span>. </span><span class="cited-content_cbyCitation_article-title">Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2020,</strong> <em>9 </em><a href="https://doi.org/10.7554/eLife.53934" title="DOI URL">https://doi.org/10.7554/eLife.53934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.53934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.53934%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DSingle-molecule%252Bfunctional%252Banatomy%252Bof%252Bendogenous%252BHER2-HER3%252Bheterodimers%26aulast%3DChoi%26aufirst%3DByoungsan%26date%3D2020%26date%3D2020%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Junbiao  Chang</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of Biologically Important Biaryl Scaffolds through Direct C–H Bond Activation: Advances and Prospects. </span><span class="cited-content_cbyCitation_journal-name">Topics in Current Chemistry</span><span> <strong>2020,</strong> <em>378 </em>
                                    (2)
                                     <a href="https://doi.org/10.1007/s41061-020-0285-9" title="DOI URL">https://doi.org/10.1007/s41061-020-0285-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s41061-020-0285-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs41061-020-0285-9%26sid%3Dliteratum%253Aachs%26jtitle%3DTopics%2520in%2520Current%2520Chemistry%26atitle%3DConstruction%252Bof%252BBiologically%252BImportant%252BBiaryl%252BScaffolds%252Bthrough%252BDirect%252BC%2525E2%252580%252593H%252BBond%252BActivation%25253A%252BAdvances%252Band%252BProspects%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26date%3D2020%26volume%3D378%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Xu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of selective degraders of EGFRL858R/T790M mutant. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112199. <a href="https://doi.org/10.1016/j.ejmech.2020.112199" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112199%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bselective%252Bdegraders%252Bof%252BEGFRL858R%25252FT790M%252Bmutant%26aulast%3DZhang%26aufirst%3DXin%26date%3D2020%26volume%3D192%26spage%3D112199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Varrone</span>, <span class="hlFld-ContribAuthor ">Katarina  Varnäs</span>, <span class="hlFld-ContribAuthor ">Aurelija  Jucaite</span>, <span class="hlFld-ContribAuthor ">Zsolt  Cselényi</span>, <span class="hlFld-ContribAuthor ">Peter  Johnström</span>, <span class="hlFld-ContribAuthor ">Magnus  Schou</span>, <span class="hlFld-ContribAuthor ">Ana  Vazquez-Romero</span>, <span class="hlFld-ContribAuthor ">Mohammad M  Moein</span>, <span class="hlFld-ContribAuthor ">Christer  Halldin</span>, <span class="hlFld-ContribAuthor ">Andrew P  Brown</span>, <span class="hlFld-ContribAuthor ">Karthick  Vishwanathan</span>, <span class="hlFld-ContribAuthor ">Lars  Farde</span>. </span><span class="cited-content_cbyCitation_article-title">A PET study in healthy subjects of brain exposure of
              11
              C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cerebral Blood Flow & Metabolism</span><span> <strong>2020,</strong> <em>40 </em>
                                    (4)
                                     , 799-807. <a href="https://doi.org/10.1177/0271678X19843776" title="DOI URL">https://doi.org/10.1177/0271678X19843776</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0271678X19843776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0271678X19843776%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cerebral%2520Blood%2520Flow%2520%2526%2520Metabolism%26atitle%3DA%252BPET%252Bstudy%252Bin%252Bhealthy%252Bsubjects%252Bof%252Bbrain%252Bexposure%252Bof%252B11%252BC-labelled%252Bosimertinib%252B%2525E2%252580%252593%252BA%252Bdrug%252Bintended%252Bfor%252Btreatment%252Bof%252Bbrain%252Bmetastases%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DVarrone%26aufirst%3DAndrea%26date%3D2020%26date%3D2019%26volume%3D40%26issue%3D4%26spage%3D799%26epage%3D807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fiamma  Buttitta</span>, <span class="hlFld-ContribAuthor ">Lara  Felicioni</span>, <span class="hlFld-ContribAuthor ">Alessia Di  Lorito</span>, <span class="hlFld-ContribAuthor ">Alessio  Cortellini</span>, <span class="hlFld-ContribAuthor ">Luciana  Irtelli</span>, <span class="hlFld-ContribAuthor ">Davide  Brocco</span>, <span class="hlFld-ContribAuthor ">Pietro Di  Marino</span>, <span class="hlFld-ContribAuthor ">Donatella  Traisci</span>, <span class="hlFld-ContribAuthor ">Nicola  D’Ostilio</span>, <span class="hlFld-ContribAuthor ">Alessandra Di  Paolo</span>, <span class="hlFld-ContribAuthor ">Francesco  Malorgio</span>, <span class="hlFld-ContribAuthor ">Pasquale  Assalone</span>, <span class="hlFld-ContribAuthor ">Sonia Di  Felice</span>, <span class="hlFld-ContribAuthor ">Francesca  Fabbri</span>, <span class="hlFld-ContribAuthor ">Giovanni  Cianci</span>, <span class="hlFld-ContribAuthor ">Michele De  Tursi</span>, <span class="hlFld-ContribAuthor ">Antonio  Marchetti</span>. </span><span class="cited-content_cbyCitation_article-title">Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of
              EGFR
              mutations in NSCLC: a new algorithm for patient selection and personalized treatment. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 982-991. <a href="https://doi.org/10.18632/oncotarget.27517" title="DOI URL">https://doi.org/10.18632/oncotarget.27517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27517%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DEarly%252Bprediction%252Bof%252Bresistance%252Bto%252Btyrosine%252Bkinase%252Binhibitors%252Bby%252Bplasma%252Bmonitoring%252Bof%252BEGFR%252Bmutations%252Bin%252BNSCLC%25253A%252Ba%252Bnew%252Balgorithm%252Bfor%252Bpatient%252Bselection%252Band%252Bpersonalized%252Btreatment%26aulast%3DButtitta%26aufirst%3DFiamma%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D11%26spage%3D982%26epage%3D991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asmin  Tulpule</span>, <span class="hlFld-ContribAuthor ">Trever G.  Bivona</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired Resistance in Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Cancer Biology</span><span> <strong>2020,</strong> <em>4 </em>
                                    (1)
                                     , 279-297. <a href="https://doi.org/10.1146/annurev-cancerbio-030419-033502" title="DOI URL">https://doi.org/10.1146/annurev-cancerbio-030419-033502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-cancerbio-030419-033502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-cancerbio-030419-033502%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Cancer%2520Biology%26atitle%3DAcquired%252BResistance%252Bin%252BLung%252BCancer%26aulast%3DTulpule%26aufirst%3DAsmin%26date%3D2020%26volume%3D4%26issue%3D1%26spage%3D279%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naoya  Shindo</span>, <span class="hlFld-ContribAuthor ">Akio  Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">
                In Vivo
              
              Targeting of Endogenous Proteins with Reactive Small Molecules. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 281-307. <a href="https://doi.org/10.1002/9783527344406.ch10" title="DOI URL">https://doi.org/10.1002/9783527344406.ch10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527344406.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527344406.ch10%26sid%3Dliteratum%253Aachs%26atitle%3DIn%252BVivo%252BTargeting%252Bof%252BEndogenous%252BProteins%252Bwith%252BReactive%252BSmall%252BMolecules%26aulast%3DShindo%26aufirst%3DNaoya%26date%3D2020%26date%3D2019%26spage%3D281%26epage%3D307%26pub%3DWiley%26atitle%3DHandbook%252Bof%252BIn%252BVivo%252BChemistry%252Bin%252BMice%26aulast%3DTanaka%26aufirst%3DKatsunori%26date%3D2020%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin D.  Courtney</span>, <span class="hlFld-ContribAuthor ">Yuanqing  Ma</span>, <span class="hlFld-ContribAuthor ">Alberto  Diaz de Leon</span>, <span class="hlFld-ContribAuthor ">Alana  Christie</span>, <span class="hlFld-ContribAuthor ">Zhiqun  Xie</span>, <span class="hlFld-ContribAuthor ">Layton  Woolford</span>, <span class="hlFld-ContribAuthor ">Nirmish  Singla</span>, <span class="hlFld-ContribAuthor ">Allison  Joyce</span>, <span class="hlFld-ContribAuthor ">Haley  Hill</span>, <span class="hlFld-ContribAuthor ">Ananth J.  Madhuranthakam</span>, <span class="hlFld-ContribAuthor ">Qing  Yuan</span>, <span class="hlFld-ContribAuthor ">Yin  Xi</span>, <span class="hlFld-ContribAuthor ">Yue  Zhang</span>, <span class="hlFld-ContribAuthor ">Jenny  Chang</span>, <span class="hlFld-ContribAuthor ">Oluwatomilade  Fatunde</span>, <span class="hlFld-ContribAuthor ">Yull  Arriaga</span>, <span class="hlFld-ContribAuthor ">Arthur E.  Frankel</span>, <span class="hlFld-ContribAuthor ">Sanjeeva  Kalva</span>, <span class="hlFld-ContribAuthor ">Song  Zhang</span>, <span class="hlFld-ContribAuthor ">Tiffani  McKenzie</span>, <span class="hlFld-ContribAuthor ">Oscar  Reig Torras</span>, <span class="hlFld-ContribAuthor ">Robert A.  Figlin</span>, <span class="hlFld-ContribAuthor ">Brian I.  Rini</span>, <span class="hlFld-ContribAuthor ">Renée M.  McKay</span>, <span class="hlFld-ContribAuthor ">Payal  Kapur</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Ivan  Pedrosa</span>, <span class="hlFld-ContribAuthor ">James  Brugarolas</span>. </span><span class="cited-content_cbyCitation_article-title">HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2020,</strong> <em>26 </em>
                                    (4)
                                     , 793-803. <a href="https://doi.org/10.1158/1078-0432.CCR-19-1459" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-19-1459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-19-1459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-19-1459%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DHIF-2%252BComplex%252BDissociation%25252C%252BTarget%252BInhibition%25252C%252Band%252BAcquired%252BResistance%252Bwith%252BPT2385%25252C%252Ba%252BFirst-in-Class%252BHIF-2%252BInhibitor%25252C%252Bin%252BPatients%252Bwith%252BClear%252BCell%252BRenal%252BCell%252BCarcinoma%26aulast%3DCourtney%26aufirst%3DKevin%2BD.%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D4%26spage%3D793%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian J.  Groendyke</span>, <span class="hlFld-ContribAuthor ">Chelsea E.  Powell</span>, <span class="hlFld-ContribAuthor ">Frederic  Feru</span>, <span class="hlFld-ContribAuthor ">Thomas W.  Gero</span>, <span class="hlFld-ContribAuthor ">Zhengnian  Li</span>, <span class="hlFld-ContribAuthor ">Hilary  Szabo</span>, <span class="hlFld-ContribAuthor ">Kevin  Pang</span>, <span class="hlFld-ContribAuthor ">John  Feutrill</span>, <span class="hlFld-ContribAuthor ">Bailing  Chen</span>, <span class="hlFld-ContribAuthor ">Bin  Li</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">David A.  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Benzopyrimidodiazepinone inhibitors of TNK2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 126948. <a href="https://doi.org/10.1016/j.bmcl.2020.126948" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.126948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.126948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.126948%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBenzopyrimidodiazepinone%252Binhibitors%252Bof%252BTNK2%26aulast%3DGroendyke%26aufirst%3DBrian%2BJ.%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D126948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm500973a&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm500973a%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=292&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of reversible and irreversible EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mutant selective EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0021.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Piperazine Amides <b>12</b>–<b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) piperazine amide, DIPEA, DMA, 140 °C (microwave); (ii) iron, NH<sub>4</sub>Cl, EtOH, water, 100 °C; (iii) acryloyl chloride, DIPEA, DCM, 0 °C; (iv) functional group deprotection if required; TFA, DCM, rt; or TBAF, THF, rt.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0022.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Basic Side Chain Compounds <b>20</b>, <b>21</b>, and <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) R<sub>1</sub>R<sub>2</sub>NH, DIPEA, DMA, 85–100 °C; (ii) iron, NH<sub>4</sub>Cl, EtOH, water, 100 °C; (iii) acryloyl chloride, DIPEA, DCM, −15 to 0 °C.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0023.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthesis of Indole Compounds <b>23</b>–<b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MeMgBr (1 equiv, 3.2 M in 2-methyl THF), indole (1 equiv), THF, 0 °C → 60 °C; (ii) sodium hydride (1.05 equiv), methyl iodide (1.05 equiv), THF, 0 °C; (iii) 4-fluoro-2-methoxy-5-nitroaniline (1.05 equiv), tosic acid (1.1 equiv), 2-pentanol, 125 °C; (iv) <i>N</i>,<i>N</i>,<i>N</i>′-trimethylethane-1,2-diamine (2.2 equiv), DMA, 140 °C; (v) iron (3 equiv), ammonium chloride (0.7 equiv), EtOH, water, 100 °C; (vi) Zn(CN)<sub>2</sub> (0.6 equiv), zinc (0.1 equiv), tris(dibenzylideneacetone)dipalladium(0) (0.1 equiv), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine (XPhos) (0.2 equiv), DMA, 95 °C; (vii) acryloyl chloride (1 M, THF, 1 equiv), DIPEA (1.1 equiv), THF, 0 °C.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mouse plasma concentration data following a 50 mg/kg oral dose of compound <b>20</b>, a 10 mg/kg oral dose of compound <b>21</b>, and a 10 mg/kg oral dose of compound <b>22</b>. Data points shown are concentrations from individual animals with mean values being represented by lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. p-EGFR inhibition time course profile in PC9 (sensitizing mutant) xenograft bearing mice following 10 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. p-EGFR inhibition time course profile in H1975 (double mutant) xenograft bearing mice following 10 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo efficacy of <b>22</b>, <b>21</b>, and <b>20</b> when dosed orally in tumor bearing immune compromised mice at 10 mg kg<sup>–1</sup> day<sup>–1</sup> q.d. H1975 efficacy is represented in blue, with PC9 data in green and A431 in red. Statistical significance (<i>p</i> values) was calculated by comparing compound treated and vehicle groups using a one-tailed <i>t</i> test. “NS” indicates % TGI was not significant from vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pyrimidine 5-substituent analysis. N-H indoles appear in red, with N-Me indoles in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Matched pair analyses for N-H-indole and N-Me examples. Each marker represents an individual compound matching the substructure shown. Lines connect exact structural matches (∗ = positions of variation). Top left mean pIC<sub>50</sub> difference is 0.61 (SE = 0.1, <i>n</i> = 11). Top right mean pIC<sub>50</sub> difference is 0.06 (SE = 0.078, <i>n</i> = 11). Middle left mean pIC<sub>50</sub> difference is 0.77 (SE = 0.09, <i>n</i> = 11). Middle right mean pIC<sub>50</sub> difference is 0.072 (SE = 0.02, <i>n</i> = 11). Bottom mean pIC<sub>50</sub> difference is 0.04 (SE = 0.02, <i>n</i> = 11).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo xenograft activity of <b>8</b> when dosed orally in tumor bearing immune compromised mice at 10 and 5 mg/kg q.d.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound effects of blood glucose levels in the rat following a single 200 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, <b>22</b>, and <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0012.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound effects of blood insulin levels in the rat following a single 200 mg/kg oral dose of compounds <b>20</b>, <b>21</b>, <b>22</b>, and <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0013.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Millipore kinase selectivity profile for compound <b>8</b>. Colors are indicative of % inhibition at 1 μM as follows: dark green, 0–20% of control; light green, 20–40% of control; yellow, 40–60% of control; orange, 60–80% of control; red, 80–100% of control. Full % inhibition data are listed in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> including IC<sub>50</sub> data for those kinases with an analogous cysteine to C797.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0014.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Modeled binding mode of compound (<b>8</b>). See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for further details. Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0015.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Compound <b>8</b> and identified circulating metabolites <b>27</b> and <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0016.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Total levels for <b>8</b>, <b>27</b>, and <b>28</b> over a 12 h period following a 25 mg/kg oral dose in the nude mouse. The markers are mean values ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0017.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. In vivo efficacy profiles (% tumor growth inhibition) of <b>8</b>, <b>27</b>, afatinib (<b>4</b>), and gefitinib (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0018.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Preliminary plasma concentration versus time plots (mean + SD) of <b>8</b>, <b>27</b>, and <b>28</b> after 8 days of once daily 20 mg oral doses of <b>8</b> to patients with advanced EGFRm+ NSCLC in AURA phase 1 study (NCT01802632) (<i>n</i> = 6). Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0019.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Serial computed tomography scans of the chest from patients before and after treatment with <b>8</b> in a phase I trial: images from a 57-year old Korean female patient diagnosed with stage IV non-small-cell lung cancer in May 2011. Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/medium/jm-2014-00973a_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0020.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Serial computed tomography scans of the chest from patients before and after treatment with <b>8</b> in a phase I trial: images from a 57-year old British female never smoker diagnosed with stage IV lung adenocarcinoma in December 2010. Adapted by permission from the American Association for Cancer Research: <contrib-group>Cross, D. A. E.</contrib-group>; AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.  <cite>Cancer Discovery</cite> <span class="NLM_year">2014</span>, <em>4</em>, 1046–1061.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-20/jm500973a/20141024/images/large/jm-2014-00973a_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500973a&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruvka, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span> <span class="citation_source-journal">J. Clin. Oncol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1200%2FJCO.2012.43.3912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=23401451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1070-1080&author=K.+Ohashiauthor=Y.+E.+Maruvkaauthor=F.+Michorauthor=W.+Pao&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor-resistant+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span></div><div class="casAuthors">Ohashi, Kadoaki; Maruvka, Yosef E.; Michor, Franziska; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose EGFR-mutant lung cancer was first described as a new clin. entity in 2004.  Here, we present an update on new controversies and conclusions regarding the disease.  Methods This article reviews the clin. implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.  Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC).  Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.  Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC.  Efforts should now conc. on making EGFR-mutant lung cancer a chronic rather than fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FJbVyt6ydLVg90H21EOLACvtfcHk0lj8bpoBz-gnBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D&md5=dfda1563a90ce24bc51e55ebbf47d981</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3912%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMaruvka%26aufirst%3DY.%2BE.%26aulast%3DMichor%26aufirst%3DF.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor-resistant%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol%26date%3D2013%26volume%3D31%26spage%3D1070%26epage%3D1080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0lj8bpoBz-gnBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span> </span><span class="NLM_article-title">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lj8bpoBz-gnBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DGefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Jaenneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0livSrHZ2L9rIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span> </span><span class="NLM_article-title">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.critrevonc.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=22257651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=407-421&author=S.-H.+I.+Ou&title=Second-generation+irreversible+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29%3A+A+better+mousetrap%3F+A+review+of+the+clinical+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence</span></div><div class="casAuthors">Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC.  First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations.  However, resistance to gefitinib and erlotinib invariably develops after prolonged clinical use.  Two second-generation irreversible EGFR TKIs, afatinib (BIBW 2992) and dacomitinib (PF-00299804), that can potentially overcome the majority of these resistances are in late stage clinical development.  Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB3Zud0oX1WCM8MEzWGjS9fW6udTcc2eYb6Rjl8V4PW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D&md5=df9e3f1fe1c2bb8f328f925725024d40</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DSecond-generation%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%253A%2520A%2520better%2520mousetrap%253F%2520A%2520review%2520of%2520the%2520clinical%2520evidence%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2012%26volume%3D83%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0livSrHZ2L9rIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liQBVm_x9d33Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0liQBVm_x9d33Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span>International Centre for Kinase Profiling. <a href="http://www.kinase-screen.mrc.ac.uk/" class="extLink">http://www.kinase-screen.mrc.ac.uk/</a> (accessed August 12,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International+Centre+for+Kinase+Profiling.+http%3A%2F%2Fwww.kinase-screen.mrc.ac.uk%2F+%28accessed+August+12%2C+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Compounds were screened in the Millipore kinase panel. Full data are described in ref <a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">20</a>.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compounds+were+screened+in+the+Millipore+kinase+panel.+Full+data+are+described+in+ref+20."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yee, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor receptor inhibitors: baby or the bathwater?</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1093%2Fjnci%2Fdjs258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=22761272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=975-981&author=D.+Yee&title=Insulin-like+growth+factor+receptor+inhibitors%3A+baby+or+the+bathwater%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?</span></div><div class="casAuthors">Yee, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The success of targeted therapies for cancer is undisputed; strong preclin. evidence has resulted in the approval of several new agents for cancer treatment.  The type I insulin-like growth factor receptor (IGF1R) appeared to be one of these promising new targets.  Substantial population and preclin. data have all pointed toward this pathway as an important regulator of tumor cell biol.  Although early results from clin. trials that targeted the IGF1R showed some evidence of response, larger randomized phase III trials have not shown clear clin. benefit of targeting this pathway in combination with conventional strategies.  These disappointing results have resulted in the discontinuation of several anti-IGF1R programs.  However, the conduct of these trials has brought to the forefront several important factors that need to be considered in the conduct of future clin. trials.  The need to develop biomarkers, a clearer understanding of insulin receptor function, and defining rational combination regimens all require further consideration.  In this commentary, the current state of IGF1R inhibitors in cancer therapy is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2brv9Teud4rVg90H21EOLACvtfcHk0lifZZTlQZL-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOjsLrM&md5=9a474634c9cbb43ce2a1cd0d576f522a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjs258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjs258%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%2520receptor%2520inhibitors%253A%2520baby%2520or%2520the%2520bathwater%253F%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D975%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Clarke, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenhow, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D.</span><span> </span><span class="NLM_article-title">Metabolism-related assays and their application to agrochemical research: reactivity of pesticides with glutathione and glutathione transferases</span> <span class="citation_source-journal">Pestic. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=385-393&author=E.+D.+Clarkeauthor=D.+T.+Greenhowauthor=D.+Adams&title=Metabolism-related+assays+and+their+application+to+agrochemical+research%3A+reactivity+of+pesticides+with+glutathione+and+glutathione+transferases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-related assays and their application to agrochemical research: reactivity of pesticides with glutathione and glutathione transferases</span></div><div class="casAuthors">Clarke, Eric D.; Greenhow, Daren T.; Adams, David</div><div class="citationInfo"><span class="NLM_cas:title">Pesticide Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-393</span>CODEN:
                <span class="NLM_cas:coden">PSSCBG</span>;
        ISSN:<span class="NLM_cas:issn">0031-613X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An HPLC-based assay system has been developed to measure the reactivity of agrochems. with glutathione (GSH) with and without catalysis by glutathione transferases (GSTs).  Metab.-related parameters based on second-order related rate consts. from nonenzymic GSH and enzymic GSH + GST assays have been derived for use in structure-activity and structure-reactivity relationship studies of exploratory agrochems.  The versatility and sensitivity of the assay system has been established using a diverse range of agrochems. and model compds., e.g. 4-nitrobenzyl chloride, 1-chloro-2,4-dinitrobenzene, atrazine, acetochlor, fluorodifen, fluazifop-Bu, tridiphane, fluazinam, chlorothalonil and diazinon.  For the enzymic GSH + GST assay, second-order related rate consts., ratioed to the assay std., 4-nitrobenzyl chloride to provide a parameter independent of assay conditions, spanned 5 orders of magnitude, fluazinam being the most reactive and atrazine the least.  Within chem. classes, significant variations in reactivity were obsd., alachlor being c. 15-fold more reactive than pretilachlor.  Applications of this assay system based on comparative measures of reactivity across and within chem. classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozE9JcsswrNbVg90H21EOLACvtfcHk0lifZZTlQZL-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D&md5=5de37b3f68e5df660d917bc17fb4fb16</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-9063%2528199812%252954%253A4%253C385%253A%253AAID-PS842%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DE.%2BD.%26aulast%3DGreenhow%26aufirst%3DD.%2BT.%26aulast%3DAdams%26aufirst%3DD.%26atitle%3DMetabolism-related%2520assays%2520and%2520their%2520application%2520to%2520agrochemical%2520research%253A%2520reactivity%2520of%2520pesticides%2520with%2520glutathione%2520and%2520glutathione%2520transferases%26jtitle%3DPestic.%2520Sci.%26date%3D1998%26volume%3D54%26spage%3D385%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morley, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span> </span><span class="NLM_article-title">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1136</span><span class="NLM_x">–</span> <span class="NLM_lpage">1138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.bmcl.2008.12.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=19168354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1136-1138&author=P.+A.+MacFaulauthor=A.+D.+Morleyauthor=J.+J.+Crawford&title=A+simple+in+vitro+assay+for+assessing+the+reactivity+of+nitrile+containing+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span></div><div class="casAuthors">MacFaul, Philip A.; Morley, Andrew D.; Crawford, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1136-1138</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A quant. assay involving the reaction of nitriles with glutathione and cysteine has been used as a simple in vitro screen to assess potential toxicity risk of candidate compds. in drug discovery.  Studies have indicated that, when benchmarked with selected compds., the reaction of the nitriles with glutathione can provide a useful tool for deciding whether or not to progress compds. in the absence of radiolabelling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro23j0VCklM7Vg90H21EOLACvtfcHk0lifZZTlQZL-EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D&md5=d949b5d0e76c6d268f3f57cc4584f0b9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.105%26sid%3Dliteratum%253Aachs%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DMorley%26aufirst%3DA.%2BD.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520simple%2520in%2520vitro%2520assay%2520for%2520assessing%2520the%2520reactivity%2520of%2520nitrile%2520containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1136%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Schwobel, J. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madden, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T. D.</span><span> </span><span class="NLM_article-title">Examination of Michael addition reactivity towards glutathione by transition-state calculations</span> <span class="citation_source-journal">SAR QSAR Environ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=693-710&author=J.+A.+H.+Schwobelauthor=J.+C.+Maddenauthor=M.+T.+D.+Cronin&title=Examination+of+Michael+addition+reactivity+towards+glutathione+by+transition-state+calculations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwobel%26aufirst%3DJ.%2BA.%2BH.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DCronin%26aufirst%3DM.%2BT.%2BD.%26atitle%3DExamination%2520of%2520Michael%2520addition%2520reactivity%2520towards%2520glutathione%2520by%2520transition-state%2520calculations%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D2010%26volume%3D21%26spage%3D693%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Mah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span> </span><span class="NLM_article-title">Drug discovery considerations in the development of covalent inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.bmcl.2013.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=24314671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=33-39&author=R.+Mahauthor=J.+R.+Thomasauthor=C.+M.+Shafer&title=Drug+discovery+considerations+in+the+development+of+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery considerations in the development of covalent inhibitors</span></div><div class="casAuthors">Mah, Robert; Thomas, Jason R.; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the no. of drug candidates with a covalent mechanism of action progressing through clin. trials or being approved by the FDA has increased significantly.  And as interest in covalent inhibitors has increased, the tech. challenges for characterizing and optimizing these inhibitors have become evident.  A no. of new tools have been developed to aid this process, but these have not gained wide-spread use.  This review will highlight a no. of methods and tools useful for prosecuting covalent inhibitor drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dY63LHbEhLVg90H21EOLACvtfcHk0lhSQkgJBIuzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlsr3O&md5=9407bcb76e83065f5a56a97b63547ede</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMah%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDrug%2520discovery%2520considerations%2520in%2520the%2520development%2520of%2520covalent%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D33%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Marks, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewart, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainée, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentin, J. P.</span><span> </span><span class="NLM_article-title">The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1016%2Fj.taap.2012.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=22714037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2012&pages=171-83&author=L.+Marksauthor=S.+Borlandauthor=K.+Philipauthor=L.+Ewartauthor=P.+Lain%C3%A9eauthor=M.+Skinnerauthor=S.+Kirkauthor=J.+P.+Valentin&title=The+role+of+the+anaesthetised+guinea-pig+in+the+preclinical+cardiac+safety+evaluation+of+drug+candidate+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds</span></div><div class="casAuthors">Marks, Louise; Borland, Samantha; Philp, Karen; Ewart, Lorna; Lainee, Pierre; Skinner, Matthew; Kirk, Sarah; Valentin, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-183</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite rigorous preclin. and clin. safety evaluation, adverse cardiac effects remain a leading cause of drug attrition and post-approval drug withdrawal.  A no. of cardiovascular screens exist within preclin. development.  These screens do not, however, provide a thorough cardiac liability profile and, in many cases, are not preventing the progression of high risk compds.  We evaluated the suitability of the anesthetized guinea-pig for the assessment of drug-induced changes in cardiovascular parameters.  Sodium pentobarbitone anesthetized male guinea-pigs received three 15 min i.v. infusions of ascending doses of amoxicillin, atenolol, clonidine, dobutamine, dofetilide, flecainide, isoprenaline, levosimendan, milrinone, moxifloxacin, nifedipine, paracetamol, verapamil or vehicle, followed by a 30 min washout.  Dose levels were targeted to cover clin. exposure and above, with plasma samples obtained to evaluate effect/exposure relationships.  Arterial blood pressure, heart rate, contractility function (left ventricular dP/dtmax and QA interval) and lead II ECG were recorded throughout.  In general, the expected ref. compd. induced effects on hemodynamic, contractility and electrocardiog. parameters were detected confirming that all three endpoints can be measured accurately and simultaneously in one small animal.  Plasma exposures obtained were within, or close to the expected clin. range of therapeutic plasma levels.  Concn.-effect curves were produced which allowed a more complete understanding of the margins for effects at different plasma exposures.  This single in vivo screen provides a significant amt. of information pertaining to the cardiovascular risk of drug candidates, ultimately strengthening strategies addressing cardiovascular-mediated compd. attrition and drug withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiPhG6sCLHrLVg90H21EOLACvtfcHk0lhSQkgJBIuzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCks7g%253D&md5=cbbd8f21bb3c17986d08ab65b91f1dd1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2012.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2012.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DL.%26aulast%3DBorland%26aufirst%3DS.%26aulast%3DPhilip%26aufirst%3DK.%26aulast%3DEwart%26aufirst%3DL.%26aulast%3DLain%25C3%25A9e%26aufirst%3DP.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DS.%26aulast%3DValentin%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520role%2520of%2520the%2520anaesthetised%2520guinea-pig%2520in%2520the%2520preclinical%2520cardiac%2520safety%2520evaluation%2520of%2520drug%2520candidate%2520compounds%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2012%26volume%3D263%26spage%3D171%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span>Eurofins. Discovery Series. KinaseProfiler Services. <a href="http://www.eurofins.com/pharma-services/pharma-discovery-services/eurofins-discovery-services/kinases-phosphatases/kinaseprofiler-services.aspx" class="extLink">http://www.eurofins.com/pharma-services/pharma-discovery-services/eurofins-discovery-services/kinases-phosphatases/kinaseprofiler-services.aspx</a> (accessed August 12,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eurofins.+Discovery+Series.+KinaseProfiler+Services.+http%3A%2F%2Fwww.eurofins.com%2Fpharma-services%2Fpharma-discovery-services%2Feurofins-discovery-services%2Fkinases-phosphatases%2Fkinaseprofiler-services.aspx+%28accessed+August+12%2C+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleasby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magriotis, P. A.</span><span> </span><span class="NLM_article-title">Importance of mechanistic drug metabolism studies in support of drug discovery: a case study with N-sulfonylated dipeptide VLA-4 antagonists in rats</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=223-237&author=W.+Tangauthor=R.+A.+Stearnsauthor=Q.+Chenauthor=K.+Bleasbyauthor=Y.+Tefferaauthor=A.+Collettiauthor=M.+Hafeyauthor=R.+Eversauthor=D.+C.+Deanauthor=P.+A.+Magriotis&title=Importance+of+mechanistic+drug+metabolism+studies+in+support+of+drug+discovery%3A+a+case+study+with+N-sulfonylated+dipeptide+VLA-4+antagonists+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DBleasby%26aufirst%3DK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DColletti%26aufirst%3DA.%26aulast%3DHafey%26aufirst%3DM.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DDean%26aufirst%3DD.%2BC.%26aulast%3DMagriotis%26aufirst%3DP.%2BA.%26atitle%3DImportance%2520of%2520mechanistic%2520drug%2520metabolism%2520studies%2520in%2520support%2520of%2520drug%2520discovery%253A%2520a%2520case%2520study%2520with%2520N-sulfonylated%2520dipeptide%2520VLA-4%2520antagonists%2520in%2520rats%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D223%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, A.</span><span> </span><span class="NLM_article-title">The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: a case study</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.2174%2F187231208784041004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1ajsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=120-124&author=A.+F.+El-Kattanauthor=J.+Poeauthor=L.+Buchholzauthor=H.+V.+Thomasauthor=J.+Brodfuehrerauthor=A.+Clark&title=The+use+of+1-aminobenzotriazole+in+differentiating+the+role+of+CYP-mediated+first+pass+metabolism+and+absorption+in+limiting+drug+oral+bioavailability%3A+a+case+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting Drug oral bioavailability: a case study</span></div><div class="casAuthors">El-Kattan, Ayman F.; Poe, Julie; Buchholz, Lisa; Thomas, Hayden V.; Brodfuehrer, Joanne; Clark, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-124</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Preliminary studies in our lab. demonstrated low oral bioavailability of Drug X in male Sprague Dawley rats.  However, the factors responsible for the obsd. poor bioavailability were not well understood.  The objective of this study was to investigate the contribution of cytochrome P 4501(s) metab. to the obsd. poor oral bioavailability of Drug X in male Sprague-Dawley rats in the presence of 1-aminobenzotriazole, a non-specific irreversible inhibitor of cytochrome P450s.  Male Sprague-Dawley rats were pre-treated with or without oral 1-aminobenzotriazole (50 mg/kg) 2 h prior to receiving a single i.v. or oral dose of Drug X (3 mg/kg).  Blood samples were collected from animals at different time points over 6 h following Drug X dosing.  Plasma concns. of Drug X were detd. using LC/MS/MS.  Pharmacokinetic data obtained from an i.v. dose study in rats suggested that Drug X exhibited a high clearance (55 mL/min/kg) and moderate vol. of distribution (1.3 L/kg) with short half-life in rats (0.7 h).  Oral dosing of Drug X to rats resulted in low oral bioavailability (19%).  1-Aminobenzotriazole pre-treatment of male Sprague Dawley rats followed by an i.v. dose of Drug X resulted in a decrease in plasma clearance by 71% and an increase in half-life by 100%, without affecting the vol. of distribution.  Furthermore, the oral bioavailability of Drug X increased markedly with 1-aminobenzotriazole pre-treatment.  However, the fraction absorbed of Drug X did not significantly change with 1-aminobenzotriazole pre-treatment.  The results of this study indicated that CYP-mediated metab. played a major role in limiting the oral bioavailability of Drug X in rats.  The data suggests that 1-aminobenzotriazole can be used as an effective tool in assessing the factors contributing to the poor oral bioavailability of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmldBUJ-PF3rVg90H21EOLACvtfcHk0lhSQkgJBIuzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1ajsLs%253D&md5=04def10dee094365b7d9c5e470927eab</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F187231208784041004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231208784041004%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DPoe%26aufirst%3DJ.%26aulast%3DBuchholz%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DH.%2BV.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DA.%26atitle%3DThe%2520use%2520of%25201-aminobenzotriazole%2520in%2520differentiating%2520the%2520role%2520of%2520CYP-mediated%2520first%2520pass%2520metabolism%2520and%2520absorption%2520in%2520limiting%2520drug%2520oral%2520bioavailability%253A%2520a%2520case%2520study%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2008%26volume%3D2%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aicholz, R.</span><span> </span><span class="NLM_article-title">The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite CGP74588</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3231</span><span class="NLM_x">–</span> <span class="NLM_lpage">3239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=3231-3239&author=P.+W.+Manleyauthor=F.+Blascoauthor=J.+Mestanauthor=R.+Aicholz&title=The+kinetic+deuterium+isotope+effect+as+applied+to+metabolic+deactivation+of+imatinib+to+the+des-methyl+metabolite+CGP74588"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DAicholz%26aufirst%3DR.%26atitle%3DThe%2520kinetic%2520deuterium%2520isotope%2520effect%2520as%2520applied%2520to%2520metabolic%2520deactivation%2520of%2520imatinib%2520to%2520the%2520des-methyl%2520metabolite%2520CGP74588%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D3231%26epage%3D3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Sjogren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westergren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanish, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindfors, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennernas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannergren, C.</span><span> </span><span class="NLM_article-title">In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=679-698&author=E.+Sjogrenauthor=J.+Westergrenauthor=I.+Grantauthor=G.+Hanishauthor=L.+Lindforsauthor=H.+Lennernasauthor=B.+Abrahamssonauthor=C.+Tannergren&title=In+silico+predictions+of+gastrointestinal+drug+absorption+in+pharmaceutical+product+development%3A+application+of+the+mechanistic+absorption+model+GI-Sim"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSjogren%26aufirst%3DE.%26aulast%3DWestergren%26aufirst%3DJ.%26aulast%3DGrant%26aufirst%3DI.%26aulast%3DHanish%26aufirst%3DG.%26aulast%3DLindfors%26aufirst%3DL.%26aulast%3DLennernas%26aufirst%3DH.%26aulast%3DAbrahamsson%26aufirst%3DB.%26aulast%3DTannergren%26aufirst%3DC.%26atitle%3DIn%2520silico%2520predictions%2520of%2520gastrointestinal%2520drug%2520absorption%2520in%2520pharmaceutical%2520product%2520development%253A%2520application%2520of%2520the%2520mechanistic%2520absorption%2520model%2520GI-Sim%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D49%26spage%3D679%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimelow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J.</span><span> </span><span class="NLM_article-title">Integrating the pre-clinical pharmacokinetic, pharmacodynamic and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating (EGFRm+) and resistant (EGFRm+/T790M) mutations and an active metabolite to predict the human pharmacokinetics and potential efficacious dose in patients</span> <span class="citation_source-journal">Mol. Cancer Ther</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">11 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">B212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=B212&issue=11+Suppl.&author=P.+Ballardauthor=S.+Ashtonauthor=D.+Crossauthor=R.+Dimelowauthor=J.+Yates&title=Integrating+the+pre-clinical+pharmacokinetic%2C+pharmacodynamic+and+efficacy+data+for+AZD9291%2C+an+oral%2C+irreversible+inhibitor+of+EGFR+activating+%28EGFRm%2B%29+and+resistant+%28EGFRm%2B%2FT790M%29+mutations+and+an+active+metabolite+to+predict+the+human+pharmacokinetics+and+potential+efficacious+dose+in+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DDimelow%26aufirst%3DR.%26aulast%3DYates%26aufirst%3DJ.%26atitle%3DIntegrating%2520the%2520pre-clinical%2520pharmacokinetic%252C%2520pharmacodynamic%2520and%2520efficacy%2520data%2520for%2520AZD9291%252C%2520an%2520oral%252C%2520irreversible%2520inhibitor%2520of%2520EGFR%2520activating%2520%2528EGFRm%252B%2529%2520and%2520resistant%2520%2528EGFRm%252B%252FT790M%2529%2520mutations%2520and%2520an%2520active%2520metabolite%2520to%2520predict%2520the%2520human%2520pharmacokinetics%2520and%2520potential%2520efficacious%2520dose%2520in%2520patients%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2013%26volume%3D12%26issue%3D11%2520Suppl%26spage%3DB212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Red Brewer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Fjm500973a&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Fjm500973a&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm500973a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+Nebhanauthor=P.+Spitzlerauthor=J.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgE6hc_wyRgJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%26aulast%3DSpitzler%26aufirst%3DP.%26aulast%3DOrme%26aufirst%3DJ.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span> </span><span class="NLM_article-title">Preliminary results from a phase I study with AZD9291: an irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S15</span><div class="note"><p class="first last">(Abstract LBA33)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S15&issue=Suppl.+3&author=M.+Ransonauthor=W.+Paoauthor=D.+Planchardauthor=Y.+Oheauthor=S.-W.+Kimauthor=D.+W.+Kimauthor=E.+Felipauthor=S.+Ghiorghiuauthor=M.+Cantariniauthor=P.+Janne&title=Preliminary+results+from+a+phase+I+study+with+AZD9291%3A+an+irreversible+inhibitor+of+epidermal+growth+factor+receptor+%28EGFR%29+activating+and+resistance+mutations+in+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%2520I%2520study%2520with%2520AZD9291%253A%2520an%2520irreversible%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520activating%2520and%2520resistance%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26issue%3DSuppl.%25203%26spage%3DS15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Eisenhauer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therasse, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaerts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dancey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwyther, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span> </span><span class="NLM_article-title">New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=228-247&author=E.+A.+Eisenhauerauthor=P.+Therasseauthor=J.+Bogaertsauthor=L.+H.+Schwartzauthor=D.+Sargentauthor=R.+Fordauthor=J.+Danceyauthor=S.+Arbuckauthor=S.+Gwytherauthor=M.+Mooneyauthor=L.+Rubinsteinauthor=L.+Shankarauthor=L.+Doddauthor=R.+Kaplanauthor=D.+Lacombeauthor=J.+Verweij&title=New+response+evaluation+criteria+in+solid+tumours%3A+Revised+RECIST+guideline+%28version+1.1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEisenhauer%26aufirst%3DE.%2BA.%26aulast%3DTherasse%26aufirst%3DP.%26aulast%3DBogaerts%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DL.%2BH.%26aulast%3DSargent%26aufirst%3DD.%26aulast%3DFord%26aufirst%3DR.%26aulast%3DDancey%26aufirst%3DJ.%26aulast%3DArbuck%26aufirst%3DS.%26aulast%3DGwyther%26aufirst%3DS.%26aulast%3DMooney%26aufirst%3DM.%26aulast%3DRubinstein%26aufirst%3DL.%26aulast%3DShankar%26aufirst%3DL.%26aulast%3DDodd%26aufirst%3DL.%26aulast%3DKaplan%26aufirst%3DR.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DVerweij%26aufirst%3DJ.%26atitle%3DNew%2520response%2520evaluation%2520criteria%2520in%2520solid%2520tumours%253A%2520Revised%2520RECIST%2520guideline%2520%2528version%25201.1%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D228%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span>Common Terminology Criteria for Adverse Events (CTCAE). <a href="http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf" class="extLink">http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</a> (accessed August 12,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Common+Terminology+Criteria+for+Adverse+Events+%28CTCAE%29.+http%3A%2F%2Fevs.nci.nih.gov%2Fftp1%2FCTCAE%2FCTCAE_4.03_2010-06-14_QuickReference_5x7.pdf+%28accessed+August+12%2C+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaligam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin Oncol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 5</span><span class="NLM_x">) </span> <span class="NLM_fpage">8009</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&issue=Suppl.+5&author=P.+A.+Janneauthor=S.+S.+Ramaligamauthor=J.+C.+H.+Yangauthor=M.-J.+Ahnauthor=D.-W.+Kimauthor=S.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+activity+of+the+mutant-selective+EGFR+inhibitor+AZD9291+in+patients+%28pts%29+with+EGFR+inhibitor%E2%80%93resistant+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRamaligam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520activity%2520of%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520AZD9291%2520in%2520patients%2520%2528pts%2529%2520with%2520EGFR%2520inhibitor%25E2%2580%2593resistant%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin%2520Oncol%26date%3D2014%26volume%3D32%26issue%3DSuppl.%25205%26spage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i44"><a href="/doi/suppl/10.1021/jm500973a">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16313"></div></div></div></div></div><hr /></hr><p class="last">Preparation and characterization for additional final compounds, cell assay statistical analyses, pharmacodynamic assay procedure, kinase selectivty data, binding mode computational modeling, and enzyme/cell correlations. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm500973a/suppl_file/jm500973a_si_001.pdf">jm500973a_si_001.pdf (629.35 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500973a&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm500973a%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500973a" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a61aa1f833d88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
